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Abstract 
The emergence of multidrug-resistant bacteria is a phenomenon of concem to 
the clinician and the pharmaceutical industry, as it is the major cause of failure 
in the treatment of infectious diseases. Staphylococci have a record of 
developing resistance quickly and successfully to antibiotics. This defensive 
response is a consequence of the acquisition and transfer of antibiotic 
resistance plasmids and the possession of intrinsic resistance mechanisms. 
The acquired defense systems by staphylococci may have originated from 
antibiotic-producing organisms, where they may have been developed and then 
passed on to other genera. There are reports of emergence and high 
occurrence of staphylococcus strains resistant to methicillin, especially MRSA, 
from various parts of the World. These organisms are mostly resistant to 
multiple antibiotics; therefore the treatment of infections due to these organisms 
and their eradication is very difficult. 
The present study was undertaken with the aim of determining epidemiology of 
clinical and carrier staphylococci and biochemical studies of their acquisition 
and dissemination of resistance. 
The prevalence of methicillin-resistant Staphylococci was determined in 750 
subjects infected/colonized with staphylococci providing 850 isolates. Of 850. 
strains 575 were isolated from clinical specimens, 100 from nasal cultures of 
hospitalized patients, 125 from nasal and 50 strains were isolated from ocular 
swabs of hospital workers. It was shown that 35.1% (180/513) of 
Staphylococcus aureus and 22.5% (76/337) of coagulase-negative 
staphylococcal isolates were resistant to methicillin. Highest percentage of 
MRSA (35.5%) was found in pus specimens (n=151) while as urine samples 
(n=153) contributed 25.0% of methicillin-resistant coagulase-negative 
staphylococci. 29.7% of methicillin resistant Staphylococcus aureus isolates 
were found in nasal swabs (n=175) while as 10.0% and 16.5% of methicillin-
resistant coagulase-negative staphylococci were observed in nasal swabs 
(n=50) and ocular cultures (n=50) respectively. The results indicated that major 
reservoir of methicillin resistant staphylococci in hospitals are 
colonized/infected inpatients and colonized hospital workers, with carriers at 
risk for developing endogenous infection or transmitting infection to health care 
workers and patients. The results were confirmed by restriction mapping and 
SDS-PAGE protein profiles of clinical and carrier methicillin-resistant 
staphylococcus aureus isolates. The multiple drug resistance of all MRSA 
(n=180) and MRCNS (n=76) isolates was detected. In case of both methicillin-
resistant as well as methicillin-sensitive staphylococcal isolates zero resistance 
was found to fusidic acid and vancomycin while as highest resistance was 
found to penicillin G followed by ampicillin. 
Selective methicillin-resistant staphylococcal isolates were subjected to plasmid 
isolation and curing treatments to study their mode of resistance. The piasmids 
were transformed into antibiotic sensitive Escherichia coli Strain DH5-a. In one 
of the experiments plasmid pJMRIO from Staphylococcus aureus coding for 
ampicillin (A'), gentamicin (G') and amikacin (Ak )^ resistance was transformed 
into Escherichia Coli. Transformation efficiency was about 2 x 10^ 
transformants/ng of plasmid DNA. The minimal inhibitory concentrations (MICs) 
for A and G were lower in E. coli than in S. aureus. However, the MIC for AK 
was higher in E. coli transformants than in S. aureus. In one of Conjugation 
Studies transfer of erythromycin resistance was observed between clinical and 
carrier strains of Staphylococcus aureus. Furthermore Enzyme mediated 
resistance particularly through y5-lactamase and chloramphenicol acetyl 
transferase was studied in selected strains. The substrate profile of /?-
lactamase so extracted was studied against different classes of pencillins and 
cephalosporins. The results indicated that Methicillin remains the most stable 
pencillin to the staphylococcal y9-lactamase. 
The anti-MRSA activities of a synthesized compound from an Inorganic Lab of 
A.M.U; was determined by in vitro testing. The results indicated that the Nickle-
metalo, complex of 2-mercaptobenzimidazole has good activity against MRSA 
(MIC > 64 |jg/ml) and demands to be analyzed for clinical applications in future. 
The widespread occurrence and dissemination of /^-lactamase and PBP 
mediated resistance leading to multiple antibiotics ineffective, thus increasing 
the cost of health care, needs to be tackled logistically by wise and judicious 
use of existing antibiotics and by developing ideal and cost effective antibiotics 
having least chances of acquiring resistance. Furthermore the hospital acquired 
MRSA infections through colonization of patients and hospital workers 
demands appropriate and timely measure to counteract this health problem. 
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Abstract 
The emergence of mult idrug-resistant bacteria is a phenomenon of concern to the 
cl inic ian and the pharmaceut ical industry, as It is the major cause of fai lure in the 
treatment of infect ious diseases. Staphylococci have a record of developing 
resistance quickly and successful ly to ant ib iot ics. This defensive response is a 
consequence of the acquisi t ion and transfer of ant ib iot ic res is tance plasmids and the 
possession of intr insic resistance mechanisms. The acquired defense systems by 
staphylococci may have or iginated from ant ib io t ic-producing organ isms, where they 
may have been developed and then passed on to other genera. There are reports of 
emergence and high occurrence of staphylococcus strains resistant to meth ic i l l in , 
especial ly MRSA, from various parts of the Wor ld . These organisms are mostly 
resistant to mult iple ant ib iot ics; therefore the t reatment of in fect ions due to these 
organisms and their eradicat ion is very di f f icul t . 
The present study was undertaken with the aim of determin ing epidemiology of 
c l in ical and carrier staphylococci and biochemical studies of their acquis i t ion and 
disseminat ion of res istance. 
The prevalence of methic i l l in-resistant Staphylococci was determined in 750 subjects 
infected/colonized with staphylococci providing 850 iso lates. Of 850 strains 575 were 
isolated from cl in ical specimens, 100 from nasal cul tures of hospi ta l ized pat ients, 
125 from nasal and 50 strains were isolated from ocular swabs of hospi ta l workers. It 
was shown that 3 5 . 1 % (180/513) of Staphylococcus aureus and 22.5% (76/337) of 
coagulase-negat ive staphylococcal isolates were resistant to meth ic i l l in . Highest 
percentage of MRSA (35.5%) was found in pus specimens (n=151) whi le as urine 
samples (n=153) contr ibuted 25.0% of meth ic i l l in- res is tant coagutase-negat ive 
staphylococci . 29.7% of methici l l in resistant Staphylococcus aureus isolates were 
found in nasal swabs (n = 175) while as 10.0% and 16.5% of methic i l l in- res istant 
coagulase-negat ive staphylococci were observed in nasal swabs (n=50) and ocular 
cultures (n=50) respect ively. The results indicated that major reservoir of methic i l l in 
resistant staphylococci in hospitals are colonized/ in fected inpat ients and colonized 
hospital workers, with carriers at risk for developing endogenous infect ion or 
t ransmit t ing infect ion to health care workers and pat ients . The results were 
conf i rmed by restr ict ion mapping and SDS-PAGE protein prof i les of cl inical and 
carrier methic i l l in-resistant staphylococcus aureus Isolates. The mult iple drug 
resistance of all MRSA (n=180) and MRCNS (n=76) isolates was detected. In case of 
both methic i l l in-resistant as well as methic i l l in-sensi t ive s taphylococcal isolates zero 
resistance was found to fusidic acid and vancomycin whi le as highest resistance was 
found to penici l l in G fol lowed by ampic i l l in . 
Select ive methic i l l in-resistant staphylococcal isolates were subjected to plasmid 
isolat ion and curing treatments to study their mode of res is tance. The plasmids were 
t ransformed into ant ibiot ic sensit ive Escherichia coli Strain DH5-a. In one of the 
experiments plasmid pJMRIO from Staphylococcus aureus coding for ampici l l in (A^), 
gentamicin (G') and amikacin (Ak') resistance was t ransformed into Escherichia Coli. 
Transformat ion eff ic iency was about 2 x 10^ t ransformants/ng of plasmid DNA. The 
minimal inhibitory concentrat ions (MICs) for A and G were lower in E. coli than in S. 
aureus. However, the MIC for AK was higher in £. coli t ransformants than in S. 
aureus. In one of Conjugat ion Studies transfer of erythromycin resistance was 
observed between cl in ical and carrier strains of Staphylococcus aureus. Furthermore 
Enzyme mediated resistance part icularly through /?- lactamase and chloramphenicol 
acetyl t ransferase was studied in selected strains. The substrate profi le of /3-
lactamase so extracted was studied against di f ferent c lasses of penci l l ins and 
cephalospor ins. The results indicated that Methic i l l in remains the most stable 
penci l l in to the staphylococcal /?- lactamase. 
The widespread occurrence and disseminat ion of /?- lactamase and PBP mediated 
resistance leading to mult iple ant ibiot ics inef fect ive, thus increasing the cost of 
health care, needs to be tackled logist ical ly by wise and jud ic ious use of existing 
ant ibiot ics and by developing ideal and cost effect ive ant ib iot ics having least 
chances of acquir ing resistance. Furthermore the hospital acquired MRSA infections 
through colonizat ion of patients and hospital workers demands appropriate and 
timely measure to counteract this health problem. 
CHAPTER-1 
INTRODUCTION 
Biochemical research in drug resistance demands its fundamental 
understanding at molecular grassroots level, and by unraveling the secrets 
of complexity of this emerging threat to human welfare, we can identify and 
devise logistic strategies for counteracting successfully the anti-
chemotherapeutic mechanisms underlying microbial drug resistance. 
The development of safe, effective antimicrobial drugs has revolutionized 
medicine in the past 60 years. Morbidity and mortality from microbial disease 
have been drastically reduced by modern chemotherapy. When antibiotics 
became widely available in the 1940s, they have been hailed as miracle 
drugs - magic bullets - able to eliminate bacteria without doing much harm to 
the cells of treated individuals.^^ Yet with each passing decade, bacteria that 
defy not only single but multiple antibiotics have emerged, and therefore are 
extremely difficult to control. '^^ ^^ Today antibiotic resistance has either 
eliminated a number of previously valuable treatments, or made treatment 
more difficult or more costly because alternative agents must now be 
used.^«'^°^ 
When penicillin became vyidely available during the Second World War, it 
was a medical miracle, rapidly vanquishing the biggest wartime killer 
infected wounds. But just four years after drug companies began mass-
producing penicillin in 1943, microbes began appearing that could resist it. 
The first bug to battle penicillin was Staphylococcus aureus.^^^ Thus, soon 
after the introduction of penicillin for clinical use a large-scale World Health 
Organization (WHO) survey showed that approximately 8% of strains were 
resistant; by 1956 the value was about 70%, consequently the emergence of 
multiply resistant S. aureus strains were responsible for many outbreaks of 
hospital infections during the 1950s.''^ ^ 
The predominance of p-lactamase producing staphylococci in the 1950s led 
to an urgent search for p-lactamase stable penicillins that could be used for 
chemotherapy. The discovery and introduction of such compounds e.g. 
methicillin, caused major decline in the incidence of multiply resistance 
S. aureus strains during the 1960s. However, during the late 1970s and early 
1980s strains of S. aureus resistant to multiple antibiotics including 
methicillin and gentamicin emerged that were responsible for outbreaks of 
hospital infections throughout the world.^^^ Such strains, referred to as 
MRSA (methicillin-resistant S. aureus), not only cause difficulty in hospitals 
but spread from them to nursing homes and to surrounding communities. 
The pattern of resistance exhibited by MRSA imposes serious constraints on 
the choice of antibiotics for therapy since the organisms involved are 
resistant to virtually all the antibiotics in the clinician's armamentarium, a 
stockpile of more than 150 drugs. Vancomycin has become the antibiotic of 
last resort, the only remaining drug effective against the most deadly of all 
hospital-acquired infections, methicillin-resistant Staphylococcus aureus. 
And yet vancomycin's power - like that of the great, experienced warrior is 
itself in jeopardy. In 1998 vancomycin-resistant S.aureus emerged in three 
geographic locations that has increasingly worried physicians and hospital 
workers.^^^'^^' 
Increasing reliance on vancomycin has led to the emergence of vancomycin-
resistant enterococci (VRE), bacteria that infect wounds, the urinary tract 
and other sites. Until 1989 such resistance had not been reported in U.S. 
hospitals but by 1993, more than 10% hospital acquired enterococci 
infections reported to CDC were resistant. Streptococcus pneumoniae 
causes thousands of cases of meningitis and pneumonia and 7 million cases 
of ear infections in the United States each year. Currently, about 30% of S. 
pneumoniae isolates are resistant to penicillin, the primary drug used to treat 
this infection. Many penicillin-resistant strains are also resistant to other 
antimicrobial drugs. In sexually transmitted disease clinics that monitor 
outbreaks of drug resistant infections, doctors have found that more than 
30% of gonorrhea isolates are resistant to penicillin or tetracycline, or both. 
In recent years there has been a global resurgence of old foe - tuberculosis 
as strains of multidrug resistant tuberculosis (MDR-TB) have emerged and 
pose a particular threat to people infected with HIV, whereby the depressed 
cell-mediated immunity of such individuals lead either to reactivation of a 
previously latent M. tuberculosis infection or susceptibility to a newly 
acquired infection. Diarrheal diseases cause almost 3 million deaths a year-
mostly in developing countries, where resistant strains of highly pathogenic 
bacteria such as Shigella dysenteriae, Campylobacter, Vibrio chloerae, 
Escherichia coli and Salmonella are emerging. A potentially dangerous 
"Superbug" known as Salmonella typhimuhum, resistant to ampicillin, salfa, 
streptomycin, tetracycline and chloramphenicol, has caused Illness in 
Europe, Canada and the United States. Infections caused by some multiply 
resistant strains of Acinetobacter and Pseudomonas aeruginosa are now 
virtually untreatable. Likewise resistance to antimalarial, antifungal and 
antiviral drugs is of increasing concern.'*° '^*^^ 
The extraordinary speed with which antibiotic resistance has spread 
amongst bacteria during the era of chemotherapy has been due, in large 
measure to the remarkable genetic flexibility of this group of organisms. 
Since the evolutionary history of living organisms is concerned with their 
adaptation to the environment, the adaptation of microorganisms to the toxic 
hazards of antimicrobial drugs is therefore probably inevitable.^ ®'^ ^ 
At last six pathways^ '^'^ '^^ ^ '^^ ^ '^*"^ may be involved in the appearance or 
spread of resistance in bacteria: 
(i) Introduction of a few resistant organisms into a population where 
resistance previously was not present. 
(ii) Acquisition of resistance by a few previously susceptible strains 
through genetic mutation. 
(iii) Acquisition of resistance by a previously susceptible strain through 
transfer of genetic material. 
(iv) Emergence of inducible resistance that is already present in a few 
strains in the population. 
(v) Selection of a small, resistant subpopulation of organisms. 
(vi) Dissemination of inherently resistant organisms locally within the 
setting. 
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Figure 1.1 A Scheme Showing the Route by which Antibiotic Resistance 
Genes are Acquired by Bacteria by Response to the Selection Pressure of 
Antibiotic Use. The resistance gene pool represents potential sources of DNA 
encoding antibiotic resistance determinants in the environment: this includes 
hospitals, farms, or other microenvironments where antibiotics are used to 
control bacterial development. After uptake of single or double stranded DNA 
by the bacterial host, the incorporation of resistance genes into stable replicons 
(DNA elements capable of autonomous replication) may take place by several 
different pathways, which have not yet been identified. The involvement of 
integrons, as shown here, has been demonstrated for a large class of 
transposable elements in the Entereobacteriacae. The resulting resistance 
plasmids could exist in linear or circular form in bacterial hosts. The final step in 
the cycle - dissemination - is brought about by different gene transfer 
mechanisms.^ ^ ^ 
Disease causing microbes thwart antibiotics by interfering with their 
mechanisms of action. For example, penicillin kills bacteria by attaching to 
their cell walls, then destroying a key part of the wall. The wall falls apart, 
and the bacterium dies. Resistant microbes however, either alter their cell 
walls so that penicillin can't bind or produce enzymes that dismantle the 
antibiotics. In another scenario, erythromycin attacks ribosomes, structures 
within a cell that enable it to make proteins. Resistant bacteria have slightly 
altered ribosomes to which the drug cannot bind. The ribosomal route is also 
how bacteria become resistant to the antibiotics tetracycline, streptomycin 
and gentamicin. 
Antibiotic resistance can be divided into seven basic groups^ ^®'^ ^^ '^ '^^ ® '^^ ®^ 
depending on the mechanism involved: 
• the presence of an enzyme that inactivates the antimicrobial agents; 
• the presence of an alternative enzyme for the enzyme that is inhibited 
by the microbial agent; 
• a mutation in the antimicrobial agent's target which reduces binding of 
the antimicrobial agent; 
• posttranscriptional or posttranslational modification of the 
antimicrobial agent's target, which reduces binding of the 
antimicrobial agent; 
• reduced uptake of the antimicrobial agent; 
• active efflux of the antimicrobial agent; and 
• overproduction of the target of the antimicrobial agent. 
It is an established fact that acquired resistance to antimicrobial agents is 
more common in microorganisms isolated from hospital patients than in 
organisms causing community acquired infections. Hospitals and nursing 
homes provide an environment in which antibiotic resistant strains collect, 
concentrate and are maintained by a higher level of antibiotic usage than is 
normally found in the community. Antimicrobial agent-resistant bacteria may 
be introduced into hospitals and nursing homes by two different routes. They 
may emerge endogenously in patient's flora during course of antimicrobial 
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Figure 1.2 Mechanisms of Antibiotic Resistance in Bacteria. Antibiotic-
resistant bacteria owe their drug insensitivity to resistance genes. For example, 
such genes might code for "efflux" pumps that eject antibiotics from cells (a). Or 
the genes might give rise to enzymes that degrade the antibiotics (b) or that 
chemically alter and inactivate the drugs (c). Resistance genes can reside on 
the bacterial chromosome or, more typically, on small rings of DNA called 
plasmids. Some of the genes are inherited, some emerge through random 
mutations in bacterial DNA, and some are imported from other bacteria. 
(Reproduced from: Levy SB, 1998, The challenge of antibiotic resistance, 
Scientific American) 
http.7/www.sciam.com/1998/0398issue/0398levvbox2.html 
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therapy, or they may enter with new residents who are already colonized or 
infected. Under antimicrobial chemotherapy the suppression of the normal 
flora - benign bacteria - innocent bystanders clearly creates a partial void 
that tends to be filled by resistant organisms from the environment or from 
other parts of the body. Such organisms behave as opportunists and may 
become pathogens. Hospital staffs and patients carry these so-called 
hospital strains and can cause epidemics of infections that were unknown 
before the antibiotic era.^ '*'^ ^^ 
Infections caused by antibiotic resistant staphylococci especially methicillin-
resistant Staphylococcus aureus (MRSA) are a growing concern, 
particularly among patients in intensive care and surgical units, 
immunocompromised patients, and elderly patients in hospitals and nursing 
homes. Nasal carriage is a significant contributor to the epidemiology and 
pathogenesis of these healthcare associated infections.^^ '^'*^ '^^ °° Molecular 
biological studies in S. epidermidis endophthalmitis demonstrated that 
eyelid; conjunctiva or nose isolates were indistinguishable from intra-ocular 
isolates in up to 82% of patients with post-operative endophthalmitis, 
suggesting that the commonest source of infection is the patient's own 
flora."'^ The epidemiological pathways include endogenous spread, 
postoperative surgical wound infections, contaminated environmental 
surfaces, and patient-to-patient spread, frequently from patient to healthcare 
worker to patient. Moreover, there is now increasing evidence of the 
appearance of MRSA in the community.^''^'^^''^^ 
Scientists and health professionals agree that decreasing the incidence of 
antimicrobial resistance will require improved systems for monitoring and 
controlling outbreaks of drug-resistant infections, developing new antibiotics, 
and a more judicious use of antimicrobial drugs.^^^•^°^ Understanding 
resistance offers the possibility of overcoming it, and so scientists also 
recognize the critical role that basic research plays in responding to this 
problem. These studies seek to define how bacterial pathogens acquire, 
maintain and transfer antibiotic-resistance genes. For example, studies of 
microbial physiology help scientists understand the biological processes that 
pathogens use to resist drug treatment. This knowledge can lead to the 
development of novel strategies to overcome or reverse these processes.^^^ 
Investigations in molecular genetics and biochemistry with the aid of rapid 
improvements in gene sequencing technology are making it faster and 
easier to pin point the actual pathways and molecules involved in drug 
resistance. For examples, the studies of the molecular basis of drug 
resistance in micro-organisms have lead to the development of molecular 
tools to identify drug resistant strains, the identification of the genetic basis of 
resistance and resulting biochemical alterations in drug resistant species; the 
identification of methods to reverse resistance; and synthesis of drugs that 
are effective against drug-resistant strains of various pathogens. 
1.1 OBJECTIVES OF THE PRESENT STUDY 
In view of the significance and magnitude of the problem, the proposed 
research, 'Biochemical Studies on Antibiotic Resistance among 
Staphylococci from Eyes and Other Clinical Sources in Health and Disease' 
was undertaken with following aims and objectives: 
1. Isolation of staphylococcal strains from eyes and other clinical sources 
in health and disease and their subsequent identification based on 
cultural, morphological and biochemical characteristics. 
2. Determination of antibiotic resistance patterns of staphylococcal isolates 
from eyes and other clinical sources in health and disease against 
different classes of antibiotics. 
3. Comparative study of antibiotic resistance profiles of methicillen-
resistant and methicillin-sensitive staphylococcal isolates from eyes and 
other clinical sources in health and disease. 
4. Comparative study of antibiotic resistance patterns of Staphylococcus 
epidermidis isolates from nose and clinically symptomatic eyes of 
patients having ocular infections, and normal eyes of hospital workers. 
5. Comparative study of antibiotic resistance profiles of Staphylococcus 
aureus isolates from different clinical sources of patients having various 
infections, and nose of hospital workers. 
6. Comparative study of antibiotic resistance profiles of Staphylococcus 
aureus isolates from wound infections and nose of patients, and nose of 
hospital workers in an Orthopaedic Surgical Ward. 
7. Susceptibility testing and MIC determination of new antimicrobials 
against MRSA by agar diffusion, macrodilution and microdilution 
methods. 
8. Isolation and characterization of plasmids from methicillin-resistant and 
methicillin-sensitive staphylococci. 
9. Comparative study of plasmid profiles of methicillin-resistant and 
methicillin-sensitive Staphylococcus aureus isolates. 
10. Comparative study of plasmid profiles of methicillin-resistant and 
methicillin-sensitive Staphylococcus epidermidis isolates. 
11. Transformation studies of staphylococcal isolates with known resistance 
markers. 
12. Plasmid curing studies of staphylococcal isolates with known resistance 
markers. 
13. Detection of conjugal transfer of antibiotic resistance among and 
between Staphylococcus aureus and Staphylococcus epidermidis. 
14. Role of local environment of eye especially lower temperature on the 
transfer of antibiotic resistance in staphylococcal isolates. 
15. DNA fingerprinting analysis of methicillin-resistant and methicillin-
sensitive Staphylococcus aureus isolates. 
16. SDS-PAGE protein patterns of methicillin-resistant and methicillin-
sensitive Staphylococcus aureus isolates. 
17. Study of /3-lactamase and chloramphenicol acetyl transferase (CAT) 
from methicillin-resistant and methicillin-sensitive Staphylococcus 
aureus isolated strains. 
CHAPTER-2 
REVIEW OF THE LITERATURE 
Few developments in the history of medicine have had such a profound 
effect upon human life and society as the development of the power to 
control infections due to micro-organisms.'*^^ World has been freed from the 
devastating disease that in earlier days decimated the population leaving a 
trail of misery and social disruption. No longer is surgery a desperate gamble 
with human life. The perils of childbirth are greatly lessened with the control 
of puerperal fever. The death of children and young adults from meningitis, 
tuberculosis and septicaemia, once commonplace is now a rarity. Research 
on antibiotics has contributed greatly to progress in chemotherapy of human, 
animal, and plant diseases, finding useful agents, developing modern 
techniques and processes of production, isolation, and identification of 
microbial products, and elucidating their structures, biosynthesis and 
mechanism of action. ^ ^^  All these benefits are now accepted without 
question, but from the first resistance to the antibacterial agents announced 
itself as a potential problem.^°^ Sulphonamide resistance was evident 
through in vitro testing and animal experiments at an early stage. The 
discovery that microorganisms could produce an enzyme that destroyed 
penicillin was made almost as soon as the therapeutic potential of the drug 
itself was realized.^ All subsequent compounds have brought greater or less 
problems of resistance in their train and no systematic antimicrobial agent 
has yet been discovered that has proved to be beyond the ingenuity of 
micro-organisms to outwit.''^ Bacteria are proved to be wily warriors, but 
even so, we have given them- and continue to give them - exactly what they 
need for their stunning success. By misusing and overusing antibiotics, we 
have encouraged super-races of bacteria to evolve.^^ '^^ ^ '^^ "^ Moreover, 
advances in microbial biochemistry, physiology and genetics that have 
paralled the development of antibacterial drugs have revealed an 
astonishing versatility, not only in the ways in which microbes can avoid or 
overcome the anti microbial assault but also in their capacity to share and 
disseminate that ability among their kind. ^^ '^'^  
2.1 HISTORY OF ANTIMICROBIAL CHEMOTHERAPY 
The history of antimicrobial chemotherapy can be devided into two major 
phases - ancient chemotherapy which takes us about 1600 A.D., and 
modern, which extends into the present. The origin of chemotherapy is lost 
in antiquity, but has some interesting points. All the ancient medicines, for 
example included eating earth, the favourite being red or yellow having a 
strong smell, or being greasy. These earths would be comparatively rich in 
moulds and may even have had a beneficial effect. Hippocrates, in 460 B.C., 
was the first to realize that disease was not caused by the anger of the 
Gods, by evil, or by magic, but rather by miasmata - impurities in the air, 
from this time the importance of magic and spells waned in their use until 
Aristotle, 150 years later, observed that phthisis, leprosy, scabies and, 
plague could be transmitted by contagion. This heralded the begning of 
medicine as a subject, which could be studied in its own right. From then 
until the 16'*^  Century little progress was made.^ ^® 
Modern antimcrobial chemotherapy developed In three eras. The first, which 
lasted from about 1600 to 1900, involved the use of an extract of the bark of 
the Cinchona tree to treat malaria successfully and the subsequent 
development and use of other alkaloids. The first recorded treatment of 
malaria with an extraction of Cinchona bark is the wife of the Spanish 
Governor of Peru. Other alkaloids included extracts of the root of 
ipecacuanha for amoebic dysentery, a remedy widely used in Brazil and Asia 
and introduced into Europe early in the seventeenth century. The active 
constituent is the alkloid ametine, identified in 1817 and shown to be 
effective against amoebic dysentery in 1891.^ ®^ 
The second era is that of synthetic compounds which began around 1900. 
The first success came from Germany, where Ehrlich's work laid the 
foundation upon which all anti-microbial chemotherapy is built. Ehrlich began 
his scientific career in Koch's laboratory (The founder of modern 
bacteriology). In 1906, in a speech at the opening of the institute he was to 
direct, he first described precisely this theory of substances, which would 
seekout and destroy microbes - the magic bullets - and he coined the word 
'Chemotherapy' to describe his work. Later, in 1909, when Hata 
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demonstrated in Ehrlich's institute that syphilis could be made to infect 
rabbits, work to find a cure was intensified. At that time 10 percent of the 
French population died of syphilis and 6 percent in Germany. The 
effectiveness of Salvarsan in treating syphilis was a milestone in 
chemotherapy. Because of some unpleasant side effects, a derivative-
neolsalvarson- was introduced in 1912. Subsequently, more drugs were 
developed as an extension of Ehrlich's work, the most notable being 
suramin, introduced in 1920, developed from Trypan red and having useful 
activity against transpanosomiasis and mepacrine (quina crine, atebrlne), 
first introduced in 1933, developed from methylene blue, as a an effective 
antimalarial agent of particular value in the Second World War. The 
interaction of chemical agents with micro-organism was recognized by 
another early scientist, Joseph Lister, who was the first scientist to study the 
inhibitory effect of chemicals on bacteria and to directly apply this knowledge 
to the practice of medicine Lister used phenol (1960s) to sterilize surgical 
instruments and in doing so greatly reduced the mordibidity and mortality 
rates associated with surgery at that time.^ ® The next major step forward 
came in 1935 when Domagk in Germany began work on the effect of a 
number of dyes on mice infected with streptococci. One compound, 
prontosil, was effective and Domagk even had the courage to use it on his 
daughter, who was desperately ill from a streptoccal infection, before the 
drug had been tested in humans. The giri recovered dramatically. Prontosil 
was the first of the sluphonamides. The observation by the husband and wife 
team, the Trefouels, in the Pasteur Institute that prontosil was ineffective in 
vitro indicated that animals and humans converted the drug to an active 
component, which was the agent lethal to bacteria. Domagk quickly 
discovered that the drug hydrolysed to give suphanilamide.^^^ In 1938 
another sulphonamide, sulphapyridine, was produced by May and Baker 
Ltd., Dagenham, and became famous as M & B 693. This drug was 
spectacularly successful against pneumonia, meningitis, staphylococci and 
gonorrhoea. Notable achievements of synthetic antimicrobial agents since 
1935 include isoniazid, p-amino salicydic acid and ethionamide for 
tuberculosis and nitroimidazole drugs for infections by anaerobes, amoebic 
dysentery, trichomoniasis and radiosensitisation of hypoxic tumours. 
The third era of modern chemotherapy called the antibiotic era, although 
began in 1929 with Fleming's discovery of penicillin from Penicillum notatum, 
the real beginning was the recognition by Florey^® and his team of the 
chemotherapeutic potential and potency of the drug. The announcement in 
1940 marks the beginning of the antibiotic revolution, which still continues 
today. Pencilln was used in the 1940s with enormous success against 
gonorrhoea, scarlet fever, pneunrionia and meningitis, and began to replace 
sulphonamides in the treatment of puerperal fever and neosalvarson for the 
treatment of syphilis.^^^ The systematic search, by an ingenious method, for 
an organism which could attack pyogenic cocci, conducted by Dubos^^°'' in 
New York, led to the discovery of tyrothricin (garmicidin + tryrocidine), 
formed by Bacillus brevis, a substance which although too toxic for systemic 
use in man, had in fact a systemic curative effect in mice. This work exerted 
a strong influence in inducing Florey and his colleagues to embark on a 
study of naturally formed anti-bacteria! substances, and penicillin was the 
second on their list. Florey '^*®'' gave a revealing account of these early 
developments in a lecture with the intriguing title "The Use of 
Microorganisms as Therapeutic Agents": This was amplified in a later 
publication.^^^*" 
Two important events in the 1950s allowed the development of 
semisynthetic pencillin. First, the total synthesis of 6-aminopenicillanic acid 
(6APA) was achieved."^^^ Subsequently Rolinson and colleagues for 
Beecham Research Laboratories^^ showed that many bacteria produce 
acylases capabaie of yielding 6APA from benzylpencillin. 
Hundreds of new antibacterial agents have been described in the world 
literature during the last 60 years. There have been many flase dawns, but 
relatively few compounds have survived the stages of development and 
licensing to reach the pharmacist's shelf. The dates of discovery and 
sources of the principal antibiotics are given chronologically in Table 2.1.^^^ 
Througout this period there has been a tremendous progress in the field of 
antibiotic research particularly the development of analogues of existing 
drugs, stable to enzymatic inactivation, able to circumvent efflux 
mechanisms or able to bind to modified target sites. For example, linezolid 
representing a new class of antimicrobials, oxazolidinones, was approved in 
the United States in early 2000/^^ and was indicated for the treatment of 
patients with infections caused by vancomycin-resistant entercocci (VRE) 
and methcillin-resistant Staphylococcus aureus (MRSA).^'*° The regulatory 
approval provided cautions aptimism in light of the growing resistance rates 
among Gram-positive organisms, which have necessitated the rapid 
development of newer agents such as linezolid, streptogramin combination 
(quinupristin/dalfopristin) and other novel antimicrobial agents 
(everninomicins, lipopeptides, glycylcyclines etc) to combat the resistance/^ 
Table 2.1 Date of Discovery and Source of Natural Antibiotics 
Name 
Penicillin 
Tyrothricin: Gramicidin 
Tryrocidine 
Griseofulvin 
Streptomycin 
Bacitracin 
Cholramphenicol 
Polymyxin 
Framycetin 
Chlortetracycline 
Cephalosporin C, N, and P 
Neomycin 
Oxytetracycline 
Nystatin 
Erythromycin 
Oleandomycin 
Spiramycin 
Date of 
Discovery 
1929-1940 
1939 
1939 
1944 
1945 
1947 
1947 
1947-1953 
1948 
1948 
1949 
1950 
1950 
1952 
1954 
1954 
Microbe 
Pencillium notatum 
Bacillus brevis 
Penicillium griseofulvum, 
Dierckx 
Streptomyces venezuelae 
Bacillus licheniformis 
Streptomyces venezuelae 
Bacillus polymyxa 
Streptomycesm lavendulae 
Streptomyces aureofaciens 
Cephalosporium sp. 
Streptomyces fradiae 
Streptomyces rimosus 
Streptomyces noursei 
Streptomyces erythreus 
Streptomyces antibioticus 
Streptomyces ambofaciens 
Novobiocin 
Cycloserine 
Vanconnycin 
Rifamycin 
Kanamycin 
Nebramycins 
Paromomycin 
Fusidic acid 
Spectinomycin 
Lincomycin 
Gentamicin 
Josamycin 
Tobranmycin 
Ribostamycin 
Butirosin 
Sissomicn 
Rosaramicin 
2.2 ANTIBIOTICS 
1955 
1955 
1956 
1957 
1957 
1958 
1959 
1960 
1961-1962 
1962 
1963 
1964 
1968 
1970 
1970 
1970 
1972 
Streptomyces spheroides 
Streptomyces orchidaceus 
Streptomyces orientalis 
Streptomyces mediterranei 
Streptomyces kanamyceticus 
Streptomyces tenebraues 
Streptomyces rimosus 
Fusidium coccineum 
Streptomyces flavopersicus 
Streptomyces lincolnesis 
Micromonospora purpurea 
Streptomyces narvonensis 
Streptomyces tenebraeus 
Streptomyces ribosidificus 
Bacillus circulans 
Micromonospora myosensis 
Micromonospora rosaria 
Antibacterial agents comprise a large group of substances that inhibit 
bacterial growth (bacteriostatic agents), cause bacterial death (bactericidal 
agents), or destroy spores (sporicidal agents). Some bactericidal agents are 
also sporicidal and vice versa, but bacteriostatic agents are ineffective 
against resting spores. Antibacetrial agents include disinfectants, 
antiseptics, preservatives and antibiotics. By tradition, bactericidal 
agents, which are used on inanimate objects, are termed 'disinfectants'. 
Disinfectants include antibacterial agents that are usually too toxic, irritant or 
corrosive to be applied to body surfaces or tissues, but are suitable for 
disinfection of equipment or the inanimate environment. Antiseptics include 
bacterial inhibitors that are sufficiently free from toxic effects to be applied to 
body surfaces or exposed tissues and are agents, which should assist and 
not impair natural defence systems of the body. Although antiseptics have 
greater selective activity against bacteria than disinfectants, they are not 
suitable for the treatment of infections by systemic adminstration. 
Preservatives are frequently added to pharmaceutical, cosmetic and food 
products to inhibit bacterial contamination and proliferation and hence 
prevent infectivity or spoilage.'*"^ The term 'biocide' includes disinfectants, 
antiseptics, and preservatives. It does not include antibiotics, which, inspite 
of being biocides in the strictest sense, tend to be categorized separately.^^° 
Antibiotics are low-molecular-weight microbial metabolites that at low 
concentrations inhibit the growth of other microorganisms. A low - molecular 
- weight substance is a molecule with a defined chemical structure having a 
relative mass of atmost a few thousand. We do not include among the 
antibiotics those enzymes, such as lysozym.e from man, essential oils and 
alkaloids from plants, complex proteins such as colicins, and such oddities 
as the substance in the faceces of blowfly larvae, that also have antibacterial 
properties. It is true that the word 'antibiosis' was coined by Vuillemin in 1889 
to denote antagonism between living creatures in general, but the noun 
'antibiotic' was first used by Waksman in 1942,'*^^ which gives him right to re-
define it, and definition confines it to substances produced by micro-
organisms antagonistic to the growth or life of others in high dilution. The 
specifier "at low concentration" or "high dilution" is added to the definition, as 
even normal cell components and metabolic products as organic acids, 
hydrogen peroxide and alcohol can cause damage at excessive 
concentrations. For example, glycine, one of the constituents of every 
protein, has a strong bacterial effect on some bacteria if it is present in the 
culture medium in high concentrations. With the term "low concentration" we 
generally mean values well below 1mg/ml. ^ ^^  
2.2.1 CLASSIFICATION OF ANTIBIOTICS 
Since antibiotics exhibit a wide variety of properties the simplest way to 
categorize them is according to their structure and mechanism of action. In 
order to include both synthetic and microbiologically produced drugs, here 
the classification of general antimicrobial agents is described. 
2.2.1.1 Classification Based on Structure 
1. Beta - lactams 
The p - lactam antibiotics are the most varied and widely used of all the 
groups of antimicrobials. Starting from the discovery of benzylpenicillin in 
1928 and its first clinical use in 1940, numerous natural and synthetic. 
Compounds have been described based upon the active structure of 
penicillin - cyclic amide - the p-lactam ring. p-Lactams account for 50% of 
all systemic antimicrobial use. Their success reflects low toxicity and the 
availability of so many derivatives. Apart from mycobateria, intracellular 
pathogens, and cellwall deficient-species, few bacteria resist all of the p -
lactams now available. 
The main classes of beta - lactams based upon the nature of the cycle or of 
heteroatom included in the cycle (Table 2.2) are: 
Table 2.2 Diversity of Beta-lactam Antibiotics; Main Ring Structures, 
Names and Representative Antibiotics ^ °^ 
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Group I: 
Penicillins 
(i) Natural Penicillin (with a five - membered ring containing sulfur 
atom): Pencillin V (Phenoxy mettiayipenicillin); Pencillin G 
(BenzyipeniciHin) 
(ii) Penicillinase- resistant Penicillin: Flucloxacillin, NafciHin, 
Methicillin, Cioxacillin, Oxacillin 
(iii) Amino penicillin: Ampicillin, Amoxycillin 
(iv) Carboxypenicillin: Carbenicillin, Ticarcillin 
(v) Ureidopenicillin: Piperacillin, Mezlocillin, Aziocillin 
(vi) Other Penicillins: Temocillin, Mecillinam 
Group II: 
Cephalosporins - Six - membered unsaturated rings with sulphur atom 
(cephems) 
ii) First-generation: Cephalexin, Cefazolin 
iii) Second-generation: Cefuroxime, Cefoxitin 
iv) Third-generation: Cefixime, Ceftriaxone, Ceftazidime, 
Cefotaxime 
v) Fourth-generation: Cefepime 
Group III: 
Manobactam (cyclic amides ina four-membered ring): Aztreonam 
Group IV: 
Carbapenems (five membered ring with a double bond): Imipenem, 
Meropenem 
Group V: 
Beta-lactamase inhibitors: (contain a five - membered ring with an oxygen 
heteroatom) Clavulanic acid (+ amoxicillin), Clavulanic acid (+ ticarcillin), 
Salbactam (+ ampicillin), Tazobactam (+ piperacillin) 
2. Aminoglycosides 
Streptomycin, Neomycin, Kanamycin, Tobramycin, Paromomycin, 
Gentamicin, Sisomicin, Amikacim, Netilmicin 
Amikacin and Nelilmicin are semisynthetic aminoglycosides, derived from 
Kanamycin and sisomicin respectively. The suffix 'mycin' and 'micin' 
indicates that the compound was isolated directly or indirectly from 
Streptomyces spp. or Micromonospora spp., respectively. 
3. Tetracyclines 
Chlortetracycline, Oxytetracycline, Tetracycline, Demeclocycline, 
Methacycline, Doxycycline, Minocycline 
4. Quinolones 
Norlfloxin, Ciprofloxacin, Ofloxacin, Pefloxacin Sparfloxacin, Trovafloxacin, 
Levofloxacin, Nalidixic acid, Cinoxacin. 
The last two are quinolones while the rest are fluroquinolones 
5. Glycopeptides 
Vancomycin, Teicoplanin 
6. Macrolids 
Erythromycin, Roxithromycin, Azithromycin, Oleandomycin, Clarithromycin 
7. Lincosamides 
Lincomycin, Clindamycin 
8. Streptogramins 
Pristinamycin, Virginiamycin, Synercid, Quinupristisn, Dalfopristin 
9. Phenicols (nitrobenzene derivative) 
Chloramphenicol, Thiamphenicol 
10. Sulfonamides 
Sulfadiazine, Sulfamethoxazole, Para-aminosaiicylic acid (PAS), Sulfadoxine 
11. Trimethoprims (diaminopyrimidines) 
Trimethoprim, pyrimethamine 
12. Ansamycins 
Rifampin 
13. Fosfomyclns 
Fasfomycin 
14. Nitrofurantoins 
Nitrofurantoin, Furazolidone 
15. Polypeptide antibiotics 
Polymyxin B, Colistin, Bacitracin, Tyrothricin 
16. Nicotinic acid derivatives 
Isoniazid, Pyrazinamide, Thionamide 
2.2.1.2 Classification Based on Mechanism of Action 
The establishment of an infection in humans and animals by a pathogenic 
bacterium usually involves the following steps: (a) Attachment to the 
epithelial surfaces of the respiratory, alimentary or urogenital tract; (b) 
penetration of the epithelial surfaces by the pathogen; (c) interference with or 
evasion of, host defence mechanism; (d) multiplication in host tissues; (e) 
damage of the host's tissues. Steps (a) and (b) do not occur if the bacterium 
is introduced into the host directly through the skin by trauma or vector bite. 
Antibiotics usually prevent step (d) either by killing the pathogens or by 
slowing their growth to the point where host defence mechanisms can clear 
the infection. Since antibacterial agents exhibit a very wide variety of 
properties, the simplest way to categorize them is according to their site of 
action in the bacterial cell: agents acting on bacterial cell wall; agents acting 
on bacterial protein synthesis; agents acting on nucleic acid synthesis; 
141,485,488 g^^^ agents acting on bacterial cell membrane (Table 2.3- Table 2.4 
and Table 2.5).^^''^"'''2 
Table 2.3 Classifications of Antibacterial Agents According to their Site 
of Action 
Cell wall 
synthesis 
Penicillins 
Cephalosporins 
Other p-lactams 
Glycopeptides 
Bocitracln 
Cycloserine 
Fosfomycin 
Isoniazid 
Protein 
synthesis 
Aminoglycosides 
Chloramphenicol 
Tetracyclines 
Macrolides 
LIncosamides 
Fusidic acid 
Streptogramins 
Mupirocin 
Nucleic acid 
synthesis 
Sulphonamides^ 
Diaminopyrimidines" 
Quinolones 
Rifamycins 
Nitroimidazoles 
Nitrofurns 
Novobiocin 
Cell 
membrane 
Polymixins 
Gramicidin 
Tyrocidine 
Valinomycin" 
Monensin" 
^Indirect action on nucleic acid synthesis 
''Not used in human medicine 
Table 2.4 Inhibitory Effects of Antibiotics and Chemotherapeutic 
Agents Interfering with the Cell Wall Biosynthesis 
Drug 
Fosfomycin 
Fludalanine 
Alafosfalin 
D-Cyc!oserine 
Inhibitory effect 
Inhibition of the enzyme pyruvate-uridine-
diphosphate-N-acetylglucosamine transferase by 
S-alkylation of a cysteine residue. 
Inhibition of the enzymes alanine racemase. 
After active transport by an L, L-stereospecific 
peptide permease into the bacterial cell, 
alafosfalin is cleaved by an L,L-peptidase to L-
alanine and L-1-aminoethyl-phosphonic acid 
which inhibits the enzymes alanine racemase and 
L-alanyl-uridine-diphosphate -muramyl ligase. 
Inhibition of the enzymes alanine racemase and 
D-alanine synthetase. 
Bacitracin 
Vancomycin and ristocetins 
Penicillins and cepalosporins 
Thienainycin 
Mecillinam 
Inhibition of the pyrophosphatase which catalyzes 
the cleaves of the C55 - isoprenoid 
alcoholpyrophosphate to the corresponding 
phosphate. 
Inhibition of the cross-linking (transpeptidation 
reaction) of the peptidoglycan chains by formation 
of stable stoichiometrc complexes with the acyl-D-
alanyl-D-alanine terminus of the peptidoglycan 
chains. 
Inhibitation of several enzymes, the penicillin-
binding proteins 1A, IBs, 2, 3, 4, 5 and 6 located 
in the cytoplasmic membrane, which are involved 
in the terminal stages of peptidoglycan synthesis. 
Morphological effects on the bacterial cell (E. coli): 
at low antibiotic concentrations: inhibition of cell 
division and formation of long filamentous cells; at 
higher concentrations: inhibitation of cell 
elongation, cell lysis and release of the cell 
content as a spheroplast, which bursts unless 
osmotic protection is provided. 
Binding to the penicillin-binding proteins 1A, IBs, 
2, 3, 4, 5, and 6 with highest affinity for penicilline-
binding protein 2 and lowest affinity for protein 3. 
Morphological effect (on E. coli): at low 
concentrations: formation of large osmotically 
stable round cells; at higher concentration; cell 
lysis and release of the cell contents as a 
spheroplast. 
Higher specific binding to penicillin-binding protein 
2. 
Morphological effect (on E. coli): formation of 
large osmotically stable round cells which 
continue to grow and eventually undergo lysis. 
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Table 2.6 Inhibitory Effects of Antibiotics Affecting the Function of the 
Cytoplasmic Membrane 
Antibiotics 
Tyrociclins 
gramicidins, 
polymyxins 
Natamycin, 
nystatin, 
ampotericin B, 
hachimycin, 
candicidin 
Inhibitory Effect 
These surface-active polypeptide antibiotics increase 
the permeability of the cytoplasmic membrane and 
thus cause a massive exit of amino acids, purine and 
pyrimidine derivatives from the bacterial cell. This 
loss of important metabolites brings the biosynthetic 
reactions to standstill and leads to the deatii of the 
cell. 
These polyene antibiotics cause impairment of the 
permeability of the cytoplasmic membrane of the 
fungal cell by forming complexes with certain 
membrane steroids such as ergosterol 
2.2.2 ANTIBIOTICS AND MICROBIAL GROWTH 
When bacteria are inoculated into a grov\/th medium there is an initial lag 
phase before the onset of growth (Fig. 2.1). This is followed by a phase of 
exponential growth, the logarithmic phase. As available nutrients decline and 
toxic products accumulate, growth slows and then halts, i.e. the stationary 
pnase 105 
Antibiotics have been divided in two groups: bactericidal antibiotics (e.g. 
Pencillin), which kill or cause the lysis (dissolution) of invading bacteria, and 
bacteriostatic antibiotics (e.g. chloramphenicol), which merely inhibit 
bacterial growth and replication. Bacteriostatic agents rely on the host 
defences finally to defeat the infection and if antibiotic therapy is suspended 
microbial growth may resume. This division, however, is not clear cut, as 
bacteriostatic agents may become bactericidal if the concentration is raised 
and vice versa. 
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Figure 2.1 Effect of Antimicrobial Agents upon the Gro\A^h of 
Escherichia coii. Antibiotic Added at Time Shown by Arrow to 
Exponentially Growing Culture 
2.3 ANTIBIOTIC RESISTANCE 
Antimicrobial action leads to the interaction of the drug with the 
microorganisms, the result of which may be inhibition or death of the 
organisms or instead may be the emergence of resistance that negates the 
effect of the antibiotic.'*''^ The use of antimicrobial agents and the emergence 
of antibiotic resistance are intimately related. It has been shown on several 
occasions that use and misuse of various antibiotics has been associated 
with the emergence of resistant bacteria. However, the definition of 
resistance becomes clear when we take both microbiological as well as 
clinical aspects into consideration. 
2.3.1 MICROBIOLOGICAL ANTIBIOTIC RESISTANCE 
Microbiologically resistant isolate or species is one that processes one or 
more identifiable resistance mechanisms.^ ®^ Fleming described the 
phenomenon of resistance very clearly, if qualitatively, in initial tests of the 
antibacterial activity of penicillin: streptococci and staphylococci were 
sensitive, while Gram-negative bacilli such as Escherichia coli, were 
resistant. This is an example of inherent or intrinsic resistance, which defines 
the spectrum of an antibiotic. The spectrum may be narrow for agents such 
as benzylpenicillin or vancomycin (active against most Gram-positive 
organisms), colistin (active against most Gram-negative) or metronidazole 
(active only against anaerobes); or broad, for a wide variety of agents such 
as Tetracycline or chloramphenicol, which are active against most species of 
bacteria. When quantitative measurements of antimicrobial susceptibility are 
made, some species are clearly less sensitive than others (Figure 2.2). 
Some strains of species that are normally inherently sensitive to an antibiotic 
may later acquire resistance to the drug. This phenomenon commonly arises 
vyhen populations of bacteria have grown in the presence of the antibiotic. In 
some cases it is easily observable in vitro. For example, a culture of a strain 
of Staphylococcus aureus will contain individual organisms that are resistant 
to fusidic acid or rifampicin that grow out in the presence of appropriate 
concentrations of the antibiotic; the same phenomenon may occur in 
individual patients treated with these agents for staphylococcal infection. On 
the other hand, it may occur among clinical bacterial isolates on a 
demographic scale when the antibiotics are used extensively to treat large 
numbers of patients: this occurs to a greater or lesser extent with virtually all 
antibiotics in clinical use. The range of 'sensitive' and 'resistant' isolates of a 
given species may overlap (Figure 2.3). In such cases most sensitive 
isolates can be distinguished from most resistant ones but for the range of 
overlap it will be necessary to demonstrate that some isolates have a 
resistance mehanism not present in others. 
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Figure 2.2 Example of Distribution of the MICs of Benzylpenicillin for 
Isolates of a Sensitive Organism (Streptococcus pyogens) and a 
Resistant Organism ( Escherichia coli) 
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Figure 2.3 Distribution of the MIC of Gentamicin for Sensitive and 
Resistant Strains of Pseudomonas aeruginosa 
2.3.2. CLINICAL ANTIBIOTIC RESISTANCE 
Clinically a bacterial strain derived from a species that is susceptible to an 
antibiotic is said to be resistant when it is not inhibited to the minimal 
concentration of the antibiotic that inhibits the growth of the typical strains of 
that species.^°° This strain may of course be inhibited by a higher 
concentration of the same antibiotic. Therefore, it is obvious that the concept 
of resistance applies to a given bacterial strain, a given antibiotic and a given 
concentration. Infact a bacterial strain is considered resistant to a given 
antibiotic if it can grow in the presence of a concentration equal to or greater 
than that which the antibiotic can reach in serum or tissues. Thus, we can 
say that a sensitive isolate is one that is likely to respond to therapy with the 
agent tested and a resistant isolate is one that will not. Between the two are 
isolates of intermediate or indeterminate susceptibility, over which range a 
positive clinical response is increasingly unlikely (Fig. 2.4). In practice the 
dividing lines imposed by breakpoints may not be so clear, since populations 
may again coalesce. 
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Figure 2.4 Distribution of MICs among Bacterial Isolates that are 
Sensitive, Intermediate or Resistant to an Antibiotic 
2.3.3 SOME DEFINITIONS 
RESISTANCE 1",153,443 
Multiple-resistance 
RELATED TO ANTIBIOTIC 
When a microorganism is resistant to two or more antibiotics through 
unrelated mechanisms of resistance, one speaks of multiple resistances. 
Cross-resistance 
There are available in the market, and even more so among the cell 
physiologist's tools, many antibiotics that inhibit bacterial growth by the same 
mechanism of action. Usually a bacterial strain that is resistant to an 
antibiotic is also resistant to other antibiotics of the same family. This 
phenomenon, called cross-resistance or co-resistance, is of considerable 
practical importance. 
One-step and Multistep-resistance 
It is possible to isolate resistant mutants from a population of bacteria 
susceptible to a given antibiotic by seeding a large number of cells on a solid 
culture medium containing a concentration of antibiotic several times higher 
than the MIC. Frequently, the bacteria in these colonies are resistant not 
only to the concentration of antibiotic used for the selection but also to higher 
concentrations. This is called one-step resistance, and occurs in the case of 
certain antibiotics for which the resistance is an all or none phenomenon, 
i.e., the cells are either susceptible to low concentrations or are not inhibited 
even by high concentrations. A typical example is resistance to streptomycin. 
In the case of other antibiotic, e.g., penicillin, it is not possible to isolate 
resistance cells by the method described above. Resistance of this type can 
be selected from liquid culture media by a method inappropriately called 
training. According to this method, the bacterial strain is grown in 
concentrations of antibiotic slightly below the MIC to select the less 
susceptible cells. These then give a population that includes cells capable of 
growing in the presence of slightly higher concentrations of antibiotic. By 
repeated passages of this type and by selecting from large populations in 
liquid culture, one can obtain strains that are notably more resistant. This 
gradual acquisition of resistance, found for pencillin and several other 
antibiotics, has been termed multistep resistance. 
Resistance and Insusceptibility 
For the purpose of clarity, it is preferable to reserve the word resistant for 
those bacterial strains that derive from a susceptible species and have lost 
their susceptibility to a given antibiotic through mutation or other alteration of 
their genetic heritage. Bacterial species that are "constitutionally" not 
inhibited by an antibiotic because, for example, they lack the structure on 
which the antibiotic acts, are called insensitive or insusceptible. The 
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expression intrinsic resistance, sometimes used instead of insusceptibility, 
should be avoided as it may create confusion. 
Hypersensitive 
There is a range of susceptibilities within a species, and some isolates of 
either sensitive of resistant species may prove to be more sensitive than 
normal: such strains are more familiar in the experimental than the 
diagnostic laboratory and are usually referred to as hypersensitive. 
Antibitic Susceptibility 
Antibiotic susceptibility (sensitive strain) is usually defined by inhibition of an 
organism at concentration of antibiotic likely to be achieved in the blood after 
therapeutic doses. Ideally, the antibiotic concentration at the site of infection 
should exceed the minimum inhibitory concentration by at least two-to-four-
fold in patients with serious infection. In practice, tissue concentrations are 
not precisely known and serum concentrations are used in the assessment 
of susceptibility. 
Minimum Inhibitory Concentration (MIC) 
The MIC is defined as the lowest concentration of an antibiotic that produces 
no visible growth after overnight (16-20 h) incubation of a standard inoculum 
of the organism with a serious of dilutions of the drug in broth or agar. Many 
antibiotics are subject to inocilum density effects that may profoundly affect 
the MIC. An inoculum of 10^ colony-forming units/ml is commonly used in 
broth titrations, but the therapeutically correct inoculum has not been 
defined. 
Minimum Bactericidal Concentration (MBC) 
The MBC is usually defined as the minimum concentration of drug that 
reduces the colony count of viable organisms to les than 99.9% of its initial 
value after overnight incubation in broth: i.e. a 1000-fold reduction in the 
original inoculum. The MBC indicates the extent, but not the rate of killing, 
which may be more relevant to successful therapy in appropriate 
circumstance. Some antibiotics, notably p-lactam agents (in their action on 
Gram-positive cocci) and quinolones, exhibit an optimal dosage effect so 
that less killing is observed as the drug concentration is raised. 
Tolerance 
Organisms are said to be 'antibiotic tolerant' when the MBC exceeds the 
MIC by 16-fold or more. The term is usually used to describe staphylococci 
or streptococci that are less susceptible than usual to the bactericidal action 
of p-lactam antibiotics. The clinical significance of tolerance is usually 
uncertain, but it may have implications for the treatment of certain forms of 
infective endocarditis. 
Postantibiotic Effect 
This effect refers to the continued inhibition of an organism for a period of 
time (sometimes several hours) after the concentration of an antibiotic has 
ostensibly fallen to below the MIC. Demonstration of the phenomenon in 
virto is prone to considerable variation depending on the conditions of the 
test, and the therapeutic significance is unclear. 
Breakpoint 
The breakpoint concenrtaion of an antibiotic is the concentration used to 
judge whether an organism is considered 'sensitive' or 'resistant' in 
antimicrobial susceptibility tests. Sometimes two breakpoints are used to 
establish categories of susceptible, resistant and reduced (intermediate) 
susceptibility. The later category implies that successful therapy may be 
possible if the drug is concentrated at the site of infection (e.g. excreted in 
high concentration in urine in urinary tract infection) or that high dosage 
might be appropriate. Breakpoint susceptibility testing refers to a method in 
which the susceptibility of organism to an antibiotic is tested only at the 
agreed breakpoint or breakpoints for that antibiotic. 
Frequency of Mutants and Frequency of Mutation 
Frequency of mutants refers to the fraction of resistant cells present in a 
sensitive population. Frequency of mutation is the fraction of resistant 
mutants that originate in a population at each generation (each doubling). 
The frequency of mutants differs numerically from the frequency of mutation 
for many reasons: 
1. The number of mutants present in a population derives both from 
those originating each generation and from the offsprings of the 
mutants formed in the preceding generations; consequently, the 
frequency of mutants tends to increase generation by generation. 
2. Retromutation may occur generating susceptible cells from resistant 
ones, thus reducing the number of mutants. 
3. The rate of growth of the resistant mutants may be different from that 
of the susceptible population; if, so often is the case, the former is 
lower, the frequency of resistant mutants tends to decrease with 
further generations. 
2.3.4 HISTORY OF ANTIBIOTIC RESISTANCE 
Paul Ehrlich gave the first account of microbial drug resistance in 1907, 
when he encountered the problem soon after the development of arsenical 
chemotherapy against trypanosomiasis. As the sulphonomides and 
antibiotics were brought into medical and veterinary practice resistance 
against these agents began to emerge. The first antibiotic resistance 
mechanism was identified a little more than 60 years ago, in 1940, when 
Abraham and Chain described the presence of a penicilinnase, an enzyme 
that inactivates penicillin, in Escherichia coli. Just 4 years later Kirby^^° 
reported the presence if a similar type of enzyme in Staphylococcus aureus. 
Therefore, even before penicillin came into widespread use, resistance to 
this drug already was recognized in both Gram-positive and Gram-negative 
organisms. Thus, soon after the introduction of penicillin for clinical use, a 
large-scale World Health Organization survey showed that approximately 8% 
of strains were resistant; by 1956 the value was about 70%.^°^ In the 1970s 
reports of organisms resistant not only to the penicillin-type drugs, but 
multiple other classes of antimicrobial agents, were common, as nosocomial 
pathogens which were responsible for many outbreaks of hospital infections, 
acquired a number of new resistance genes, such as those to 
aminoglycosides, chloramphenicol, and tetracycline.''^^ The predominance of 
p-lactamase-producing staphylococci in the 1950s led to an urgent search 
for p-lactamase - stable penicillins that could be used for chemotherapy. 
The discovery and introduction of such conripounds, e.g. methicillin, caused 
a major decline in the incidence of multiply resistant S. aureus strains during 
1960s. Although Jevons first reported methicillin resistance in S. aureus in 
1961,^^^ but during the late 1970s and early 1980s strains of S. aurues 
resistant to multiple antibiotics including methicillin and gentamicin emerged 
that were responsible for outbreaks of hospital infections throughout the 
world. Such strains, referred to, as MRSA not only cause difficulty in 
hospitals but spread from them to nursing homes and to surrounding 
communities. Vancomycin, which is somewhat toxic antibiotic requiring 
intravenous administration, is often the only drug effective against such 
staphylococci. However, there are several recent reports of vancomycin 
intermediate S. aureus (VISA) infections from different parts of the 
world.'*'* '^'*^^ Moreover in the past few years a handful of organisms resistant 
to all known antimicrobial agents have emerged.^°^ Infections caused by 
some strains of enterococci, Acinetobacter, and Pseudomonas aeruginosa, 
are now virtually untreatable.^°^ Fortunately, these organisms remain rare; 
however, the conditions that favor the development and spread of such 
organisms are abundant. Therefore, we can expect resistant organisms to 
continue to emerge. 
2.3.3 REASONS FOR THE EMERGENCE OF ANTIBIOTIC RESISTANCE 
Pathways by Which Resistance Appears 
At least six pathways (Table 2.7) may be involved in the appearance or 
spread of resistance in bacteria.^°^ 
Table 2.7 Pathways of Resistance Introduction or Spread 
Pathwav: 
1. Introduction of a few resistant organisms into a population where 
resistance previously was not present 
2. Acquisition of resistant by a few previously susceptible strains through 
genetic mutation 
3. Acquisition of resistance by a previously susceptible strains through 
transfer of genetic material 
4. Emergence of inducible resistance that is already present in a few 
strains in the population 
5. Selection of a small, resistant subpopulation of organisms 
6. Dissemination of inherently resistant organisms locally within the setting 
This assumes that laboratory and surveillance artifacts, which can produce a 
false impression of resistance, have been eliminated.^^'' Both genetic 
determinants and epidemiological elements of spread are involved. Each of 
the six pathways will be considered in turn. 
Introduction of Resistant Organisms Into a Previously Susceptible 
Population 
Resistant strains often find new locales. For Example, new strains may be 
introduced in the hospital setting by way of a patient from the outside, a 
health-care worker from outside or another institution, or a contaminated 
commercial product. This is illustrated by an episode in which strains of 
Burkholderia cepacia, an organism resistant to many antimicrobials, were 
introduced into a hospital in association with a contaminated iodophor 
solution; only patients treated with the implicated solution were affected. 
Introduction of resistant strains into hospitals from nursing homes and 
extended care facilities, as well as transfer in the opposite direction from 
hospital to nursing home, has become common for certain pathogens. After 
resistant organisms are introduced into a new hsalth-care setting, they often 
are difficult to eradicate. For example, very few hospitals have been able to 
eradicate methicillin-resistant Staphylococcus aureus (MRSA) strains once 
they have been introduced, although some recent efforts were successful. 
Transfer from medical settings to the community also is common. For 
example, in some parts of the United States, MRSA strains recently became 
prominent in community-acquired infections, whereas previously they were 
prominent only in health-care institutions. ^^•^^^•'^^^ 
Genetic Mutation 
Changes in only a few base pairs, causing substitution of one or a few amino 
acids in a crucial target (enzyme, cell structure, or cell wall) can affect 
chromosomal structural or control genes leading to new resistant strains. 
The changed defense often is able to inactivate whole groups of 
antinnicrobials that were thought capable of controlling the organism for 
years to come. Hospitalized patients treated with antimicrobials prone to 
select altered resistance traits can quickly become colonized or infected with 
these resistant strains.^^^ 
Transfer of Genetic Material 
Resistance can be acquired by a previously susceptible strain from another 
species or genus. Many of the antibacterial resistance genes are on 
plasmids that can, and do transfer themselves to another genus or species 
of bacteria. Although the ability of microorganisms to exchange genetic 
information has been known for several decades, the extent of this DNA 
exchange network is far greater than researchers previously imagined. 
Exchange of genetic information even between gram negative and gram-
positive organisms has been reported, although the frequency of such 
events is hard to determine. Of particular interest is the pathway of exchange 
between staphylococci and enterococci. Already, the genes encoding p-
lactamase production and high-level gentamicin resistance have moved from 
staphylococci into enterococci. This has resulted in resistance to penicillin, 
ampicillin, and the aminoglycosides, which has in many cases eliminated the 
synergistic activity of penicillins and aminoglycosides against these 
organisms. Of greatest concern, however, is that the transfer of vancomycin 
resistance genes from enterococci to staphylococci, and in particular S. 
aureus, will occur in vivo, as has already happened in the laboratory. This 
could make some methicillin resistant S. aureus strains, which are usually 
multiply resistant, virtually impossible to treat. ^ ^^ •^ ^^ •'*^ ^ 
Many resistance genes encode proteins that either inactivate antimicrobial 
agents or block their site of action. One example of this is the TEM-type p-
lactamase, which mediates resistance to penicillin, ampicillin, and first 
generation cephalosporins by hydrolyzing the p-lactam nucleus of the drug. 
The TEM p-lactamase (the name of which was derived from the initials of the 
little girl in a London hospital from whom the first ampicillin-resistant E. coli 
was isolated) is present in more than 70% of ampicillin-resistant E. coil as 
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well as in other enteric gram-negative rods. The enzyme is normally not 
capable of mediating resistance to drugs such as ceftazidime, cefotaxime, 
and ceftriaxone, the drugs usually held in reserve for the most difficult to 
treat infections. However, a change in just 3, 2 or even a single amino acid in 
the protein sequence of the TEM p-lactamase, at or around the active site of 
the enzyme, modifies the enzyme such that other antimicrobial agents, such 
as the cephalosporins, can now be hydrolyzed.''^'*'^^'*'''°^''^° 
Emergence of Strains With Inducible Resistance 
Chromosomal determinants for resistance to a given drug may not be 
expressed until the organism comes in contact with it or similar compounds. 
When permissive conditions appear (e.g., new antibiotics in use, introduction 
of new conjugative plasmids), the resistance can be manifested rapidly. The 
trigger for emergence may be the antimicrobial agent to which resistance is 
directed. In some case, exposure to another antimicrobial results in induction 
or derepression of a determinant (enzyme, etc.) that stimulates resistance as 
well to the studies drug. ^ ^^ '^ ^^  
Selection of Resistant Stains 
Exposure to a stimulus that inhibits or kills the susceptible majority of a 
population allows a resistant subset of strains to grow at the expense of 
susceptible organisms. A minority of strains present in a given population 
may be resistant to the antimicrobial under study. The selecting factor 
usually is the antibiotic to which the subpopulation is resistant, but on 
occasion, a related agent can have a great impact as well. Non-drug factors 
such as those stimulating activity of reactions like acetylation or 
glucuronylation also can provide a selective advantage to organisms.^ '^* 
Dissemination of Resistant Strains 
Organisms can spread from patient to patient, from one patient to another 
via a health care worker (e.g., on the hands of ward personnel), in 
contaminated commercial products (e.g., antiseptics), on other inanimate 
objects, or by widespread transfer of genetic material from the initial 
organism to others. This sixth pathway of transfer can be viewed as a 
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"common denominator" for both abrupt and less-abrupt increase in 
resistance/^^"^'^^^ 
Investigating the Relative Importance of Different Pathways of 
Resistance 
Several new microbiologic techniques now are being used in conjunction 
with epidemiologic analysis to sort out the factors that play major roles in 
problems of multi-resistance. These tools can answer several questions: 1) 
Are the cases clustered by place? 2) Is there a common procedure being 
performed? 3) Are affected patients being treated with a common drug (the 
one for which resistance has developed, a drug of the same class as the one 
for which resistance has developed, or a drug that is an effective inducer? 4) 
Is the same type of resistance present in other organisms in the 
populations? 5) Are there single or multiple strains/ clones/ cassettes 
involved? These points and others must be analyzed to identify the 
pathways present and to identify selection factors (antimicrobial use etc.) 
that permit the resistant organisms to thrive. For examples, use of a 
ribosomal RNA probe allowed analysis of isolates of MRSA that were 
resistant as well to ciprofloxacin; the primary means by which reistant strains 
arose was found to be by transfer within the hospital setting (pathway 6), 
whereas mutational development of resistance in many strains at once 
(pathway 2), which was suspected initially, was not a major factor.'*^^ 
Why Does Resistance Develop? 
Most current outbreaks of resistance in hospital or community settings, and 
virtually all endemic occurrences of resistance, involve a number of these 
pathways, each to a greater or lesser degree. For example all isolates of 
multiresistant Serratia marcescens in a hospital outbreak were related to 
transmission on the hands of health-care workers who handled 
contaminated collection basins while emptying the urine catheter collection 
bags. Here, both introduction of a new organism (pathwayl) and transfer 
within the hospital setting (pathway 6) explained the episode. In addition, 
there may be several concurrent manifestations of any one of these factors 
present in a given setting. Sorting out the multiple and concurrent means 
that lead to appearance and spread of resistance is an important but difficult 
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problem. Unfortunately, even reports of abrupt increase in resistance seldom 
have revealed which of the six pathways of resistance mechanism detailed 
above were operative. Therefore, the magnitude of each means of 
appearance or spread in today's settings still is not clear. Despite these 
methodologic problems, three factors emerge as particularly important in the 
evolution of resistant microorganisms. First, simple mutations in common 
resistance genes have extended their spectrum of activity. Second, the 
exchange of genetic material (i.e. DNA) among microorganisms has moved 
some resistance genes from their original hosts into new organisms, causing 
them to become resistant to additional antimicrobial agents. Finally, the use 
of large quantities of antibiotics not just within the hospital environment but in 
community, farm, and aquaculture settings, has aided in the selection of new 
resistant organisms.2^ '^^ ^ '^^ ^ '^^ ^2 
Selective Pressure Caused by Use of Antimicrobial Agents 
Selective pressure refers to the environmental conditions that allow 
organisms with novel mutations or newly acquired characteristics to survive 
and proliferate. Mutations that increase an organism's resistance to 
antimicrobial agents occur naturally in bacteria. These mutations often 
involve changes in the cell wall that limit access of a drug to its site of action, 
or are alterations of the target site for an antibiotic. Whether the strain that 
harbors a mutation survives and replicates depends in large degree on the 
selective pressure placed on it (such as sub-inhibitory concentrations of 
antibiotics in the hospital environment). This is also true for an organism that 
acquires new DNA through genetic exchange. In an environment where 
large quantities of antimicrobial agents are present, or when inadequate 
doses of drugs are taken to eradicate infections, such as with 
Mycobacterium tuberculosis, the strains acquiring mutations or new DNA 
that lead to resistance will proliferate, whereas those susceptible to the 
antimicrobial agents will be killed. One organism that has developed 
significant levels of resistance likely in response to antibiotic pressure is 
Streptococcus pneumoniae. This organism causes more than 7 million cases 
of otitis media, 500,000 cases of pneumonia, and 3,000 cases of meningitis 
each year in the United States alone. '^* '^*^^ 
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Hospitals are usually the major breeding grounds and reservoir of resistant 
organisms. However, during the past decade, this began to change. The use 
of antimicrobial agents in animal feeds, in fish farming, and in children 
attending day care centers has provided the selective pressure for the 
development of new breeding grounds for resistant microorganisms. We are 
beginning to appreciate more fully the interrelatedness of bacterial 
pathogens causing disease in animals and humans. Thus, when quinolones 
were introduced into poultry to prevent infections in The Netherlands, strains 
of the diarrheal pathogen Campylobacter jejuni resistant to quinolones 
appeared not only in animals but in humans, too. Similar problems with 
increasing resistance to fluoroquinolones have been recognized in Spain 
and Finland. Therefore, our goal for prudent use of antimicrobial agents must 
extend beyond human medicine to include the veterinary, agriculture, and 
animal husbandry industries.''^ ^-^^ '^^ ^ '^'^ '^^ ^^ 
2A MECHANISMS OF ANTIBIOTIC RESISTANCE 
Two broad categories of antibiotic resistance are recognized: intrinsic (or 
intrinsic insusceptibility) and acquired. These categories also apply to 
biocides. The term 'intrinsic' is used to imply that inherent features of the cell 
are responsible for preventing antibiotic action and to distinguish this 
situation from acquired resistance, which occurs when resistant strains 
emerge from previously sensitive bacterial populations, usually after 
exposure to the agent concerned. Intrinsic resistance is usually expressed 
by chromosomal genes or by acquisition of plasmids and transposons. In the 
clinical setting, acquired antibiotic resistance results essentially from the 
selective pressure exerted on bacteria during the administration of antibiotics 
for chemotherapy. At the grass roots level mechanisms of antibiotic 
resistance can be learned on the basis of genetic and biochemical 
s t u d i e s . 3^9.389,402 
2.4.1 GENETIC MECHANISMS OF ANTIBIOTIC RESISTANCE 
Antibiotic resistance can be determined by genes that reside in the host cell 
chromosome, on plasmids or on transposons. The genetic basis of these 
mechanisms is outlined below.^^^ 
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2.4.1.1 Resistance Determined by Chromosomal Genes 
It is well established that resistance to certain antibiotics can be acquired by 
chromosomal mutations, i.e. changes in the base sequence of DNA. These 
mutations can be divided into two broad categories: microlesions, in which a 
single base pair has been altered, and macrolesions, in which more 
extensive changes have occurred. Both categories of mutations can be 
further subdivided. Microlesions comprise transition, transversion or frame 
shift mutations. Transition mutations involve base pair changes in which one 
purine is substituted for another purine, and consequently one pyrimidine for 
another pyrimidine. Transversions involve substitution of a purine for a 
pyrimidine and vice versa, whereas addition or loss of one or two base pairs 
constitutes a frameshift mutation. Macrolesions involve deletions, 
duplications, inversions and translocations (insertions).^^^'^^^ 
2.4.1.2 Resistance Determined by Plasmids 
Plasmids, i.e. extrachromosomal genetic elements that replicate 
independently of the chromosome, frequently carry genes that confer 
antibiotic resistance. The evolution and existence of plasmid-determined 
resistance mechanisms can be attributed to a number of factors, (a) In the 
absence of selection pressure by an antibiotic, the majority of cells in a 
particular need not maintain plasmids, thereby reducing the biochemical 
stress on the cell that would otherwise be required for replication and 
expression of plasmid DNA. (b) Genes encoded by plasmids are mobile 
because plasmids can be transferred both within and between certain 
species. Thus plasmids can be acquired from other bacteria in addition to 
inheritance from mother cells. In naturally occurring systems, plasmid 
transfer occurs by either conjugation or transduction. Conjugation is a 
process requiring cell-to-cell contact whereby DNA is transferred from a 
donor bacterium to a recipient. Transduction involves the transfer of genes 
by bacterial viruses (bacteriophages) and plays an important role in the 
natureal transmission of antibiotic resistance plasmids amongst strains of S. 
aureus and of Strep. Pyogenes.^^^-^^^ 
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2.4.1.3 Resistance Determined by Transposons 
Transposons are mobile DNA sequences capable of transferring 
(transposing) themselves from one DNA molecule (the donor) to another (the 
recipient). Unlike plasmids, transposons are not able to replicate 
independently and must be maintained within a functional replicon (e.g. 
plasmid or chromosome). 
Transposons contain at their ends short regions that in any particular 
transposon are almost identical. These regions, or repeats, as they are 
termed, can lie in the same direction with respect to each other (direct 
repeats) or, more commonly, in the opposite direction (inverted repeats). The 
terminal repeats are believed to serve as recognition sequences for 
transposition enzymes (transposases) in their role of fusing the ends of the 
transposon with the recipient DNA. The central, or core, regions of 
transposons lying between the repeated ends frequently carry antibiotic 
resistance genes (Table 2.8), in addition to genes necessary for the process 
of transposition itself.^ °2,369,335 
Table 2.8 Properties of Some Antibiotic Resistance Transposons 
Transposon Size (kilobase pairs) Resistance encoded 
Found in Gram-negative bacteria 
lr\1 
Tn2 
Tn3 
Tn5 
Tn7 
Tn9 
Tn^O 
1\\21 
Tn1721 
5.0 
5.0 
5.0 
5.1 
14.0 
2.7 
9.3 
19.0 
11.2 
Ampicillin 
Ampicillin 
Ampicillin 
Kanamycin 
Sterptomycin, trimethoprim 
Chloramophenicol 
Tetracycline 
Streptomycin, 
suiphonamides 
Tetracycline 
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Found in staphylococci 
Jn551 
Tn552 
Jn554^ 
Jn4001 
Tn4002 
Tn4003 
Jn4201 
Found in enterococci 
Tn1546 
5.3 
6.1 
6.7 
4.7 
6.7 
3.6 
6.6 
10.8 
MLS group^ 
Penicllin 
MLS group, spectinomycin 
Gentamicin, trimethoprim, 
kanamycin 
Penicillin 
Trimethoprim 
Penicillin 
Glycopeptides 
^MLS group: macrolids, lincosamides and streptogramins 
^Jn554 is unusual among transposons in that it does not possess inverted or 
direct repeat sequences at its termini. 
The existence of transposons that confer antibiotic resistance is one factor 
accounting for the emergence of multiply resistant (multiresistant) bacteria. 
Since transposons do not require extensive DNA homology to insert into the 
recipient molecule, it is possible for bacteria to acquire several different 
resistance genes by a series of transposon insertions in resident 
plasmids.^^' ' ' ' ' ' ' ' ' ' ' '° ' ' ' ' ' ' ' ' ' ' ' ' 
2.4.2 BIOCHEMICAL MECHANISMS OF ANTIBIOTIC RESISTANCE 
A variety of biochemical mechanisms for antibiotic resistance have been 
described, the most important of which are summarized in Table 2.9. 
However, it should be noted at the outset that resistance to a particular 
antibiotic could result from the combined expression of several of the listed 
mechanisms. For instance, the efficacy of a p-lactam antibiotic against a 
Gram-negative organism will be determined by the diffusion rate of the 
antibiotic across the outer membrane, its susceptibility to any periplasmic (5-
lactamase that may be present, and finally its affinity for target penicillin-
binding proteins (PBPs) located in the cytoplasmic membrane. 
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Consequently, p-lactam resistance may evolve by affecting one or more of 
these parameters.^^^'^°^ 
Table 2.9 Biochemical Mechanisms of Acquired Antibiotic Resistance 
Mechanisms 
(1) Alteration (antibiotic inactivation) 
(2) Target site in the cell in 
insensitive to the inhibitor but still 
able to perform its normal 
physiological function 
(3) Decreased antibiotic 
accumulation: 
(a) Impaired uptake 
(b) Enchanced efflux 
(4) Bypass of antibitic-sentisive step 
by duplication of the target site, the 
second version being insusceptible 
to drug action. 
(5) Overproduction of target so that 
higher antibiotic concentrations are 
needed to inhibit bacterial growth. 
(6) Absence of an enzyme-metabolic 
pathway 
Examples 
Resistance to aminoglycosides, p-
lactams, fosfomycin and 
chloramphenicol 
Resistance to aminoglycosides, p-
lactams, gylcopetides, marcolides, 
quinolones, rifampicin, trimethoprim, 
tetracycline and mupicrocin 
Resistance to many antibiotics 
Resistance to tetracycline, 
macrolides, chloramphenicol and 
quinolones 
Resistance to methicillin, 
sulphonamides, trimethoprim and 
mupircocin 
Resistance to trimethoprim 
Resistance to isoniazed in 
mycobacteria 
Biochemical mechanism of antibiotic resistance is grouped into four classes, 
i.e. as resistance to inhibitors of nucleic acid, protein, and peptidoglycan 
synthesis and of membrane integrity. 
2.4.2.1 Resistance to Inhibitors of Nucleic Acid Synthesis 
2,4.2.1,1 Compounds That Interrupt Nucleotide Metabolism 
Sulphonamides 
Both chromosomal and plasmid-mediated resistance to sulphonamides has 
been described. Chromosomal resistance can result from two mechanisms. 
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The first involves hyperproduction of p-aminobenzoic acid (PABA) that 
overcomes the metabolic block imposed by the inhibition of dihydropteroate 
synthetase (DHPS). Resistance of this type was observed in certain 
organisms (e.g. S. aureus) soon after the introduction of sulphonamides for 
therapeutic purposes. Plasmid-mediated resistance to sulphonamides 
involves a bypass of the drug sensitive step by duplication of the 
corresponding target enzyme, the second (plasmid-encoded) version 
conferring resistance. Tv\/o different types (I and II) of plasmid-encoded 
sulphonamide - resistant DHPS enzymes have been found in Gram-
negative bacteria. These enzymes bind sulphonamides about 10000-fold 
less efficiently than the chromosomally encoded (sensitive) enzyme, but 
resistance is achieved without sacrificing the efficiency with which natural 
substrate is bound. ''^"•"^ 
2, 4- Diaminopyrimidines 
Chromosomal mutations have been reported in E. coli that cause 
overproduction of dihydrofolate reductase (DHFR). Plasmid - and 
transposon-mediated resistance to trimethoprim have been found in a variety 
of Gram-positive and Gram-negative bacteria. Resistance involves a bypass 
of he antibiotic-sensitive step by duplication of the chromosomally encoded 
target DHFR enzyme, the plasmid-or transposon-encoded version conferring 
resistance. Ten different trimethoprim-resistant bacterial DHFR enzymes 
have been identified. These enzymes contain altered active sites, which 
render them resistant to trimethoprim. ^^^•^^'^ 
2.4.2.2 Resistance to Compounds That Inhibit Enzymic 
Processes in Nucleic Acid Synthesis 
2.4.2.2.1 Inhibitors ofRNA Polymerase 
Rifampicin inhibits RNA synthesis in bacteria by binding to the p subunit of 
DNA-dependent RNA polymerase. In E. co//acquired resistance to rifampicin 
results from amino acid substitutions, or small insertions and deletions, 
within three short highly conserved regions of the p subunit of RNA 
polymerase. The majority of mutations occur within region II between amino 
acid residues 507 and 534. Similar alterations within the corresponding 
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region of the RNA polymerase from strains of M. tuberculosis and M. leprae 
are associated with acquired resistance to rifampicin in these organisms/^^ 
2.4.2.2.2 Inhibitors of DNA Gyrase 
The quinolone antibiotics inhibit bacterial DNA gyrase activity. Acquired 
resistance to the quinolones in several organisms (e.g. E. coll, S. aureus, 
Campylobacter jejuni, M. tuberculosis, and M. smegmatis) results from point 
mutations located within a part of gyrA (encoding the A subunit of DNA 
gyrase) termed the quinolone-resistance-determining region (QRDR). Two 
other types of chromosomal mutations that confer quinolone resistance have 
been reported in E. coli. norB mutants show low level resistance to some 
quinolones and other unrelated antibiotics as a consequence of decreased 
OmpF porin content and norC mutants are less susceptible to certain 
quinolones (e.g. norfloxacin and ciprofloxacin), but hypersusceptible to 
others. norC mutants are altered in both OmpF porin content and 
lipopolysaccharide structure. Efflux-based resistant to quinolones has 
recently been described in clinical isolates of S. aureus and Proteus vulgaris. 
The gene mediating resistance in S. aureus, norA, encodes a membrane 
protein that displays homology with other transport proteins coupled to the 
electrochemical proton gradient. A possible pathway for the selection of 
organisms expressing efflux-based resistance to quinolones has been 
suggested by recent studies. Several organisms express endogenous 
chromosomally encoded efflux systems that are to some extent able to 
remove quinolones from the cell. Selection pressure, exerted by the clinical 
use of quinolones, may have resulted in the emergence of resistant strains 
carrying acquired mutations within the endogenous transport system that 
improve affinity of the efflux system for quinolones. 1'6.175,228,302,365,438,466,507 
2.4.2.2 Resistance to Inhibitors of Protein Synthesis 
IVIupirocin 
Mupirocin inhibits isoleucyi tRNA synthetase, thereby leading to depletion of 
charged isoleucyi tRNA and cessation of protein synthesis. Because it is 
metabolized in vivo, mupirocin is restricted to topical use and it is within 
isolates of the skin pathogen S. aureus that acquired resistance to the 
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antibiotic has been reported. Resistant staphylococcal strains fall into two 
categories: those expressing high level resistance (i.e. upto lOOO-fold more 
resistant than sensitive strains) and those expressing moderate level 
resistance (i.e. upto 60-fold more resistant than sensitive strains). High level 
resistance is associated with possession of two isoleucyl tRNA synthetases, 
the normal resident chromosomal enzyme (mupirocin sensitive) and a 
second mupirocin-resistant enzyme, which is usually plasmid encoded. 
Staphylococcal strains exhibiting moderate level resistance do not contain 
the gene encoding high-level resistance and possess only a single resistant 
isoleucyl tRNA synthetase which has presumably arisen by one or more 
point mutations in the resident chromosomal gene.^^°'^ ^^ 
Aminogiycoside-aminocyclitol Group 
Acquired resistance to these antibiotics can arise by mechanisms 1 (altered 
anti-biotic), 2 (altered target site) and 3a (impaired uptake) described in 
Table 2.9. The most widespread mechanism of resistance involves 
modification of the antibiotics by bacterial enzymes that are either plasmid or 
transposon encoded. There are three classes of enzymes that modify 
aminogiycoside-aminocyclitol (AGAC) antibiotics: acetyltransferases (AACs), 
adenylyl-transferases (AADs) and phosphotransferases (APHs) AACs use 
acetyl CoA as a cofactor, whereas in the phosphorylation and 
nucleotidylation reactions ATP is the cofactor. AGAC resistance can also be 
expressed by mechanism 2 (Table 2.9). For instance, mutations in the rpsL 
gene of E. coli K-12 led to high level resistance to streptomycin by altering 
the nature of ribosomal protein S12 thereby preventing the antibiotic from 
binding to its target. Similar types of chromosomal mutations occur in other 
bacterial species, e.g. clinical isolates of S. at/reas. '^*"'''* '^^ ^ '^^ ^^ 
Chloramphenicol 
Acquired resistance to chloramphenicol is frequently due to inactivation of 
the drug. Inactivation is mediated by plasmid- or transposon-encided 
chloramphenicol acetyltransferases (CATs) that convert the drug to 3-
acetoxy chloramphenicol followed by conversion to 1, 3 
diacetoxychloramphenicol, the final inactivation product. The acetoxy 
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derivatives are antibiotically inactive because they fail to bind to the 
ribosomai target. The type 1 enzyme has been most studied and the 
complete amino acid sequence of its subunits is known. A histidine residue 
at position 193 plays a critical role in the catalytic modifications of 
chloramphenicol and is likely to be located at the active site of the enzyme. 
Although the majority of plasmids conferring chloramphenicol resistance in 
E. coli encode CATs, at least one example of a plasmid-encoded non-
enzymic resistance mechanism has been described. This type of resistance, 
encoded by the gene cmlA (contained in transposon Jn1696) involves active 
efflux of chloramphenicol mediated by the membrane-located CmlA protein. 
In gram-negative bacteria low-level resistance to chloramphenicol can arise 
by mutational loss of outer membrane porins through which the drug normaly 
diffuses to reach the periplasm. 225,423,424 
Fusidic acid 
Fusidic acid is a steroid antibiotic that prevents bacterial protein synthesis by 
inhibiting functions associated with translocation factor protein (G factor or 
EFG). Gram-negative bacteria are intrinsically resistant to fusidic acid by 
virtue of poor antibiotic penetration across the outer membrane. Acquired 
resistance also occurs in Gram-positive bacteria that do not express intrinsic 
resistance to the antibiotic. Acquired resistance results from either 
chromosomal mutations or possession of plasmids. Chromosomal mutants 
invariably have a modified G factor, which has decreased affinity for the 
drug. In S. aureus, plasmid-mediated resistance to fusidic acid may involve 
decreased uptake of antibiotic across the cytoplasmic membrane, but the 
molecular basic of resistance is unknown. Surprisingly, the gene encoding 
resistance to fusidic acid also encodes a type I CAT. Firm evidence has 
been obtained that the CAT itself confers fusidic acid resistance and that a 
separate fus product not translated from an initiation codon internal to the cat 
message. However, fusidic acid is not inactivated or modified by enzyme, 
which appears to have a binding domain that seque sters a variety of 
aromatic compounds that are not necessarily closely related structurally.^^ 
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Macrolides, Lincosamides and Streptogramins (MLS Group) 
MLS antibiotics arrest protein synthesis by binding to the 508 ribosomal 
subunit. Resistance mechanisms specific to individual members of the MLS 
antibiotics occur but, in addition, resistance to all these antibiotics can be 
conferred by a single mechanism involving mono- or di-methylation of an 
adenine residue in 23S rRNA. Three distinct RNA methylase genes {ermA, 
emrB, emrC) have been reported in staphylococci, all of which confer 
complete cross-resistance to MLS antibiotics. Methylation prevents the drugs 
from binding to the SOS ribosomal subnit probably as a consequence of a 
conformational change in the 23S rRNA. Genes specifying MLS resistance 
by rRNA methylation are carried by plasmids and transposons. Recently a 
new resistance phenotype (MS) was observed in clinical isolates of S. 
aureus, in which cells are resistant to macrolides (M) and streptogramins (S) 
but remains sensitive to lincosamides.''^ ^ '^^ ^ '^^ ^ '^'^ ^ '^^ '^^  
Resistance To Tetracyclines 
Eight genetic determinants {tetA through tetF, tetK, and tetL) have been 
described in bacteria that encode tetracycline efflux proteins. Efflux is 
dependent on the proton-motive force and involves an electrically neutral 
proton-tetracycline antiport system with exchange of a monocationic 
magnesium-tetracycline chelate complex for a proton. It is assumed that a 
substrate (tetracycline) binding site fluctuating between high and low affinity 
states and a proton transfer site whose protonation-deprotonation affects the 
affinity of the binding site are present in the efflux proteins. Recently two 
types of ribosomal protection factors have been described, TetM and TetO, 
both of which are plasmid or transposon encoded. The tetM resistance 
system occurs naturally in certain streptococci, gonococci and Ureaplasma 
urealyticum, whereas tetO has been described in Campylabacter jejuni. The 
TetM and TetO proteins probably act in a catalytic manner to modify the 
tetracycline-binding site on the SOS ribosomal subunit. This might involve 
methylation of either ribosomal RNA or ribosomal protein, thereby rendering 
ribosomes insensitive to tetracycline. Chromosomal mutations in E. coli 
leading to loss of the outer membrane porin ompF, through which the 
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antibiotic normally diffuses, confer low level resistance to tetracycline (and 
other unrelated compounds)/^'^^'^°^'^^^'^°^ 
2.2.4.2 Resistance to Antibiotics That inhibit Peptidogiycan Synthesis 
D-cycloserine 
D-cycloserine is transported across the bacterial cytoplasmic membrane by 
the D-alanine transport system. In E. co//this transport system is encoded by 
the chromosomal gene cycA, which is involved in accumulation of D-alanine, 
D-glycine and D-serine as well as D-cycloserine. Mutation in cycA confers 
resistance to cycloserine as well as defects in the transport of the other 
molecules. In streptococci, transport mutants analogous to those in E. coli 
have been isolated as well as resistance mutants, which produce more of 
the target enzymes inhibited by D-cycloserine. Acquired resistance to 
cycloserine in M. tuberculosis has been attributed to point mutation in the 
synthetase, but the mutants have been characterized in detail.^^^ 
Fosfomycin 
Fosfomycin acts at the level of phosphoenol-pyruvate: UDP-A/-
acetyglucosamine enoylpyruvil transferase, an enzyme involved in the 
biosynthesis of peptidogiycan. Resistance to the antibiotic has been 
reported in several types of Gram-negative bacteria and occurs principally by 
general mechanism 1 (drug alteration) and 3a (impaired uptake) (Table 2.9). 
Mechanisms of type 3a (impaired uptake) involve chromosomal mutation in 
the hexose-6-phosphate or L-glycerophosphate uptake systems by which 
fosfomycin is transported into susceptible bacteria.'*"^ 
Bacitracin 
Bacitracin forms a complex with the membrane-bound pyrophosphate form 
of the lipid carrier molecule involved in transferring disaccharide-
pentapeptide unit to the nascent peptidogiycan chain. Gram-negative 
bacteria are intrinsically resistant to bacitracin so that discussion of acquired 
resistance to this antibiotic is only relev'ant for Gram-positive organism. 
Bacitracin-resistant mutants of S. aureus have been isolates in the 
laboratory, but the mutations appear to revert at high frequency because 
resistant is readily lost on removal of the selective pressure. Clinical isolates 
49 
of Gram-positive bacteria resistance to bacitracin have been reported which 
may reflect the unstable nature of resistance mentioned above.^ ® '^^ °^ 
Glycopeptide antibiotics 
Glycopeptide antibiotics interefere with glycan unit insertion by combining 
directly with peptidoglycan, in particular to the acyl-D-alanyl-D-alanine 
terminus of the peptidoglycan precursors. Acquired resistance to 
glycopeptides occurs in the enterococci, the genes conferring resistance 
residing within transport Jn1546. Conjugal transfer of various plasmids that 
have acquired Tn1546 contributes to the spread of glycopeptide resistance 
genes in enterocci. Tn1546 encodes two key proteins (VanA and VanH) that 
are responsible for changing the pathway of peptidoglycan synthesis to 
produce a modified peptidoglycan structure no longer able to bind 
glycopeptides.^^^'3'2'''^ 
B-Lactam antibiotics 
Acquired resistance to B-lactam antibiotics can arise by three different 
mechanisms: (1) in Gram-negative organisms through reduction in 
permeability of the outer membrane to the antibiotic, (2) by synthesis of beta-
lactamases, and (3) by modification of one or more PBPs. These 
mechanisms, either separately or jointly, account for acquired resistance to 
P-lactams. It has been known for many years that change in the Gram-
negative outer membrane may affect the influx rate of p-lactams and thereby 
affect the resistance level. In particular, mutational loss of porins (e.g. OmpF 
and OmpC), through which many p-lactams normally diffuse, provides low 
levels of p-lactams resistance. p-Lactamses hydrolyse the cyclic amid bond 
in molecules thereby rendering the drugs unable to bind to bacterial PBPs. In 
the case of Gram-negative bacteria the enzymes are synthesized within the 
cell and are then secreted into the periplasmic region. Resistance results 
from the strategic location of p-lactamses between the antibiotic penetration 
barrier (the outer membrane) and the antibiotic targets (PBPs) located in the 
cytoplasmic membrane whereby the p-lactamses can sequentially destroy 
antibiotic molecules as they enter the periplasm. Therefore, in Gram-
negative bacteria resistance due to p-lactamses produced by Gram-positive 
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bacteria are mainly excreted from the cell so that resistance is a population 
phenomenon, i.e the excreted enzyme spread into the external environment 
and can reduce the level of p-lactam to a concentration that permits growth 
of both enzyme-producing and non-enzyme producing bacteria. ^^^^-'^^•^^ 
Since (J-lactam antibiotics are analagous of the cell wall substrate, mutations 
in PBPs affecting binding of the inhibitor (and thus potentially conferring 
resistance) might be expected to be lethal, as binding of the natural 
peptidoglycan substrate would also be affected. Streptococcus pneumoniae 
resistant to penicillin has several PBPs of altered size and deceased affinity 
for penicillins. Molecular analysis of PBP2 genes from susceptible and 
resistant organisms revealed that the gene from susceptible strains was 
uniform in sequence, whereas those from resistant isolates had a mosaic 
structure, containing regions identical to those in susceptible strains and 
regions up to 23% divergent in sequence. The modified PBP2 genes thus 
appear to have arisen by block replacement of parts of the pneumococcal 
PBP2 gene with homologous regions from some other species, probably by 
DNA transformation. Resistance mechanism (mechanism 4, Table 2.9) 
concerns p-lactam-lactam resistance in clinical S. aureus isolates mediated 
by the mec determinant. Resistance result from the synthesis of antibiotics 
unique PBP (molecular weight 74000) designated PBP2' or PBP2a that has 
a low affinity for p-lactam antibiotics. PBP2 is the only functional PBP at 
concentrations of p-lactam sufficient to inhibit the normal complement of 
PBPs in sensitive cells. The mec determinant confers resistance to all p-
lactam antibiotics, including p-lactamses resistant compounds such as 
methicillin. The origin of the mec determinant is unknown, but may have 
been transferred to a single strain of S. aureus and then disseminated 
worldwide by clonal descent. 17.23,194.208 
2.4.2.4 Resistance to Antibiotics That Inhibit Membrane Integrity 
Plasmid-determined resistance to polymyxin has been described, but 
chromosomal mutants of Ps. aeruginosa resistant to polymyxin have been 
isolated. Resistance is associated with an increase in the content of an outer 
membrene protein (H1), which apparently decreases the requirement for 
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divalent cations from the outer membrane, it is suggested that protein H1 
replaces cations at sites in the outer membrane, which would otherwise be 
susceptible to the antibiotics. Chromosomal mutations conferring resistance 
to polymyxin also occur in Gram-negative enteric bacteria such as S. 
typhimurium and E. coli. In these organisms the molecular basis of 
resistance differs from that of Ps. aeruginosa. In E. coli snd S. typhimurium 
resistance to polymyxin is accompanied by decrease in the net ionic charge 
of outer membrane lipopolysaccharide following subsitution of phosphate 
groups in the molecule by aminoethanol and aminocarabinose. These 
charges are responsible for decreased binding of the outer membrane, 
resulting in decreased susceptibility to polymyxin.^°^'^°^ 
2.5 STAPHYLOCOCCI 
Staphylococci were first observed and cultured by Pasteur and Koch. But 
Ogston in 1881 and Rosenbach in 1884 made the first thorough studies on 
staphylococci. The genus Stapfiylococcus was given its name by Ogston in 
1881 when he observed grape-like clusters of bacteria in pus from human 
abscesses. Three years later, Rosenbach was able to isolate and grow 
these microorganisms in pure culture. He gave these bacteria the specific 
epithet Staphylococcus aureus Rosenbach because of the yellow- to-
orange-pigmented appearance of their colonies. Rosenbach showed that S. 
aureus was responsible for wound infections and furunculosis, and that 
Staphylococcus epidermidis was a normal colonizer of the skin. Ever since 
Rosenbach first described the growth of this 'golden' coccus, sugeons have 
feared staphylococcal wound infections after surgery. Staphylococci also 
caused life-threatening disease after trauma and fatal pneumonia during the 
influenza season, killing young people in the prime of their lives. Therefore, 
in the pre-antibiotic era, S. aureus was known as a major life- threatening 
pathogen.^°^^^ '^^ ^« 
Because of penicillin's important contribution to the fight against S. aureus 
disease, the period between 1946 and 1950 was referred to as ' a golden 
age' for the treatment of staphylococcal disease. However, the rapid spread 
of resistant staphylococci soon led to this return of a major pathogen.^ "^^ 
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TAXONOMY 
The family of Micrococcaceae consists of four genera: 
• Planococcus 
• Stomatococccus 
• Micrococcus, and 
• Staphylococcus 
Planococci are not found in humans, wheras Stomatococcus and 
Micrococcus can colonize humans, but rarely produce disease. 
Staphylococci are Gram-positive nonmobile cocci that characteristically 
divide in different patterns to form irregular grape-like clusters (Fig. 2.5). 
They usually produce catalase. They are facultative anaerobes, but grow 
better under aerobic than under anaerobic conditions. Traditionally, they 
have been divided into coagulase-positive and coagulase-negative 
staphylococci. The coagulase-negative staphylococci can be subdivided at 
present into 32 different species (Table 2.10).^^^'^^'^°^'2®^'^ Of the large 
number of staphylococci only three are commonly associated with human 
disease. 
• S. aureus, 
• S. opidermidis, and 
• Staphylococcus saprophyticus 
Figure 2.5 Staphylococcus aureus Showing Bunched Grape-like 
Colonies 
53 
Table 2.10 Currently Recognized Staphylococcus Species 
Species 
S. epidermidis 
S. capitis 
S. caprae 
S. saccharolyticus 
S. hominis 
S. haemolyticus 
S. wameri 
S. pasteuii 
S. lugdunensis 
S. auricularis 
S. aureus 
S. saprophyticus 
S. cohnii 
S. xylosus 
S. kloosii 
S. equorum 
S. arlettae 
S. gallinarum 
S. simulans 
S. carnosus 
S. piscifermentans 
S. fells 
S. Intermedius 
Reference 
Winslowand Winslow 1908, Evans 1916, Schleiferand 
Kilos 1975 
Kloos and Schlelfer 1975 
Devriese at al. 1983 
Fourbert and Douglas 1948, Kilpper-Balz and Schleifer 
1981 
Kloos and Schleifer 1975 
Schleiferand Kloos 1975 
Kloos and Schleifer 1975 
Chesneauetal 1993 
Freneyetal. 1988 
Kloos and Schleifer 1983 
Rosenbach 1884 
Shaw, Still and Cowan 1951, Schleifer and Kloos 1975 
Schleifer and Kloos 1975 
Schleifer and Kloos 1975 
Schleifer, Kilpper-Balz and Devriese 1984 
Schleifer, Kilpper-Balz and Devriese 1984 
Schleifer, Kilpper-Balz and Devriese 1984 
Devriese et al. 1983 
Kloos and Schleifer 1975 
Schleifer and Fischer 1982 
Tanasupawat et al. 1992 
Iglmletal. 1989 
Hajek1976 
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A>I18 ^ ^ ^ , ^ i f t r 
;'^^h 
S. schleiferi 
S. delphini 
S. hyicus 
S. chromogenes 
S. muscae 
S. sciuri 
S. lentus 
S. vitulus 
S. caseolyticus 
<C . i i > \ 1 
Freneyetal. 1988 < r^T-^lSO . ^^' 
Varaldoetal. 1988 % - V'^f 
Devrieseetal. 1978 
Devriese et al. 1978, Hajek et al. 1986 
Hajeketal. 1992 
Kloos, Schleifer and Smith 1976 
Kloos, Schleifer and Smith 1976, Schleifer et al. 1983 
Webster etal. 1994 
Schleifer et al. 1982 
2.5A CLINICAL SIGNIFICANCE OF S. AUREUS 
The major habitats of the most pathogenic species, S. aureus, are the 
anterior nares and perineum.^^^ Newborn infants usually acquire S. aureus 
first on the skin (umbicial area) and later in the nose. Soon after the neonatal 
period some individuals become permanent carriers, often with the same 
strain. Although some spread of S. aureus may occur within a family, 
generally the established flora of the nose prevents acquisition of new 
strains. However, colonization with other strains may occur when antibiotic 
treatment is given that leads to elimination of the susceptible carrier strain. 
Because this situation occurs in the hospital, patients may become colonized 
with resistant staphylococci. Carriage rate of S. aureus in the nares of 
people outside the hospital varies from 10 to 40%. Hospital patients and 
personnel have higher carriage rates.^^^ The carriage rates of patients may 
increase during their stay in hospital due to colonization and nosocomial 
transmission. The rates are especially high in patients undergoing 
hemodialysis and in diabetics, drug addicts and patients with a variety of 
dermatologic conditions.^ ^® The carrier state is clinically relevant because 
carriers undergoing surgery have more infections than non-carriers.^ '^^ ^^ 
This has led to the application of mupirocin (a local antibiotic) to the anterior 
nares in some centers just before open-heart surgery to lower the incidence 
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of postoperative wound infection.^'* Dispersers among the carriers are 
important because dispersers not only transmit stapiiylococci by direct 
contact, but also by air-borne transmission. Heavy perineal carriers almost 
always disperse large amounts of staphylococci. Staphylococci may 
accumulate rapid on the clothes and bedding of dispersers and may 
disseminate when these fomites are disturbed. Dust particles containing 
staphylococci may be carried for considerable distances.^ '^^ '^*'^ ^ '^'*^^ 
Since 1944, an increasing proportion of hospital-acquired S. aureus strains 
have developed resistance to penicillin because of their ability to produce 
beta-lactamase. By 1950, approximately 80% of hospital- acquired infections 
were caused by these penicillinase producers. In the mid 1950s, penicillin-
resistant S. aureus of a new phage type (the so-called phage type 80) was 
first detected in Australia and then spread rapidly, causing a major pandemic 
of hospital-acquired infection. Because of the 'resistance advantages' of the 
new S. aureus strain, referred to as "hospital staph", there were again 
outbreaks on hospital wards. In 1959, the British Ministry of Health published 
guidelines for the prevention of further spread of the multi resistant 
[penicillin-streptomycin-tetracycline-erythromycin-resistant (PSTE)] S. 
aureus strains. A temporary respite in the war against resistant S. aureus 
occurred in the early 1960s, when Rolinson and Stevens discovered beta-
lactamase stable penicillin, (methicillin). In the following years the 
introduction of the semisynthetic penicillins (methicillin. Oxacillin, 
flucloxacillin) and the application of infection control measures probably 
contributed to the spontaneous decrease in the epidemic of S. aureus 
strains. However, coinciding with the disappearance of PSTE-strains was the 
appearance of celbenin (methicillin) -resistant staphylococci (MRSA). Early 
MRSA epidemics were reported in the early 1960s.^^^ Later, two surveillance 
studies conducted by the Cross Infection Reference Laboratory in London 
showed that the frequency of methicillin reistance in clinical isolates from 
London hospitals and from hospitals in south East England increased unitil 
1963, when it was followed by a stationary phase (below or around 1%) until 
1968. The rate of methicillin resistance rose sharply in the period 1968-1969 
(upto 5%). After another decline of major MRSA epidemics, the first serious 
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hospital outbreaks were reported in 1970. The early MRSA epidemics could 
have been controlled by aminoglycosides. In the late 1970s however, 
resistance to gentamicin emerged in S. aureus and led to a new wave of 
hospital outbreaks.^° '^'*^^ Since then the MRSA strains have spread all over 
the world, not only in hospitals, but also in the community. In the USA, the 
percentage of MRSA among all hospitals in the National Nosocomial 
Infection Survey System increased from 2.4% in 1975 to 29% in 1991. The 
incidence varied according to bed size, with hospitals of less than 200 beds 
reporting 14.9% of S. aureus isolated as MRSA, and hospitals of 500 beds 
reporting a 38.3% frequency. Within European countries a systematic survey 
of 40 laboratories documented a wide variation in incidence ranging from 
0.1% in Northern European countries to over 30% in Spain, France and Italy. 
Patients at highest risk for MRSA infection are: 
• Those in large tertiary-care hospitals, particularly the elderly and 
immunocompromised; 
• Those in intensive care units; 
• Burns patients; 
• Those with surgical wounds; and 
• Patients with intravenous lines. 
Duration of hospitalization, previous antibiotic treatment and proximity to a 
patient colonized or infected with the organism also predispose to MRSA 
infection. In acute care and nursing facilities, colonized and infected patients 
are the major MRSA reservoir. Person-to-person transmission of MRSA 
usually occurs via the hands of health care workers.®"'*^^ 
2.5.2 CLINICAL SIGNIFICANCE OF COAGULASE NEGATIVE 
STAPHYLOCOCCI 
As a group, the coagulase-negative Staphylococcus species (CNS) are 
among the most frequently isolated bacteria in the clinical microbiology 
laboratory. One of the major problems facing the laboratory is distinguishing 
clinically significant, pathogenic strains of CNS from contaminant strains. 
The vast majority of infections (or diseases) assumed to be caused by CNS 
are a significant consequence of hospitalization.^^^ Recent reports on 
surveillance data taken from the National Nosocomial Infections Surveillance 
System during the late 1980s and early 1990s have indicated that CNS are 
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among the five most commonly reported pathogens (in fifth place at 9 to 
9.7%, compared with 10 to 11.2% for Staphylococcus aureus) in hospitals 
conducting hospital-wide surveillance. CNS were the most frequently 
reported pathogens in nosocomial blood-stream infections (27 to 27.9%, with 
S. aureus next at 16 to 16.5%). The ranking and infection rates of CNS were 
quite similar among hospitals conducting surveillance in intensive care untis 
(ICUs) and in those conducting surveillance hospital-wide. In contrast to the 
situation in the 1970s, major shifts have occurred in the decade of the 1980s 
and in the early 1990s in the etiology of nosocomial infection. Most 
noticeably, the shifts have been towards the more antibiotic resistant 
pathogens, of which the CNS are a major group. Current antibiotic-
prescribing practices, including preoperative antibiotic prophylaxis, have led 
to the selection of antibiotic-resistant organisms. The increasing importance 
of CNS also may be due in part to the growing appreciation of this group of 
organisms as opportunistic pathogens and to the increase in the use of 
transient or permanent media devices, such as intravascular catheters and 
prosthetic devices, in seriously ill and immunocompromised patients (i.e. 
intensive care patients, premature newborns, and cancer and transplant 
patients). CNS infections often can be life threatening in these patients. CNS 
are a major component of the normal flora of the cutaneous ecosystem, 
including the skin and mucuous membranes. In the cutaneous ecosystem, 
CNS generally have a benign relationship with their host and function as 
commensal or saprophytic organisms. However, if the cutaneous organ 
system has been damaged by trauma, inoculation by needles, or direct 
implantation of foreign bodies, these organisms can gain entry to the host. 
Depending upon their ability to adhere to host or foreign body surfaces, 
breach or avoid the host immune system, multiply, and produce products 
that damage the host, they may develop the lifestyle of a 
pathogen:'^'-'''''''' 
Historical Perspective 
In 1958, Smith and coworkers noted the potential pathogenicity of CNS by 
collecting data from patients with speticemia. Several years later, Pulverer 
and Halswick reported on 128 cases of endocarditis believed to be caused 
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by CNS. Prior to the 1970s, clinicians and microbiologists generally regarded 
CNS as contaminants in clinical specimens and S. aureus as the only 
pathogenic Staphylococcus species. In his Theodor Billroth Memorial 
Lecture at the Fifth International Symposium on Staphylococci and 
staphylococcal Infections, Pulverer shared his frustration with the medical 
community when he said, " In 1965 we sent a paper entitled 'Coagulase-
negative staphylococci as pathogenic agents' to one of the leading medical 
journals in Germany. We had great problems in convincing the editors that 
we had no joke in mind but wished to report seriously about a lethal case of 
CNS endocarditis. In 1964, we observed this rather malignant disease in a 
57-year-old man who died several months later despite a long-lasting and 
high-dosage penicillin treatment." Brandt and Swahn reported that more than 
1% of all cases of endocarditis might be due to CNS. In 1965, Wilson and 
Sturat reported that CNS were found in pure culture in 53 of 1,200 (4.4%) 
cases of wound infections. In 1971, pulverer and Pillich investigated the 
incidence of CNS pyogenic infections in Cologne, Germany, presenting data 
for the years 1960. 1969 and 1970. CNS were found in about 10% of all 
pyogenic lesions observed in hospital patients, and in about 50% of these 
cases, CNS were believed to be present in pure culture. In 1962, Pereira 
reported that a certain group of CNS (now known as S. saprophyticus 
caused urinary tract infections (UTIs). A few years later, Gallagher and 
coworkers and Mabeck also presented evidence that CNS cause UTIs. In 
1971, Holt reported the colonization of ventriculoatrial shunts by CNS. 
Colonization was usually followed by septicemia. Looking through the 
literature Pulverer collected data from 2,276 ventriculoatrial or peritoneal 
shunt operations and estimated that 8% of the patients acquired shunt 
infections, with 58% of the cases probably caused by CNS.^ ^ '^^ ^ -^^ ^^ 
In light of recent advances there has been a considerable progress in the 
classification of staphylococci and in the development of methods for 
identifying them at the genus, species, subspecies, and strain levels has 
been made. By the 1980s, the range of infections believed to be caused by 
CNS, and especially by S. epidermidis, was quite wide and included 
bacteremia native valve endocarditis (NVE) and prosthetic valve 
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endocarditis; osteomyelitis; pyoarthritis; peritonitis; during continuous 
ambulatory dialysis; mediastinitis; prostatitis; infections of permanent 
pacemakers; vascular grafts and intravascular catheters; cerebrospinal fluid 
shunts and prosthetic joints and a variety of orthopedic devices; and UTIs. 
The CNS species S. saprophyticus was often regarded as a more important 
opportunictic pathogen than S. epidermidis in human UTIs, especially in 
young, sexually active females. It was considered to be the second most 
common cause of acute cystitis or pyelonephitis in these patients.^^'* Several 
other CNS species have been implicated at low incidence in a variety of 
infections. S. haemolyticus is the second most frequently encountered CNS 
species in the clinical laboratory. This species has been implicated in NVE, 
septicemia, peritonitis; S. wameri is believed to be the cause of some cases 
of vertebral osteomyelitis, NVE, and UTIs. S. hominis has been associated 
with endocarditis, peritonitis, septicemia, and arthritis. Some of the earlier 
reports indicating an association of S. hominis with infections may have been 
in error due to the" confusion of this species with phosphatase-negative 
strains of S. epidermidis. S. simulans has been associated with some cases 
of chronic osteomyelitis and pyarthrosis.^'^^'^'^^^'^''^'^^^'^^^'^" 
2.6 STAPHYLOCOCCI AND CLINICAL MANIFESTATIONS 
Staphylococcal infections are characterized by intense suppurative 
inflammation of local tissues with a tendency for the infected area to become 
encapsulated leading to abscess formation.^^ '^^ ^ '^^ ^^ 
2.6.1 CLINICAL MANIFESTATIONS OF STAPHYLOCOCCUS AUREUS 
FURUNCLE 
The most common staphylococcal infection is the furuncle or boil, which is a 
localized painful superficial skin infection that develops in a hair follicle or 
gland. Similar infections at the base of the eyelashes are the common styes. 
The most common sites for boils are the neck and the buttocks, often as a 
result of wearing tight clothes. The infected patient is often a carrier of the 
Staphylococcus that causes the infection, usually in the anterior nares. A 
total of 65% of furuncles, especially those on the head and neck, are caused 
by a strain indistinguishable from that in the patient's nose, and there are 
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indications that perineal carriage is associated with furuncle on the legs. No 
specific pathogenicity factors are responsibly for the pathology of furuncles. 
Although about 50% of strains involved in carbuncles and furuncles have 
been found to produce PVL, only 2% of all S. aureus are producers. The 
course of infection is usually benign. No specific treatment is needed and 
most often the infection resolves after sponstaneous drainage of the pus or 
surgical incision.^^ 
CHRONIC FURUNCULOSIS 
Approximately 2-3% of the populations have chronic furunculosis, with 
repeated attacks of boils are often caused by the same phage type of S. 
aureus. The most appropriate management of patients with recurrent 
furunculosis includes a course of an oral antibiotic combined with 
chlorhexidine washes and the use of an antistaphylococcal intranasal 
ointment. 
CARBUNCLE 
Staphylococcal infections may spread from a furuncle to the deeper 
subcutaneous tissues resulting in the development of one or more absesses 
known as carbuncles. These abscesses occur mostly on the back of the 
neck, but may involve other skin sites. They may result in bloodstream 
invasion. 
BULLOUS IMPETIGO 
Certain strains of S. aureus can cause bullous impetigo. This characterized 
by small bullae, which form and burst. When this occurs in infants it may be 
described as pemphigus neonatorum. Bullous impetigo is a highly 
contagious superficial skin infection characterized by large blisters 
containing many staphylococci in the superficial layers of the skin. Bullous 
impetigo is most often seen in the infants and children under conditions 
where direct spread can occur (e.g. sharing of contaminated towels). 
Impetigo mainly occurs on the face and limbs. Extensive atypical bulluos 
impetigo is associated with HIV infection. The strains often produce 
exfoliative toxin and impetigo can therefore be considered as a localized 
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form of scalded skin syndrome. The bullae are the result of epidermolytic 
toxins, which are serine proteases. 
BOTRYOMYCOSIS 
Botryomycosis is a rare chronic skin infection that resembles mycetoma or 
actinomycosis. The lesions may be nodular or granulomatous and many 
have draining sinuses. 
SECONDARY CUTANEOUS INFECTION 
The most common secondary infection occurs in people with eczema, 
especially atopic dermatitis. Colonization of lesions in adults approaches 
100%; children are colonized only slightly less often. Skin ulcers, especially 
those of the legs in the elderly, may also become heavily colonized by S. 
aureus. Similarly, hidradenitis suppurativa, a chronic suppurative disease of 
the skin that occurs in areas bearing apocrine glands, most often the axilla 
and groin, also yields S. aureus. 
PARONYCHIA 
Another common S. aureus infection is paronychia, which involves the soft 
tissue around the nails. 
DEEP LESIONS 
Staphylococcus aureus can cause a wide variety of deep tissue, often 
metastatic, infections. These infections include osteomyelitis, arthritis, 
endocarditis and cerebral, pulmonary and renal abscesses, and breast 
abscesses in the nursing mother. Staphylococcus aureus can also cause 
bacterial pneumonia, which is almost always secondary (e.g. after influenza 
or other viral infections). In many of these situations, diabetes mellitus, 
leukocyte defects or a general reduction of host defenses by alcoholism, 
malignancy, old age or corticosteroid or cytotoxic therapy are predisposing 
factors. Severe S. aureus infections, including endocarditic, are particularly 
common in intravenous drug abusers. 
WOUND INFECTIONS 
Staphylococcus aureus is a notorious cause of wound infection. Infections 
can be major complications following surgery. The source may be the 
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patient's own carrier state, other carriers (e.g. physicians or nurses) or other 
infected patients. Whether a staphylococca\ wound infection occurs following 
surgery depends upon a complex interaction between: 
" Host factors, including the status of the immune system and the 
presence of disease such as diabetes mellitus; 
• Surgical factors, such as the disruption of tissue perfusion that 
accompanies the surgical procedure and whether foreign bodies are 
used; 
• Staphylococcal factors, including substances that mediate tissue 
adherence and invasion or that enable staphylococci to survive the 
host defenses and antibiotics in the tissues; and 
• The use of antimicrobial prophylaxis. 
Staphylococcal infections at the site of intravenous lines can result in 
bacteremia with metastatic infection.°° 
STAPHYLOCOCCAL SCALDED SKIN SYNDROME 
This refers to a group of primarily cutaneous diseases (e.g. generalized 
scalded skin syndrome, staphylococcal scarlet fever and bullous Impetigo) 
caused by the staphylococcal exfoliatin toxins, exfoliatoxin A or exfoliatoxin 
B. Toxic epidermal necrolysis or Lyell's disease is also known as generalized 
scalded skin syndrome. It results from the production of exfoliatin toxin in a 
staphylococcal lesion, which can be quite minor. The toxin is absorbed into 
the bloodstream, and intraepidermal desquamation may occur at remote 
sites from which S. aureus cannot be isolated. The disease is most common 
in neonates and in children under 8 years of age, and epidemics may occur 
in nurseries. The face, axilla and groin are most often affected first, but the 
erythema, bullous formation and subsequent desquamation of epithelial 
shets can spread to all parts of the body. Generalized scalded skin 
syndrome is the most severe manifestation of exfoliatin-producing 
staphylococcal infections.^ ^® 
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TOXIC SHOCK SYNDROME 
Toxic shock syndrome is a serious diseases associated with S. aureus. As 
mentioned above it has been most commonly seen in young women during 
or immediately after menstruation and is associated with the use of highly 
absorbent intravaginal tampons. In such cases, S. aureus grows in large 
numbers in and around the tampon and liberates TSST- 1. The disease is 
characterized by the development of high fever, vomiting, diarrhea, sore 
throat and muscle pain. Within 48 hours it may progress to server shock with 
evidence of renal and hepatic damage. A Skin rash may develop, followed 
by exfoliatin at a deeper level than in scalded skin syndrome. Blood cultures 
are usually negative.^" 
STAPHYLOCOCCAL FOOD POISONING 
Staphylococcal food poisoning results from the production of staphylococcal 
enterotoxin in food before ingestion. It is intoxication, not an infection. 
Because of the heat resistance of the toxin, toxicity persists even if the food 
is heated to boiling. Ingestion of the food results in acute vomiting and 
diarrhea within 1-5 hours. There is prostration, but usually no fever. 
Recovery is rapid, except sometimes in the elderly and in those with other 
disease. The diagnosis is suspected on the basis of exposure history and of 
the typical symptoms (nausea, vomiting, abdominal cramping and diarrhea). 
Worldwide, 30% of cases of food-borne illness are caused by staphylococci. 
Table 2.11 Examples of Infections with Staphyfococcus aureus 
Primary infection 
Superficial infection 
Folliculitis 
Furunculosis 
Impetigo 
Deep infection 
Abscess 
Wound infection 
Pneumonia 
Osteomyelitis 
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Septicaemia 
Secondary Infection 
Eczema 
Decubitus ulcers 
Toxin mediated disease 
Food poisoning 
Toxic shock syndrome 
Scalded skin syndrome 
2.6.2 CLINICAL MANIFESTATIONS OF STAPHYLOCOCCUS 
EPIDERMIDIS 
CATHETER-RELATED INFECTIONS 
Staphylococcus epidermidis is the most frequently isolated coagulase 
negative staphylococci species in catheter-related infections, especially in 
children. These infections have been reported in association with central 
hyperalimentation catheters, peripheral intravenous catheters, subclavian 
catheters, Hickmann and Broviac central lines and Swan-Ganz catheters. 
The diagnosis of a catheter-related infection is often a physician's nightmare. 
Catheters may be colonized without local signs of infection (i.e. without gross 
evidence of purulence or erythema at the insertion site of the catheter). 
Furthermore, blood cultures may yield S. epidermidis without the patient 
showing major clinical symptoms. A diagnosis of catheter-related infections 
is based on a proper collection of at least three blood cultures taken from 
different sites of venepuncture within 24 hours. In addition, culture of the 
intravascular catheter segment should be performed according to current 
standards. In most clinical microbiology laboratories, the intravascular 
segment of the catheter is cultured according to the method of Maki and 
colleagues: catheter segments are cultured after being 'rolled' over a blood 
agar plate and after incubation for 18 hours at 98.6°F (37°C), the number of 
CFUs are counted. Cultures yielding more than 15CFU/blood agar plate are 
associated with catheter-related bacteremia.^ ^® 
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CEREBROSPINAL FLUID SHUNT INFECTIONS 
Both S. epidermidis and S. aureus strains are the most frequently 
encountered isolates in CSF shunt infections. Infections usually occur within 
2 weeks of implantation or manipulation of the shunt. Clinical manifestations 
are usually nonspecific.^'*^ 
PERITONITIS 
About 40% of patients who have CARD develop peritonitis during the first 
year (overall incidence ranging from 0.6-6.3 episodes/patient-year) Criteria 
for diagnosis include a combination of: 
• abdominal pain 
• cloudy fluid containing more than 100 white blood cells/mm^ (the 
majority of which are PMNLs), and 
• a positive dialysate culture. 
Staphylococcus epidermidis is by far the most frequently isolated organism 
in patients with CARD peritonitis 
ENDOCARDITIS 
Infections of native cardiac valves with coagulase-negative staphylococci are 
uncommon, accounting for only about 5% of all cases of infective 
endocarditis. However, S. epidermidis and S. aureus account for the majority 
of nosocomial-acquired infective endocarditis infections. These bacteria are 
the single most common cause of infections of prosthetic cardiac valves, and 
S. epidermidis is the cause of approximately 40% of cases of prosthetic 
valve endocarditis. In more than 80% of patients, S. epidermidis valve 
endocarditis is associated with valve dysfunction or persistent fever during 
therapy. The infection is most frequently located in the valve sewing-ring, 
resulting in complications such as dehiscence, dysrhythmia and obstruction 
of the valve orifice. Fever usually persists during therapy because the valve 
ring abscess is relatively protected from antibiotics. Staphylococcus 
epidermidis prosthetic valve endocarditis shows an indolent clinical picture 
without the classic endocarditis findings such as peripheral emboli and 
multiple positive blood cultures. Valve dysfunction and fever are the most 
frequent symptoms. Most patients are infected at the time of cardiac surgery, 
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but the incubation period can vary, with a latency of 1-2 months before 
symptoms arise/'*^'^^^ 
INFECTIONS IN IMMUNOCOMPROMISED PATIENTS 
The coagulase-negative staphylococci have emerged as pathogens in 
immunocompromised hosts, notably neonatal ICCU patients and oncology 
patients. Most coagulase-negative staphylococci infections in these patients 
are related to the use of foreign devices, notably central intravascular 
catheters. 
URINARY TRACT INFETION 
Among the coagulase-negative staphylococci S. saprophyticus can cause 
spontaneous acute urinary tract infection in previously healthy people. With a 
few exceptions these are women aged 16-25 years. The disease appears 
soon after the woman becomes sexually active and the symptomatology 
closely resembles that of urinary tract infection caused by Escherichia 
1-213,214,304,483 
2.7 HEALTHY FLORA OF STAPHYLOCOCCI AND SOURCES 
OF INFECTIONS 
The majority of staphylococcal infections arise from endogenous sources. 
This is true not only of sporadic infections, minor wound sepsis and post 
influenzal pneumonia in the community, but also of a considerable proportion 
of surgical wound infections and neonatal sepsis. Sometimes, however, 
staphylococci from another carrier or a contaminated object will reach, and 
cause infection in, a patient. Air-borne transmission may also occur. 
Carriage of S. aureus can be considered in the light of self-infection or as a 
source for cross-infection.2 '^^ ^ '^2^2''^ ° 
2.7.1 CARRIAGE 
The carriage of S. aureus was first described by Halman (1937)^ °® and has 
since been studied intensively (William 1963).^°° At any time about 35% of 
normal adults carry S. aureus in the anterior nares. Populations of primitive 
peoples are reported with lower carrier rates (7-25%) usually associated with 
high carrier rates of Enterobacteriaceae, However, successive monthly 
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random samples of about 240 individuals from a normal European 
population yielded variable nasal carrier rates, making it difficult to asses the 
significance of different rates usually measured in a small population. About 
65% of anterior nasal carriers also carry on the turbinates and posterior 
nasal space and seeding from this site may account for apparent intermittent 
carriage in the anterior mares. High carrier rates are recorded for infants: by 
the age of 2 weeks rates of 60-70% of those born at home and 80-100% of 
those born in hospital. The rate declines to 20% by the end of infancy and 
rises again to reach the adult level by about 5-8 years. In eldely persons it 
declines to 20-25%. Repeated sampling of the same population yields 
cumulative nasal carrier rates of 60-90%; 20-35% of persons are persistent 
carriers, 30-70% are intermittent carriers and 10-40% are never carriers 
(Williams 1963).^°° Persistent carriers usually harbour the same strain for 
months or years, indicating a marked stability in the nasal flora. Those who 
acquired a 'hospital Staphylococcus' in the nose while an in-patient, were 
frequently readmitted carrying their original domestic strain. ''°'''°9''''*8'356 
Information on throat carriage of S. aureus is discrepant, with reported rates 
varying from 4 to 64% (Williams 1963).^°° A random sample survey of a 
normal population showed winter carriage rates of about 15% but in spring 
these dropped to about 3%, suggesting that the discrepant rates may be 
seasonally related. Faecal carriage rates in infants generally reflect nasal 
carriage; in normal adults faecal carrier rates are about 20% at a single 
examination and only small numbers of cells are found. This probably also 
reflects nasal carriage. Patients with chronic skin disease, especially the 
eczemas, are almost universally heavily colonized by S. aureus. Patients 
with other skin diseases are less prone to colonization unless large amounts 
of steroid have been used in therapy.^^°'''^'''^^'' 
2.7.2 AIR BORNE DISSEMINATION 
Few staphylococci are disseminated directly into the air from the respiratory 
tract; much larger numbers reach the environment from the body surfaces 
carried on air-borne desquamated skin scales. Some individuals disperse 
organisms very efficiently in this way; some, but not all, are heavy nasal 
carriers and may contribute to environmental contamination in hospital 
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wards. Profuse dispersal is more cornmon in males than females and Is 
related to dispersal from skin areas below the waist. Much dispersal results 
from friction of clothing removing scales from the skin surface but some 
dispersal takes place even from those who are naked. Nevertheless, only 
about 10% of air-borne staphylococci survive the first 24 h, about half dying 
during the initial desiccation process; the infectivity of these dried organisms 
is not known.^^^ 
2.7.3 DISSEMINATION BY CONTACT 
The undoubted reduction in wound sepsis rate which followed the 
introduction of 'no touch' dressing techniques and clear accounts of the role 
of hands in contaminating wounds indicate the importance of the this route 
of infection. Nasal carriers of S. aureus frequently contaminate their fingers 
with their nasal strain and suppression of nasal carriage with antibiotic 
mupirocin has been shown to result in a reduction in hand carriage.^®'°° 
2.7.4 ACQUISITION AT CARRIER SITES 
2.7.4.1 The Neonatal Period 
Newborn babies are very susceptible to colonization with S. aureus, which is 
the usual consequence of their first exposure to the organism; clinical sepsis 
seldom develops without prior colonization. Colonization of the nose, 
umbilical stump, or both rapidly approached 100% but if the stump was 
treated with hexachlorophane the nasal carrier rate was reduced. When the 
use of hexachlorophane ceased in the early 1970s carrier rates rose but the 
introduction of chorhexidine treatment reversed this trend. All are agreed that 
colonization predisposes to infection. Staphylococci may be spread in 
nurseries by the airborne or contact route. Rammelkamp and his colleagues 
compared the rate of colonization from an index source in the same room 
when they were attended to: 
1. with unwashed hands 
2. with effectively washed hands 
3. with gloved hands and 
4. without direct manual contact with the source of infection. 
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Briefly, contact with unwashed hands caused 5 times as many acquisitions 
as air-bome Infection but if the hands were carefully washed or gloved the 2 
routes of acquisition were about equal.^^ '^^ ^^ 
2.7.4.2 Later Acquistions 
Patients admitted to hospital-acquired staphylococci in the nose roughly in 
proportion to the duration of stay in hospital and to the amount of air-borne 
staphylococci to which they are exposed,^^^ suggesting that the inhalation of 
air-borne particles bearing staphylococci is the most important route. 
However, patients admitted to dermatology wards also acquired S. aureus 
on the chest and perineum, though at slightly lower rates than in nose. 
Patients with eczema acquired S. aureus on the chest more often than did 
those with psoriasis, but nasal and perineal acquisition occurred at the same 
rate in each group of patients. Application of topical antibiotics was more 
likely to lead to nasal and chest acquisition than were systemic antibiotics 
but any antibiotic therapy was more likely to lead to acquisition than was 
absence of antibiotic therapy. This agrees generally with the many studies of 
nasal acquisition and the role of antibiotic therapy.^^°'^^^ 
2.8 INFECTIONS OF THE EYE AND STAPHYLOCOCCI 
Staphylococci are the most common, as well as the most thoroughly studied, 
cause of ocular infections. Staphylococci were once regarded simply as 
harmless conjunctival saprophytes. Staphylococcus (usually S. epidermidis) 
is present on the lid margins and very frequently in the corresponding 
conjunctival sac. Therefore, it is recommended that separate specimens be 
taken from the conjuctiva and lids. It is significant that experiments have 
established that ophthalmic Staphylococci produce powerful toxins (Allen). 
The development of tests for pathogenicity is also of major importance. With 
the advent of antibiotics, acute Staphylococcal infections (especially 
cellulites), which were previously dangerous can now be successfully 
treated. However, treatment of chronic Staphylococcal infections and 
prevention of their recurrence are still serious problems in ophthalmology. 
The importance of allergic reactions to staphyhcoccal Infections is now 
frequently discussed; all staphylococci may be antigenic. Unfortunately, 
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allergy cannot be satisfactorally provern until the various types of 
sensitization are more fully understood. 86,135,182,299,385,433 
2.8.1. BLEPHARITIS 
Two clinical forms of blepharitis are seen: ulcerative form and squamous. 
Staphylococci play a primary role in the ulcerative form and a secondary role 
in the squamous type (usually seborrheic), where the Staphylococcus acts 
as secondary invader. Either type may recur and persist for years. The 
conditions are usually associated with conjunctivitis and purulent 
inflammation of the hair follicles as well as of the adjacent meibomian glands 
(hordeolum externum and internum). Accumulation of bacteria under the 
crusts of the ulcer or inside the meibomian glands results in a process of 
long duration and, often, hypersensitivity phenomena. Tylosis ciliaris 
(thickening of the lid margins) and madarosis (loss of cilia) caused by 
destruction of the hair follicles are unpleasant complications of the process. 
These irreversible changes are dangerous to the cornea because of 
exposure and dysfunctions of the lacrimal film.'*^^ 
2.8.2 HORDEOLUM 
Hordeolum internum is an acute inflammation of the meibomian glands, 
aggravated by Staphylococci. The process is stubbornly resistant to 
treatment (drugs do not readily penetrate the glands). Hoedeolum externum 
(acute inflammation of the Zeis gland) is usually a staphylococcal infection. 
The process is more accessible to treatment. If it is localized at the angulus 
externus, a tremendous edema may develop, as the lymphatic ways cross 
here. Hordeolosum, the persistent recurrence of several hordeola, may be 
seen in patients with chronic blepharitis or conjunctivitis or in debilitated 
persons. Staphylococci can also cause such dangerous diseases as orbital 
cellulitis and intraocular postoperative infection. Most cases of bacterial 
postoperative endophthalmitis are caused by Staphylococcus. Frequently it 
is a hospital-acquired strain. The lid margins and nasal passages are 
potential sources of infection. For diagnosis, the aspiration of the anterior 
chamber and vitreous is necessary. Unfortunately, diagnosis is not always 
successful, particularly after treatment."^® 
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staphylococci are the most common secondary invaders in many 
conditions: dacryocystitis, trachoma, pemphigus, keratomalacia, and some 
others. In such viral infections as measles, influenza, and adenoviral 
infection, superimposed staphylococcal infection may lead to serious 
complications. Most frequently, staphylococcal infections of the eye are 
associated with skin diseases.'*^ ® 
2.8.3 CONJUNCTIVITIS 
In adults, conjunctivitis is usually chronic and secondary to blepharitis, which 
is sometimes unnoticed, especially when mild. Chronic conjunctivitis is most 
troublesome, particularly in old people, since it is of long duration and 
recurrent. In these cases, factors besides staphylococci have to be 
considered: dryness of the conjunctiva, wearing of contact lenses, use of 
mascara, metabolic disturbances, and others. Acute conjunctivitis, seen 
usually in children, is less frequent than the chronic form and may develop 
independently of blepharitis. Acute conjunctivitis has a rather typical 
appearance: (1) the lower palpebral conjunctiva is predominantly affected, 
(2) the discharge may be scanty or heavy, but the underlying tissue is little 
involved, (3) the condition is initially acute and if not properly treated may 
easily become chronic, and (4) corneal complications are not infrequent. 
Acute staphylococcal conjunctivitis of the newborn differs from the condition 
as manifested in later life. It is a purulent but superficial type with very little 
tissue involvement, probably due to prevention by coagulase action. 
Nevertheless, it can occasionally be as acute as gonococcal conjunctivitis. 
Corneal involvement is uncommon, and there is no tendency to chronicity. 
The explanation for these peculiarities probably lies in some anatomic 
characteristics (absence of lymphatic tissue in the conjunctiva and 
rudimentary meibomian glands) peculiar to the neonate. Phyctenules are a 
frequent reaction to staphylococcal conjunctivitis, particularly in children. The 
lesions often ulcerate.^ '^^ '^ ^^ '^^ ^^.srs 
2.8.4 KERATITIS 
Surprisingly, primary central staphylococcal hypopyon keratitis rarely results 
from corneal injury. The keratitis usually develops secondary to 
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staphylococcal conjunctivitis or blepharoconjunctivitis. The most frequent 
type of keratitis is marginal, characterized by a small, grayish infiltrate 
adjacent to but always separated from the limbus by a narrow clear zone. 
The small, multiple infiltrates may run along the entire limbus and the 
infiltrated area ulcerates readily. The process may be caused by 
staphylococcal toxin, and bacteria are usually not found in the scraping from 
the ulcer itself. The keratitis is mild and is generally cured together with the 
conjunctivitis. Epithelial punctate keratitis also may complicate 
staphylococcal infection. Tiny punctate epithelial erosions, most marked in 
the lower half of the cornea, can be seen only by staining with fluorescein. 
This condition is most often observed in staphylococcal conjunctivitis and is 
probably an allergic or mechanical phenomenon.^°^'^''°'^°^ 
2.9 EMERGENCE OF RESISTANCE IN STAPHYLOCOCCI 
Staphylococci have a record of developing resistance quickly and 
successfully to antibiotics. This defensive response is a consequence of the 
acquisition and transfer of antibiotic-resistance plasmids and the possession 
of intrinsic resistance mechanisms, some of which may have evolved prior to 
the formation of the genus Staphylococcus. The acquired defense system by 
staphylococci may have originated from antibiotic producing organisms, 
where they may have been developed and then passed on to other genera. 
Presumably the genus Staphylococcus has been one of the recipient genera 
as a consequence of coming in contact with antibiotic-producing bacteria 
and fungi in their natural habitats. Staphylococcoi are sometimes exposed to 
heavy metal ions present in their natural habitat or in the environment, e.g. 
by contact with certain metal-containing cosmetics, ointments, antiseptics 
and soils. They may also participate in genetic exchange with related soil 
bacteria, acting as reservoirs of heavy metal ion resistance genes. ^ ^^  
Three different mechanisms of resistance to p-lactam antibiotics have been 
identified for staphylococci: the inactivation of penicillin (and cephalosporin) 
by penicillinase ((3-lactamase) mediated hydrolysis of the p-lactam ring of the 
antibiotics; an intrinsic resistance resulting from a reduction in the affinity or 
the amount of the PBPs; and tolerance to the bactericidal effect of p-lactam 
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antibiotics due to an excess of autolysin inhibitor.^ ^"^ Penicillin-resistant S. 
aureus strains began emerging shortly after the introduction of penicillin in 
medicine in the early 1940s. Today the percentage of penicillin-resistance 
strains has risen to 75-95%, with the highest percentage found among 
hospital (nosocomial) strains. Similar percentages have been observed for 
penicillin-resistant strains of the S. epidermidis species group. Most 
penicillin-resistance staphylococcal strains produce p-lactamase. p-
Lactamase genes (bla) are most often found on class II plasmids that are 
distributed among many staphylococcal species.^^'^^ Resistance to 
methicillin and other p-lactamase-resistant penicillins was first observed in S. 
aureus soon after the introduction of methicillin into clinical use in Britain.^^^ 
The methicillin-resistant strains isolated in Britain came from hospitalized 
patients, were multiply antibiotic-resistant, belonged to phage III, and their 
resistance to methicillin was heterogeneous, affecting only a minority of the 
cell population.^^ After the mid-1970s, large outbreaks of infection by 
methicillin-resistant S. aureus (MRSA) were recorded in many hospitals in 
Australia, USA, Britain, and Ireland.'*°®'*^ ^ Many of these out breaks appear 
to have been caused by a single epidemic strain that was transferred 
between hospitals by the movement of patients.^^^ Genetic analyses and 
molecular typing methods have indicated that various isolates of MRSA may 
have had a clonal origin, and suggest that the methicillin-resistance 
determinant was acquired by S. aureus at some point in time before or 
around the time of the introduction of methicillin.^^°'^^'' During the 1980s, 
attention was drawn to the high incidence (20-85% of strains) of methicillin-
resistant S. epidermidis (MRSE) in nosocomial infections. Methicillin 
resistance has now been detected in several other staphylococcal species, 
including S. haemolyticus, S. hominis, S. capitis, S. wameri, S. caprae, S. 
simulans, S. saprophyticus and S. 3c/unV'®'^ ®°''*^ ^ 
Erythromycin-resistant staphylococci often have . cross-resistance to 
macrolides (erythromycin, oleandomycin, spiramycin, clarithromycin, 
azithromycin), line cosamides (lincomycin, clindamycin) and streptogramin 
type B antibiotics (designated MLS-resistant). The different types of MLS 
antibiotics bind to the 50S ribosomal subunit at overlapping binding sites. 
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and binding interferes with transpeptidation and translocation reactions 
needed for peptide chain elongation. These sites are protected by the N^,N^-
dimethylation of an adenine-2058 residue at the peptidyi transferase center 
of 23S rRNA, a reaction performed by an rRNA methylase.'* '^* Three distinct 
rRNA methylase genes have been detected in staphylococci: ermA,^^^ 
ermB,^^^ and ermC.^^^ Even though each of the erm gene classes can be 
distinguished by hybridization, the amino acid sequences of the encoded 
methylases are highly conserved, which suggests that they evolved from a 
common ancestor, possibly originating in the antibiotic- producing organism. 
Tetracycline resistance is widespread among staphylococcal species and 
ranks along with p-lactam and MLS resistance as one of the most frequent 
types of antibiotic resistance found in natural populations of 
staphylococci.^ '^^ '^^ °®'''^ ^ There are 3 major mechanisms responsible for 
aminoglycoside resistance in staphylococci. One mechanism involves 
changes in ribosomal proteins as a consequence of certain mutations in their 
structural genes, such that ribosomes can no longer bind streptomycin. A 
second mechanism involves the energization and permeability of the cell 
membrane. Some energy deficient, small-colony mutants of S. aureus have 
been shown to be resistant to aminoglycosides due to a diminished uptake 
of the antibiotics, presumably as a consequence of cell membrane 
impermeability. The third and most common mechanism of resistance 
involves modifaction of aminoglycosides by aminoglycoside-modifying 
enzymes so that the antibiotics are no longer capable of binding to 
Trimethoprim resistance is either mediated by alterations in the expression 
of the intrinsic chromosomal dfr gene possibly resulting in overproduction of 
the native dihydrofolate reductase (DHFR) or a reduced affinity of the native 
DHFR for trimethoprim, or by the acquisition of a second chromosomal or 
plasmid dfr gene that encodes a trimethoprim-resistant DHFR capable of 
rescuing the reduction step leading to tetrahyhdrofofolate in the presence of 
trimethoprim.^^ '^^ ^ '^^ ^^ 
Glycopeptides are being used to treat severe infections caused by methicillin 
and other p-lactam-resistant staphylococci. Teicoplanin resistance 
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(MIC >16 \iQ ml"^) and/or moderate vancomycin susceptibility (MIC 8-16 |ag 
ml"^) have been observed in S. haemolyticus, especially in methicillin-
resistant strains of this species. Strains of S. haemolyticus and S. 
epidermidis that are moderately susceptible to teicoplanin (MIC 16 ng mf^) 
are relatively common.^ '^^ ^^ Recently, infections with strains of MRSA that 
did not respond to vancomycin therapy have been reported. In May 1996, a 
vancomycin hetero-resistant strain (MIC, 18 ng / ml) was cultured from a 
chronically infected surgical wound in a 4-month old boy in Japan, who had 
been treated with the drug for 29 days. There have now been several reports 
of vancomycin intermediate-resistant S. aureus (VISA) infections in the USA, 
France, UK, Germany, Italy, Greece, Korea, Thailand and Australia. VISA 
has been isolated from patients of all age groups who received prolonged 
courses of vancomycin.^'''^°^''*^°'''^''*''^ However it was not until June 2002 
that the first clinical "VRSA" isolate was reported from a patient having 
chronic foot ulcer in Michigan, U.S.A.^ ^ 
Wide use of the fluoroquinolone ciprofloxocin has resulted in a steady 
increase in the incidence of fluoroquinolone-resistant (MIC > 8 ^g/ml'^) 
staphylococci, especially among clinical isolates. The newer 
fluoroquinolones such as fleroxacin, levofloxacin and clinafloxacin are more 
active than ciprofloxacin against ciprofloxacin-susceptible staphylococci by in 
vitro testing; however the problem still remains that fluoroquinolone-resistant 
mutants emerge following exposure to these antibiotics. Fluoroquinolone 
resistance has been identified in the species S. aureus, S. epidermidis, S. 
haemolyticus, S. hominisiesand S. wameri.^^'^^-^^-^^^ 
2.10 STAPHYLOCOCCAL PLASMIDS 
The genome of staphylococci consists of a chromosome to which may be 
added or subtracted various accessory elements, such as prophages, 
plasmids and transposons. The chromosome of S. aureus strain NCTC 8325 
is about 2800 kbp, and has been mapped by genetic and physical methods 
by Pattee^^^''. More than 100 loci have been mapped to date, including 
phenotypic markers and silent transposon insertions. The average size of 
the S. aureus chromosome is 2741 + 277 kbp. 
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Plasmids are facultative extrachromosoni^l genetic systems (eletif ents) and, 
for the most part, they may be regarded^'ois^^ndpsymtiionts't^pplying the 
host ceil with protective and various other adaptlw-rl/HeTOns. Plasmids are 
common in natural populations of most staphylococcal species. 
The characteristics of many of the plasmids from S. aureus have been 
reviewed by Lyon and Skurray (1987)^^^ and Novick (1989).^^^ S. aureus 
plasmids have been classified into 3 general classes, I through III. Class I 
plasmids are of small size (1-5 kbp) and have a high copy number (10-55 
copies per cell), and they usually encode a single antibiotic resistance or are 
cryptic. These plasmids are the most widespread throughout the genus 
Staphylococcus. Novick (1989) has subdivided class I plasmids into 4 
subgroups or families on the basic of their nucleotide sequence and 
functional organization.^^^ Plasmids in this class are largely composed of 
cassettes or specific segments that are not transposons. They represent at 
least 10 different incompatibility groups and replicate by an asymmetric 
rolling-circle mechanism.^^ '^^ ^^ Tetracycline-resistance plasmids (4-4.6 kbp) 
belonging to this family are highly conserved and are very common in a wide 
range of staphylococcal species.^ ^^"*^^ The erythromycin-resistance plasmids 
belonging to this family are usually 2-2.5 kbp in size and except for variation 
in the control region of the eirnC gene, are also highly conseved.^ ^®'^ ^^ 
Class II plasmids of S. aureus have been subdivided into 2 major families on 
this basis of incompatibility. These plasmids, commonoly referred to as 
penicillin or p-lactamase plasmids, are relatively large (15-33 kbp), have a 
low copy number (4-6 per cell), and replicate using the 6 replication 
mechanism."^^^ They carry various combinations of antibiotic and heavy 
metal resistance genes, many of which are located on transposons.^ ^ '^^ ^® 
Class II plasmids have been identified in many other staphylococcal species 
but unlike class I plasmids, they are very uncommon in the species S.hyicus, 
S. intermediuSr S. simulans and S. lugdunensis}^^'^^^'^^^ 
Most of the conjugative plasmids are class III plasmids that encode 
resistance to gentamicin and certain other aminoglycosides, such as 
tobramycin and kanamycin. Many also encode resistance to ethidium 
bromide and quaternary amines, whereas some also encode resistance to 
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penicillin and trimethoprim. These plasmids are relatively large (30-60 kbp) 
and have a conjugative transfer {tra) region that is often flanked by directly 
repeated 900 bp IS257 elements.'*" They are also capable of mobilizing or 
cotransferring certain smaller coresident plasmids, which are not 
independently transferable.^ 
2.10.1 PLASMID STABILITY AND THE EFFECT OF CURING AGENTS 
The spontaneous loss of a particular trait or phenotypic characteristic in a 
strain may be the first indication that the character is plasmid-determined, 
though such loss does not necessarily mean that the genes responsible are 
plasmid-borne. Chromosomal mutations in other bacterial species occur at 
frequencies, which might be mistaken for plasmid loss. However, point 
mutations are often reversible whereas loss of a complete set of genes as 
occurs with loss of an entire plasmid is irreversible. 
2.10.1.1 Plasmid Loss In Vitro 
Plasmid loss does occur spontaneously in growing cultures at normal 
temperature but has also been found to occur in ageing broth cultures, or 
after storage on slope for several months. Plasmids determining penicillinase 
production and others determining tetracycline resistance, have been shown 
to be lost at higher frequencies during incubation at 42 °C-44 °C than at 
37°C. Temperature-sensitivity is often a property of the plasmid itself rather 
than the host cell for introduction of the plasmid into a new host still leads to 
temperature-instability of the plasmid determinant. However, in some strains 
temperature sensitivity may be controlled by the host.^^ '^^ ^° 
Growth at elevated temperature to accelerate plasmid loss is known as 
curing. There are a number of chemical curing agents, which have been 
shown to eliminate plasmids from various bacteria, such agents increase the 
rate of loss of plasmids without having any mutagenic effect on the cell. The 
usefulness of such agents lie chiefly in the identification of plasmid-
determined properties. Various intercalative compounds, which interfere with 
DNA replication, have been found to efficiently eliminate resistance 
determinants from bacteria. Hahn and Ciak (1976) tested the ability of 18 
DNA-complexing compounds to eliminate antibiotic resistance determinants 
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from Salmonella typhimurium. The compound, which caused most efficient 
elimination of resistance determinants, was nitroacridine II, an intercalative 
agent. In Staphylococcus aureus acriflavin has been reported to eliminate 
erythromycin resistance and penicillin resistance. The precise mechanism of 
palsmid elimination by the acridine dyes is not yet clearly understood, but 
ethidium bromide, also an intercalative agent inhibits plasmid DNA synthesis 
by binding between the base pairs of DNA and inhibiting both DNA-
polymerase and RNA-polymerase. An increased rate of loss of the 
penicillinase plasmid in S. aureus strain NCTC 8325 has also been achieved 
using rifampicin, a derivative of rifamycin, but attempts by other workers to 
cure the plasmid from the same strain were less effective and less reliable. 
An agent, which apparently cures by a completely different mechanism, is 
sodium dodecyl sulphate (SDS). This anionic surface-active agent eliminates 
R and F factors from Escherichia with high efficiency and also the 
penicillinase plasmids from S. aureus. The effect of SDS in S. aureus is 
obscure but in E. coli increased plasmid loss is thought to occur by selection 
of spontaneous variants rather than true curing. Other reported plasmid 
curing agents include novobiocin and guanidine hydrochloride. Because of 
the unreliability of the activity of curing agents in genral, it is difficult to 
envisage any practical of therapeutic application in vivo of these chemical 
compounds. Attempts have been made to investigate the effects of some 
curing agents in mice infected with multi-resistant plasmid-carrying bacteria. 
However, the work indicated that no practical effectiveness could be 
expected from the curing drugs currently used.^^ '^^ ''°'^ '^' 
2.10.1.2 Plasmid Loss In Vivo 
Evidence for plasmid or antibiotic resistance loss in vivo is limited. Loss of 
resistance to five antibiotics from a strain of S. aureus, isolated repeatedly 
from a patient has been attributed by Lacey et al., (1973) to treatment with 
cloxacillin.^^"' Indeed, exposure of the strain to cloxacillin in vitro resulted in 
the loss of one or more of the antibiotic resistance markers. Loss of 
methicillin resistance, penicillinase production and neomycin resistance from 
a strain of S. aureus investigated over a three-month period in a hospital has 
also been observed. The prevalence of antibiotic resistant staphylococci 
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from the skin and nares of dermatology patients has been investigated by 
Noble (1977). He reported that in individuals colonized with antibiotic 
resistant S. aureus more sensitive variants v\/ere found in the nose compared 
to the skin. This probably represented plasmid loss in vivo and the particular 
distribution found may have been the result of either selection for resistance 
on the skin or for sensitive variants in the nose. The factors or mechanisms 
controlling plasmid loss or the selection of either resistant or sensitive 
variants in vivo are not yet clearly understood. However, on skin the fatty 
acids, e.g. linoleic acid, may play an important role in determining the 
distribution of plasmid-bearing and plasmid-less cells.^ '^'•^^ '^^ ''^  
2.11 TRANSFER OF ANTIBIOTIC RESISTENCE IN STAPHYLOCOCCI 
Antibiotic resistant strains may occur as the result of (i) a pre-existing 
resistant strain (ii) a pre-existing mutant or (iii) as the result of transfer of 
resistance genes. These stains may then be selected to form a resistant 
population as a result of antibiotic use. In the last category, genes are often 
carried by plasmids, which can be transferred from one bacterial strain to 
another. A resistance gene can also be organized as part of a transposon 
which can transfer between bacterial replicons both chromosomal and 
plasmid to build up more complex groups of genes on single plasmids or to 
introduce them into the bacterial chromosome. The widespread presence of 
resistance plasmids for the same maker or a group of makers suggests that 
transfer occurs in vivo; as it is unlikely that each has evolved separately on a 
large number of different occasions. However, an alternative explanation 
could be that the plasmid has been conserved to a high degree during the 
evolution of the bacterial host strain. In the staphylococci, transfer by 
transduction occurs readily in vitro. Transfer can also be demonstrated by 
transformation and by a process requiring mixed culture in which phage can 
sometimes be shown to be directly involved. Protoplast fusion can also be 
used for the study of chromosomal recombinants and for the transfer of 
resistance plasmids.^ ^ •^"^ ^ •^"^ ^ 
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2.11.1 TRANSDUCTION 
Among the staphylococci, in vitro transduction techniques are well 
documented and have been invaluable in the elucidation of the genetics of 
antibiotic resistance in S.aureus.^^^'^^ Transduction was first reported using 
a u. V induced lysogenic strain (PS 53 lysogenzed with phage 53) as donor 
and a phage sensitive culture (PS 53) as recipient. Transfer of streptomycin 
or novobiocin resistance at frequencies around 10"^  to 10'° per phage particle 
indicated that co-transfer of genes by chance would be rare and co-
transduction would indicate that genes were closely linked. Successful 
transduction has since been achieved for a wide range of chromosomal and 
plasmid markers at frequencies per phage particle ranging from about 10"^  to 
10"^ ° using lysogenic recipient strains, temperate phage propagated by lytic 
growth and virulent phage. The fragments of DNA carried by transducting 
phage particles are largely homogenous .The amount of bacterial DNA, 
which can be transferred, depends on the amount, which can be 
incorporated into the phage particles. The size of the phage genome is 
about 28 X lO^daltons for transducing phage 011 (previously P11) and 31 x 
10® for the transducting and typing phage 80. This genome size probably 
represents about 1%of the total amount of DNA carried by the staphylococci 
cell. Plasmid isolated so far in staphylococci have a moleculer weight range 
of about 1 X 10® to an upper limit of about 32 x 10® so that only at the larger 
end of scale will the transfer of the complete plasmid be restricted if it 
assumed that size is the only limiting factor. Many bacteria including 
staphylococci have restriction and modification systems, which degrade and 
modify DNA. This can be shown to affect the ability of a strain to act as 
recipient in in vitro experiments and could de important in the spread of 
resistance in vivo. Most examples of transduction in staphylococci have the 
characteristics of a generalized transduction system in which many different 
markers can be transferred. Novick (1967) isolated a high frequency 
transducing element in S. aureus us a result of recombination between the 
transducing phage P11 and a plasmid coding for penicillin and erthromycin 
resistance carried in the same donor strain.^^ '^^ ^ '^^ ^^ 
81 
2.11.2 TRANSFORMATION 
Transformation involves the uptake and expression of DNA from a donor 
strain by a recipient strain and has been shown for both chromosomal and 
plasmid markers in S. aureus}^^ The ability of a strain to be transformed is 
desccibed as competence, although strictly the term should only apply to the 
uptake of DNA itself. Competence depends on a number of different factors, 
which have been well defined. The conditions under which transformation 
occurs are very similar to those required for the uptake of free phage DNA 
by transfection. The competence of a strain is dependent on the presence of 
a high concentration of divalent ions. Ba^ "^ , Mg^ "^  and Ca^* ions all enhance 
competence in strain 8325 but Ca^* ions are the most effective at an 
optimum concentration of 0.1 mmol. If transformation is unsuccessful, this 
may also be due to nuclease production by the recipient strain or to the 
presence of host restriction. Experimentally, the former may be overcome by 
the isolation of nuclease-negative mutants in the recipient and the latter 
either by heating the recipient at 56°C for 2 min, which temporarily 
inactivates the restriction enzymes, or by the use of restriction-negative 
mutants. The method of preparation of the transforming DNA is also 
important.^^^'^^' 
Transformation provides an important technique for studying the genetic 
organization of the choromosome in S. aureus and has certain advantages 
over transduction in this respect. Larger fragments of DNA are involved and 
these are more heterogenous than those generated in transduction. The 
uptake of DNA by transformation enables the study of fragments of plasmid 
DNA generated by restriction endonucleaces or fragments, which have been 
cloned into a suitable plasmid carrier. Plasmids can also be studied in strains 
other than their normal host. These include naturally occurring plasmids and 
hybrid plasmids derived by the techniques of genetic engineering. In the 
former category, staphylococcal antibiotic resistance plasmids have been 
transferred into Bacillus subtilis to study the mechanisms of DNA uptake of 
these readily identifiable molecules and transfer of resistance plasmid from 
S. epidermidis and B. subtilis to S. aureus has also been demonstrated. In 
the later, penicillinase genes from a staphylococcal penicillinase plasmid 
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inserted into an E. coll vector plasmid, have been introduced into E. coll 
where gene expression occurs.'*^^ . 
2.11.3 TRANSFER OF PLASMID GENES IN MIXED CULTURES 
The conventional transduction process described for staphylococci may not 
operate in vivo in the classical way due to the different environmental 
conditions. Transduction procedures usually employ high litres of free phage 
particles and high concentrations of cells, conditions that do not occur in the 
natural envionment. A number of recent reports have shown that antibiotic 
resistance can be transferred from one strain to another in mixed broth 
culture. As staphylococci are often found in close proximity to one another 
under natural conditions, this form of transfer may well have contributed to 
the spread of antibiotic resistance in vivo?^'^ 
Transfer In Vitro 
Lacey and his colleagues have demonstrated the transfer of tetracycline, 
neomycin, penicillin, erythromycin and gentamicin resistances individually in 
mixed broth culture. The simultaneous transfer of three plasmid-mediating 
resistances to tetracycline, chloramphenicol and penicillin, in mixed broth 
culture has also been described. Apart from plasmid-mediated resitances, 
the transfer of chromosomal novobiocin, rifampicin and streptomycin 
resitances has also been shown to occur when donor and recipient culture 
are incubated together.^^^ 
Engel et al. (1980) have achieved transfer of plasmid resistance from 
Streptococcus pneumoniae to S. aureus in mating experiments on filters. If 
phage were involved in this sort of transfer it would have to have an 
extremely broad host range. Further schaberg et al. (1982) have reported 
the conjugative transfer of plasmids between Strep. Faecalis and S. aureus 
in which phage appears to play no part. Conjugation in the streptococci is 
now well established so it would not seem surprising if other Gram-positive 
cocci also had the ability to transfer plasmids by a conjugation system. The 
transfer of antibiotic resistance plasmids between S. epidermidis and 
S. aureus also occurs in mixed broth culture. However, there is evidence 
against phage-mediated transfer in this report. The use of an encapsulated 
recipient strain and treatment of donor and recipient cells with y-globulin. 
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which inhibit phage adsorption, did not inhibit plasmid transfer. Transfer of 
the gentamicin resistance plasmid occurred in the absence of calcium ions 
and in the presence of DNase. The frequency of transfer was markedly 
increased when donor and recipient cultures were incubated on filters, 
indicating a conjugative process involved in the transfer. Further the 
gentamicin resistance plasmids of two different species of coagulase-
negatlve staphylococci could mobilize and facilitate the transfer of other 
resistance plasmids, analogous to the conjugative R-plasmids of the Gram-
negative bacteria. It is therefore probable that conjugation occurs between 
S. aureus strains and also between coagulase-negative staphylococci and 
S. aureus. In vivo staphylococci accumulate in large numbers in pathological 
situations, e.g. boils, abscesses and on the skin of dermatology patients who 
are often subjected to antibiotic therapy. The close contact of cells in 
conditions such as these would favor conjugation as a means of transferring 
resistance.'^''''' 
2.11.3.2 Transfer In Vivo 
Transfer of tetracycline resistance in mice has been demonstrated by the 
intravenous injection of the recipient strain of S. aureus followed by 
transducing phage. If transfer occurs naturally in vivo the site is more likely 
to be the skin or nasal epithelium rather than the internal tissues. The 
transfer of resistance to neomycin, pencillin, erythromycin, tetracycline and 
gentamicin has been attained on skin. Transfer of resistance to 
chloramphenicol and tetracycline has been shown to occur between strains 
of S. aureus in local lesions in mice.'^° All these reports illustrate the 
potential of skin as the environment for the transfer of antibiotic resistance 
and probably other factors also. Naidoo and Noble (1981) found that the 
transfer of a plasmid mediating gentamicin resistance from S. hominis to 
clinical isolate of S. aureus and various S. aureus phage propagating strains 
occurred for some strains at higher frequency on skin than in broth 
culture.'^' It would seem that for some strains skin facilitates transfer of 
plasmids. The few reports of plasmid transfer in vivo indicate that skin may 
be the environment for the transfer of resistance plasmids not only between 
S. aureus but also between the resident coagulase-negative staphylococci 
and S. aureus.^^''^' 
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2.12 MOLECULAR BASIS OF METHICILLIN RESISTANCE IN 
STAPHYLOCOCCI 
Methicillin-resistant strains of staphylococci were Identified immediately upon 
the introduction of methicillin into clinical practice.^ '^^ ^^ Resistance was 
termed "intrinsic" because it was not due to destruction of the antibiotic by p-
lactamase. The first outbreaks of infections caused by methicillin resistant 
staphylococci aureus occurred in European hospitals in the early igSOs.'*^^ 
Since then, strains of methicillin-resistant Staphylococcus aureus and 
methicillin resistant coagulase-negative staphylococci have spread 
worldwide^^^ and have become established outside of the hospital 
environtment, particularly among patients in chronic care facilities and in 
parenteral drug abusers.^^* There has been a steady increase in the 
prevalence of methicillin-resistant strains of S. aureus isolated in hospitals in 
the United States over the years such that now approximately 25% of 
nosocomial isolates of S. aureus are methicillin resistant. 
2.12.1 mec DNA 
Approximately 30 to 50 kb of additional chromosomal DNA, mec, not found 
in susceptible strains of staphylococci is present in methicilin-resistant 
strains,^°^ mec is always found near the pur-nov-his gene cluster on the S. 
aureus chromosome (Figure 2.6). mec contains mecA, the structural gene 
for penicillin- binding protein 2a (PBP 2a); mecl and mecR1, regulatory 
elements controlling mecA transcription; and 20 to 45 kb of mec-associated 
DNA.^ ^^ 
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Figure 2.6 mecA Region of Different Staphylococcal Strains ^ ^ 
IS; insertion sequence; mecA, methicillin-resistant gene; R1, regulatory 
element; Tn, transposon, vertical lines; position on restriction enzyme 
cleavage sites. 
l.MAA mecA 
mecA encodes PBP 2a (also termed PBP 2'), an inducible 76-kDa PBP that 
determines methicillin resistance. There is no mecA homolog in susceptible 
strains. Both susceptible and resistant strains of S. aureus produce four 
major PBPs, PBPs 1, 2, 3, and 4, with approximate molecular masses of 85, 
81, 75 and 45 kDA.^ ^^ PBPs are membrane bound DD-peptidases that have 
evolved from serine proteases,^^^ and their biochemical activity is 
mechanistically similar to that of the serine proteases. These enzymes 
catalyze the transpeptidation reaction that cross-links the peptidoglycan of 
the bacterial cell wall. p-Lactam antibiotics are substrate analogous that 
covalently bind to the PBP active site serine, inactivating the enzyme at 
concentrations that are approximately the same as the MICs. PBPs 1, 2, and 
3, which have high affinity for most p-lactam antibiotics, are essential for cell 
growth and for the survival of susceptible strains, and binding of p-lactam by 
these PBPs is lethal.^^ In methicillin-resistant cells, PBP 2a, with its low 
•affinity for binding p-lactam antibiotics, can substitute for the essential 
functions of high-affinity PBPs at concentrations of antibiotic that are 
otherwise lethal.^^'' mecA is highly conserved among staphylococcal 
species. ^^ '^ ^ The mecA gene product, PBP 2a, is a high-molecular weight 
class B PBP.^ '^* The same penicillin-binding motifs as those found in the 
penicillin-binding domains of high-affinity PBPs also are present in PBP 2 a, 
but the precise structural basis for its low affinity is not understood. The 
mecA promoter region, the first 300 nucleotides of mecA, and its regulatory 
genes are similar in sequence to the analogous regions of the 
staphylococcal p-lactamases.''^^ The origins of mec are obscure. A mecA 
homolog with 88% amino acid silimarity to mecA of methicillin-resistant 
staphylococci has been identified is Staphylococcus sciuri. Interestingly, the 
mecA homolog is ubiquitous in this species, but its phenotype is susceptible. 
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These and other data support the hypothesis that mecA originated in a 
coagulase-negative Staphylococcus speices, possibly a close evolutionary 
relative of S. sciuri. All methicillin-resistant strains of S. aureus are clonal 
descendents from the few ancestral strains that acquired mecAV'^°^'^^^ 
How mecA was acquired by methicillin-resistant staphylococci is not known, 
but transposition is a plausible mechanism. The presence of one or more 
copies of the \S431 element (also known as IS257, a putative mobile 
element often associated with genes encoding a variety of resistance 
determinants) within mec, inverted repeats at the ends of mec, and 
identification of two open reading frames within mec that may encode 
recombinases all suggest that mecA and its associated DNA are mobile 
elements. The p-lactamase plasmid may provide a temporary insertion site 
for the mec-containing transposon. There is one report, somewhat 
controversial because it has never been confirmed, of a mecA containing 
transposon, Tn429'/, residing in an insertion site on the p-lactamase plasmid 
p,524.15,167,207 
2.12.1.2 mec/and mecR1 
mecl and mecR1 are divergently transcribed regulatory genes located 
immediately upstream from the mecA promoter. They are similar in 
molecular organization, structure function, and mechanism of regulation to 
staphylococcal p-lactamase regulator/ elements, blal and blaR1. Blal is a 
DNA-binding protein that represses p-lactamase gene transcription. BlaR1 
is a signal-transducing PBP that in the presence of p-lactam antibiotics 
leads to p-lactamase gene transcription, although the precise mechanism by 
which this occurs is not known, mecl and mecR1 perform analogous 
regulatory roles for mecA. It seems likely that mecl polymorphisms and 
mecA promoter mutations found in most clinical isolates of methicillin-
resistant S. aureus reflect the selective pressure of p-lactam antibiotics for 
mutants lacking strong repressor activity, so that the amount of PBP 2a 
poroduced is sufficient to offer a survival advantage. PBP 2a production in 
stains with mecl or mecA promoter mutations is under the control of both 
mec and p-lactamase regulatory genes.^ '^^ ® '^^ °^ ''*'*^  
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2.12.1.3 mec-Associated DNA 
mecA, mecR1, and mecl are encoded by approximately 5 kb of DNA that is 
itself located within 25 to 50 kb of additional DNA that may contain up to 100 
open reading frames.^°^'^°^ Transposons and Insertion sequences are 
present, including Tr)554 (which contains ermA, the gene encoding inducible 
erythromycin resistance), located 5' of mecA, and one to four copies of 
\S431, at least one of which, \S431mec, is located 3' of mecA. The distance 
between mecA and \S431mec is highly variable due to deletion, 
rearrangement, and recombination events that may occur In this region. 
\S431 is an extremely common insertion sequence in the staphylococcal 
chromosome and plasmids and can be associated with a host of resistance 
determinants, including mercury, cadmium, and tetracycline resistance. For 
example, the addD gene, which encodes an enzyme for tobramycin 
resistance, is located on plasmid pUBIIO, which has intergrated into mec 
associated DNA within \S431mec. The ability of \S431 elements through 
homologous recombination to trap and cluster resistance determinants with 
similar IS elements explains the multiple drug resistance phenotype that is 
characteristic of methicillin-resistant staphylococci.^^'^^ 
2.12.2 HETEROGENEOUS RESISTANCE 
A distinctive feature of methicillin resistance is its heterogeneous nature with 
the level of resistance varying according to the culture conditions and p-
lactam antibiotic being used.^ ®^ The majority of cells in heterogeneous 
strains (typically 99.9% or more) are susceptible to low concentrations of p-
lactam antibiotic, e.g., 1 to 5 ^g/ml of methicillin, with only a small proportion 
of cells (e.g., 1 in 10 )^ growing at methicillin concentrations of 50 )ag/ml or 
greater. Most clinical isolates exhibit this heterogeneous pattern of 
resistance under routine growth conditions. Heterogeneous strains can, 
however, appear homogeneous (i.e., 1% or more of cells grow at 50 jig/ml of 
methicillin per ml) under certain culture conditions, such as growth in 
hypertonic culture medium supplemented with NaCI or sucrose or incubation 
at 30°C. Addition of EDTA (pH 5.2) or incubation at 37 to 43°C favours a 
heterogeneous pattern and may suppress resistance entirely. These 
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changes in expression of resistance with different culture conditions are 
transient and entirely phenotypic. Passage of a heterogeneous strain in the 
presence of p-lactam antibiotic alters the resistance phenotype by selecting 
for highly resistant nnutant clones. These clones produce a homogeneous 
population of highly resistant cells that can grow at methicillin concentrations 
of 50 to 100 |ag/ml. The trait tends to be unstable in these laboratory -
selected clones. With repeated sub-culture in antibiotic-free medium, the 
proportion of highly resistant cells gradually diminishes and the original 
heterogeneous pattern reemerges. There are rare clinical isolates, with the 
COL strain of S. aureus being most extensively studied, and some 
laboratory-derived mutants that consistently are homogeneous despite 
repeated subculture.^°'^^^'*°^ 
2.12. 3 BORDERLINE RESISTANCE 
Another type of methicillin resistance is that exhibited by so -called 
borderline (or low-level) mechicillin-resistant strains. These strains are 
characterized by methicillin MICs at or just above the susceptibility 
breakpoint (e.g., oxacillin MICs of 4 to 8 i^g/ml). Borderline strains may be 
divided into two categories on the basis of whether mecA is present. 
Borderline strains that contain mecA are extremely heterogeneous 
methicillin-resistant strains that produce PBP 2a. These strains have 
resistant subpopulations of cells, although it may be quite small, that can 
grow at high drug concentrations. Borderline strains that do not contain 
mecA can be differentiated phenotypically from extremely heterogeneous 
mecA -positive strains in that highly resistant clones do not occur. Borderline 
resistance in mecA -negative strains has been hypothesized to result from 
modification of normal PBP genes or overproduction of staphylococcal p-
lactamase.^^^ There is good evidence that modified PBPs can produce 
borderline resistance. Tomasz et al. reported alterations of penicillin binding 
by PBPs 1,2, and 4 in p-lactamase-negative, mec/\-negative borderline 
clinical isolates. Methicillinase activity distinct from plasmid-encoded 
stayhylococcal p-lactamase also has been reported in borderline p-
lactamase hyper-producers, suggesting that a novel p-lactamase, rather 
than overproduction per se, may be important. However, the putative 
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methecillinase gene has yet to be identified. Finally, PBP 2 sequence 
analysis of some p-lactamase-hyper- producing borderline strains has 
revealed mutations identical to some of those found in a p-lactamase-
negative borderline strain that has modified PBPs.^ ®^ No clinical data 
suggest that the level of resistance expressed by mecA -negative borderline 
strains leads to treatment failure. Data from animal studies show that the 
semisynthetic penicllinase- resistance penicillins are effective for infections 
caused by mec^ A -negative borderline strains. Hence, other than the diffculty 
in differentaiting mecA -negative from mecA -positive strains expressing 
borderline resistance, the phenomenon is probably of little, if any, clinical 
significance.^^ •^°^ 
2.12.4 FACTORS AFFECTING RESISTANCE PHENOTYPE 
Numerous genes that influence methicillin resistance phenotype have been 
identified. Staphylococcal p-lactamase plasmid can affect resistance in 
several ways. It may prevent spontaneous deletion of mec from the 
chromosome, which would produce a susceptible phenotype.^°° Introduction 
of a p-lactamase plasmid into a homogeneously resistant recipient can lead 
to a heterogeneous pattern of resistance.^^ p-Lactamase regulatory genes 
may affect the expression of resistance. Mutations altering the inducibility of 
p-lactamase have been associated with reduced (i.e., heterogeneous) 
expression of methicillin resistance. Inactivation of blaR1 can produce 
heterogeneous resistance, presumably by the unopposed repressor activity 
of blal. Similarly, strains containing functional mec regulatory genes produce 
little or no PBP 2a basally and are poorly inducible by many p-lactamase 
antibiotics, and induction is slow when it does occur, so that expression of 
resistance is relatively or completely suppressed. Mutations in the mecA 
promoter region that affect repressor binding to its operator or otherwise 
alter gene transcription so that little or no PBP 2a is produced, or structural 
gene mutations that render the expressed protein nonfunctional may also 
result in a susceptible phenotype. 
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2.12,4.1 fern Factors 
Transposon insertional mutagenesis producing susceptible mutants from 
methicillin-resistant strains has led to the identification of chromosomal 
genes, physically distinct from mec, that are necessary for full expression of 
resistance. These fern (for factor essential for methicillin resistance) or aux 
(auxiliary) factors are present in both susceptible and resistant strains.^ '^^ ^^ 
Six fern genes, femA, femB, femC, femD, femE, and femF, which map to 
numerous sites throughout the staphylococcal genome, have been 
characterized. Even more determinants affecting resistance are likely to be 
identified. Except for femE, which is of unknown function fern mutants have 
altered peptidoglycan composition.^^^ The agr (accessory) gene regulator) 
locus and the sar (staphylococcal accessory regulator) locus are involved in 
controlling the expression of numerous staphylococcal virulence factors and 
exoproteins. Inactivation of either locus in a heterogeneous strain resulted in 
a slight decrease in the number of highly resistant cells, although the level of 
resistance expressed by these cells was unaffected. PBP 2a production was 
unaffected, but the amounts of PBP1 and PBP 3 were reduced, suggested 
that these PBPs could play a role in expression of resistance.^^'*'^^ 
Although the fern, aux, and other factor appear not to explain heterogeneous 
or homogeneous resistance in wild-type strains (i.e. those that have been 
adequately characterized are present and functioning normally regardless of 
whether the phenotype is susceptible, heterogeneous, or homogeneous), a 
working model of resistance can be proposed based on an understading of 
these factors. Heterogeneous strains may be deficient in a factor or lack a 
critical modification in a biochemical pathway, possibly for cell wall synthesis, 
that is important to the functions of PBP 2a, which, after all, is a "foreign" 
PBP. Homogeneous strains then arise from heterogeneous strains by p-
lactam antibiotic selection pressure favouring mutants whose genetic 
background allows for a fully functional PBP 2a.^°^'^''^ 
2.13 VANCOMYCIN RESISTANCE IN STAPHYLOCOCCI 
The glycopeptide antibiotic vancomycin was introduced clinically in 1958 for 
the treatment of Gram-positive bacteria. Data from the December 2000 
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Report of the National Nosocomial Infection Surveillance (NNIS) System 
indicated that about 75% of coagulase-negative staphylococci and 47% of S. 
aureus isolates from intensive care units were resistant to methicillin.^^^ 
Vancomycin remains the drug of choice for these infections. Vancomycin 
resistance among staphylococci was developed in laboratories even before 
the drug was in use clinically. However, this resistance was so difficult to 
induce that many felt it would be unlikely to occur in a clinical setting. That 
no vancomycin-resistant staphylococci were reported in the first 20 years the 
drug was used only strengthened this assumption. Unfortunately, this 
confidence was shattered by the first reports of vancomycin resistance in 
coagulase-negative staphylococci in 1979 and 1983. Though a cause for 
concern these reports did not generate a great deal of attention as 
coagulase-negative staphylococci are generally considered to be relatively 
avirulent organisms. A very different response greeted the first report of 
decreased susceptibility to vancomycin in S. aureus in 1997. Similar ones 
from other countries, including the United States, quickly followed this report. 
Given the well-known virulence of S. aureus, the isolation of these 
organisms generated enormous concern in the medical community and has 
prompted a flurry of activity aimed at limiting their emergence. '^^ '^ ^ '^'^ '* 
Definition of Vancomycin Resistance 
NCCLS guidelines define staphylococci for which the MIC of vancomycin is 
< 4 \xg/rr\\ to be susceptible, while isolates for which the MIC is 8 to 16 (ig/ml 
are intermediate and those for which the MIC is 8 to 16 |xg/ml are 
intermediate and those for which the MIC is > 32 jag/ml are resistant. Japan, 
however, considers some isolates for which the MIC is 8 ^g/ml to be 
resistant; as a result, some isolates reported as resistant in Japan have been 
reclassified as intermediate in the United States.'*^^ 
Confusion with respect of vancomycin resistance in staphylococci is also 
engendered by use of the term "heteroresistant staphylococci." This 
phenomenon, which is seen in both coagulase-negative staphylococci and 
S. aureus, refers to the variability of vancomycin susceptibilities among 
subpopulations of single isolate. A heteroresistant isolate contains two 
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populations of cells, a majority population that is susceptible to vancomycin 
and a minority population that is resistant. Heteroresistant is likely more 
common than pure resistant or diminished susceptibility, as evidenced by the 
fact that it was found in up to 20% of S. aureus isolates in one hospital in 
Japan. 
Laboratory Detection of Vancomycin Resistance 
Vancomycin resitance can be difficult to detect in the clinical microbiology 
laboratory. Disk diffusion sensitivity testing using the standard SO-^ g 
vancomycin disk frequenctly misclassifies intermediately susceptible isolates 
as fully susceptible. In a recent study, 75% of microbiology laboratories from 
around the world misreported a glycopeptible-intermediate strain of 
Staphylococcus epidermidis as susceptible based on the results of disk 
diffusion testing. At this time, however, nonautomated MIC determinations by 
broth or agar dilution or by E test are the "gold standard" for determining 
vancomycin susceptibility. The Centers for Disease Control and Prevention 
(CDC) has published recommendations to guide vancomycin susceptibility 
testing of S. aureus isolates. These recommendations state that (i) primary 
testing of S. aureus requires at least 24 h of incubation, (ii) susceptibility 
determination with disk diflusion is not an acceptable method, and (iii) an 
MIC testing method should be used to confirm vancomycin susceptibility. 
Any S. aureus isolate for which the MIC is > 4 \xglm\ should be sent to the 
CDC for confirmatory testing.^^ 
Infection Control Issues 
The epidemiologic importance of vancomycin resistance has brought a great 
deal of attention to infection control issues regarding the spread of 
vancomycin-resistant staphylococci. The infection control community is 
understandably nervous, given the rapid dissemination of vancomycin-
resistant enterococci that has occurred in hospitals around the world. It has 
been established that S. aureus can be transmitted between patients by 
several routes, including environmental surfaces, hands of health care 
workers, and nasal shedding. It is also assumed that vancomycin-resistant 
staphylococci can be transmitted by the same mechanisms as their sensitive 
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counterparts. Indeed, there has been one reported outbreak of vancomycin-
intermediate S. aureus (VISA) in a French hospital among patients who had 
not received any glycopeptide antibiotics and whose primary risk for 
acquiring the organism was environmental exposure. Given the enormous 
public health concerns regarding the dissemination of these organisms, the 
Hospital Infections Control Practices Advisory Committee (HICPAC) of the 
CDC published infection control guidelines for all staphylococci for which the 
MIC of vancomycin is >8ng/ml in 1997.^ -^^ ^° 
2.12.1 VANCOMYCIN RESISTANCE IN COAGULASE-
NEGATIVE STAPHYLOCOCCI 
Epidemiology of Vancomycin Resistance 
Resistance to vancomycin among coagulase-negative staphylococci was 
first reported more than 20 years ago. However, the first report of a clinically 
significant isolate was in 1987. Since that time, there have been at least five 
other case reports of clinically relevant coagulase-negative staphylococci 
that had diminished susceptibility to vancomycin.^^^''^^'*" 
Mechanisms of Vancomycin Resistance 
The true mechanism of vancomycin resistance in these species, though 
currently unknown, is a topic of active investigation. Vancomycin acts by 
binding irreversity to the terminal D- alanyl-D-alanine of cell wall 
disaccharide-pentapeptide precursors, thereby inhibiting production of the 
bacterial cell wall Enterococci have developed vancomycin resistance by 
replacing the terminal alanine with a lactate, which has a greatly reduced 
affinity for vancomycin. Studies of vancomycin resistant, coagulase-negative 
staphylococci have shown that these altered cell wall precursors are 
produced, but in amounts that are likely too small to account for the degree 
of resistance observed. Analysis of the cell wall peptidoglycans from highly 
resistant coagulase-negative staphylococci has demonstrated the presence 
of altered cross-links as compared to susceptible strains. It has been 
suggested that these altered cross-links may inhibit vancomycin binding to 
target peptides, but this hypothesis has yet to be proven. Vancomycin 
resistance in coagulase-negative staphylococci is likely multifactorial, but the 
exact mechanism await elucidation.'*'*^ 
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2.12.2 VANCOMYCIN RESITANCE IN S. AUREUS 
Since first being reported in 1997, the threat of vancomycin resistance in S. 
aureus has been the topic of intense research and discussion. Although 
vancomycin resistance in S. aureus remains extremely rare and is less 
common than vancomycin resistance in enterococci or even coagulase-
negative staphylococci, there is widespread concern that vancomycin-
resistant S. aureus (VRSA) poses, by far, the greatest risk to patients, given 
the virulence of the organism. Though there have been only a few reports of 
S. aureus isolates with reduced susceptibility to vancomycin, the high 
prevalence of MRSA and vancomycin use, both thought to be risk factors for 
VRSA, make the widespread dissemination of these organisms an 
alarmingly realistic possibility. Furthermore, there is the equally alarming 
threat of the risk of transmission of these organisms between patients.^^ '^* '^* 
Epidemiology of Vancomycin Resistance in S. aureus 
Until June 2002, there had been no verified clinical isolates of S. aureus that 
were truly resistant to vancomycin by the NCCLS standards. Instead, the 
organisms have had intermediate susceptibility, which has led to the term 
"vancomycin intermediate S. aureus" or "VISA". The term "glycopeptide S. 
aureus" or "GISA" is synonymous, but because vancomycin is the only 
glycopetide used in USA, most American physicians are more familiar with 
the acronym VISA. VISA isolates were first found in nature more than 15 
years ago while investigators were screening isolates for vancomycin 
susceptibility.'*®'^  However, it was not until 1995 that the first clinical isolate 
was reported, which was from a French child who had been receiving 
vancomycin for an MRSA line infection. In 1996, a wound infection caused 
by VISA was reported in Japan in a child receiving vancomycin for an MRSA 
wound infection. The following year, the first VISA isolate was reported in the 
United States from Michigan. Since then, there have been at least seven 
confirmed cases of VISA from USA (Table 2.12).'*^^ In June 2002, "VRSA" 
was isolated from a swab obtained from a catheter exit site from a Michigan 
(USA) resident aged 40 years with diabetes, peripheral vascular disease, 
chronic renal failure and foot ulcer. The Michigan Department of Community 
Health and CDC confirmed the identity of the strain. The MIC results of 
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Vancomycin, Teicoplanin and Oxacillin were >128 ng/nnl, 32 |ag/ml, and 16 
^g/mL, respectively, by the broth microdilution method. The isolate 
contained the vanA vancomycin resistance gene from enterococci and 
oxacillin-resistance gene mec/K. The isolate was susceptible to 
chloramphenicol, linezolid, minocycline, quinupritin/dalfopritin, tetracycline, 
and trimethoprim/ sulfamethoxazole.^® The emergence of second clinical 
isolate of "VRSA" was reported in October 2002, from a patient admitted to a 
hospital in Pennsylvania and evaluated for a chronic foot ulcer and possible 
osteomyelitis. The isolate was again confirmed by CDC to be "VRSA" 
(Vancomycin MIC > 32 |ag /ml by broth microdilution testing).® '^' 
Table 2.12 VISA Cases In The Untied States'"^ 
state and year 
Michigan, 1997 
New Jersey, 1997 
New York, 1998 
Illinois, 1999 
Minnesota, 2000 
Nevada, 2000 
Maryland, 2000 
Source 
Peritoneal fluid 
Blood 
Blood 
Blood 
Blood 
Abcess fluid 
Blood 
Underlying illness (es) 
Renal failure, MRSA peritonitis, 
cancer 
Acute renal failure, MRSA 
bacteremia 
Renal failure, MRSA bacteremia 
Renal failure, MRSA endocarditis 
Renal failure, MRSA osteomyelitis 
CoiTiplicated cholecystectomy with 
polymicrobial intrahepatic abscess 
(including MRSA) 
MRSA endocarditis, psoriasis, sleep 
apnea 
Vancomycin 
exposure (wk) 
18 
18 
6 
3.5 
18 
10 
14 
Mechanisms of Vancomycin Resistance 
The true mechanism of vancomycin resistance in S. aureus is not known. It 
was initially feared that S. aureus would acquire the van genes that code for 
vancomycin resistance in Enterococcus species; epecially after this transfer 
was successfully accomplished in the laboratory. Further, vancomycin-
resistant Enterococcus faecalis emits a sex pheromone that promotes 
plasmid transfer, and it has been recently demonstrated that this same 
pheromone is produced by S. aureus}^^ Emission of this pheromone by S. 
aureus organisms that are in proximity to vancomycin -resistant enterococci 
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that contain plasmids encoding van genes could result in transfer of these 
resistance genes. However, thus far, neither the van genes nor their altered 
peptidoglycan products have been recovered in vancomycin intermediate or 
resistant S. aureus isolates. Instead, it appears that vancomycin resistance 
in S. aureus is conferred by other alterations in the bacterial cell wall.'*®'* 
Several years prior to the first clinical VISA isolates being reported, Daum et 
al. produced laboratory strains of VISA and VRSA that had much thicker cell 
walls than the sensitive parent strains. Subsequent investigators have 
demonstrated that cell wall synthesis and turnover are upregulated in VRSA 
isolates, leading to thicker and more disorganised cell walls. Further, it 
appears that resistant isolates have significantly less cross-linking in the 
peptidoglycan component of the cell wall. In order to excert an effect, 
vancomycin must reach the cytoplasmic membrane and bind with nascent 
cell wall precursors, thereby inhibiting their incorporation into the growing cell 
wall. It has been proposed that the thicker, disorganized cell walls can 
actually trap vancomycin at the periphery of the cell, thereby blocking its 
action. In fact, it has been shown that vancomycin can be recovered intact 
from the cell walls of VISA and VRSA isolates, indicating that the antibiotic is 
not being inactivated but merely sequestered by the bacteria. Furthermore, 
the altered cell walls appear to have a reduced affinity for vancomycin, as 
soluble targets are able to bind more antibiotic in the presence of 
vancomycin resistant isolates. Clearly, more research is needed to further 
elucidate the exact mechanism of vancomycin resistance, however, given 
what is currently known, it seems safe to assume that it will be 
multifactorial.'*'*^ 
Microbiology of VISA and VRSA 
The cell wall alterations in VRSA can cause difficulties with laboratory 
identifications. Morphologically, colonies of VISA and VRSA isolates often 
look smaller than their susceptible counterparts, which can lead some to 
confuse them with coagulase-negative staphylococci. Furthermore, 
vancomycin resistant strains may require more incubation time for coagulase 
detection. If the coagulase reactions are incubated for less than 4 h, the 
result may be falsely negative and the isolate may be misclassified as 
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coagulase-negative staphylococci. Thus, for any Staphylococcus with 
suspected vancomycin resistance, the coagulase test should be incubated 
for more than 4 h before being interpreted/"^ 
Treatment of Infections Caused by VISA and VRSA 
Given the rarity of these infections, it is impossible to say what role the 
recently approved antibiotics quinupristin-dalfopristin and linezolid will play in 
their management. One study did show that both agents had good activity 
against three separate VISA strains; however, at least one of the clinical 
isolates was resistant to quinupristin-dalfopristin (Conway et a|., if^ Annu 
Meet Soc Healthcare Epidemiol Am.) Only linezolid has been used in 
reported clinical cases, being used once in conjunction with trimethoprin-
sulfamethoxazole and doxycycline and once as a single agent (Conway et 
al., 11^^ Annu Meet Soc Healthcare Epidemiol Am.) Again, though there was 
a microbiologic cure in both cases, only one of the patients survivied. 
Though VISA isolates thus far have all been susceptible to linezolid, the 
recent report of linezolid resistance in an isolates of MRSA, combined with 
growing use of this agent, raises real concern over how long this uniform 
suscepotibility will hold. Thus, there do appear to be at least a few treatment 
options for VISA and VRSA infections. However, until more experience 
exists, the best treatment strategy would appear to be to tailor therapy to the 
susceptibilities of the isolate in each case.''^'' 
2.14 CARRIER METHICILLIN-RESISTANT STEPHYLOCOCCUS AUREUS 
2.14.1 NASAL CARRIAGE 
The prevalence of carriage of S. aureus in the anterior nares varies widely 
according to the population studied (Table 2.13) and is influenced by race, 
age, and exposure to antibiotics and the hospital environment. The 
particularly high rates for 5-7 year old normal children; nurses and 
hospitalized neonates are well known. ^°° 
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Table 2.13 Colonization and Sepsis in Reported Outbreaks of Infection 
with Multiply- resistant S. aureus (after Keane & Cafferkey, 1984)^ ^ 
Report 
Saraglou, Cromer & Bisno (1980) 
Myers & Linnemann (1982) 
Saravolatz, Pohold & Arking (1982) 
Locksleyetal. (1982) 
Shanson & McSwiggan (1980) 
Peacock etal, (1980) 
Craven at al, (1981) 
Total 
Number of 
Patients 
7 
286 
193 
35 
5 
31 
174 
731 
%aqe of Patients with 
Sepsis Colonized 
100 
91 
85 
80 
80 
52 
47 
77 
0 
9 
14 
20 
20 
48 
53 
23 
Repeated sampling of individuals reveals three categories: those who never 
carry, those who intermittently carry and those who are presistant nasal 
carriers of S. aureus. This suggests that both true non-carriers and 
persistent carriers of sensitive strains unlikely to acquire methicilln-resistant 
strains, possibly owing to host genetic factors '^^ ^ or bacterial interference by 
the pre-exisiting nasal flora or bacterial interference by the pre-existing nasal 
flora. The throat may be a reservoir for the re-colonization of the anterior 
pares. Solberg (1965) found that 51% of nasal carriers also that throat 
isolates of S. aureus of which 69% were distinguishable from those in the 
nose.^^ Adherence is doubtless a pre-requisite for colonization and there is 
evidence that S. aureus has a greater affinity in vitro for nasal epithelial cells 
derived from carriers than from non-carriers and greater affinity for epithelial 
cells from aczematous patients.^° Fibronectin, a family of high molecular 
weight glycoproteins is found in body fluids and on muscosal surfaces. The 
amount present varies with the cell cycle and with certain pathological 
conditions. S. aureus possesses a protein with two components of molecular 
weights 60,000 and 197,000 which bind specifically to fibronectin. This 
adherence in independent of protein A or the teichoic acid content of the 
staphylococcal cell wall and this may explain why they are so uncommonly 
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part of the nasal flora. Another family of glycoproteins, the lectins, is also 
present on human cell surfaces and as their function is to bind 
carbohydrates specifically they may bind to bacterial surface 
polysaccharides and thus promote adherence.'*®® 
The acquisition of MRSA has been associated with previous administration 
of two or more antibiotics, even when the site and timing of the infection was 
controlled by matched-pair analysis. Another case-matched study 
determined that patients acquiring MRSA infection received a mean cf 5.1 
antibiotics compared with 1.4 for those acquiring methicillin - sensitive 
S. aureus. Patients with MRSA infection received ampicillin and gentamicin 
significantly more often than controls and the duration of antimicrobial 
therapy was also longer (22 versus 9 days). The use of cephalosporins and 
aminoglycosides has also been significantly associated with acquisition of 
MRSA infection.''^'^ 
2.14.2 CARRIAGE OF THE SKIN 
The preferential colonization of the anterior nares, the perineum and axillae 
in normal subjects suggests site-specific factors and it is of interest that the 
lower part of the nasal vestibule is lined with skin which, like the skin of the 
perineum and axillae, contains vibrissae and sebaceous and apocrine 
glands. Although S. aureus may be deposited by transitory flora on other 
skin sites," especially the fingers and face, stable carriage at the sites is rare 
when compared with the anterior nares, the axillae and the perineum. 
Nevertheless in infants, S. aureus may colonise other sites including the 
umbilicus, groin and circumcision area.^ ^ '^^ ®°'^ ^ '^^ ^^ 
2.14.3 DISPERSAL OF S. AUREUS FROM CARRIAGE SITES 
Using a definition of dispersal as the shedding of more than 10 cfu/cu ft of 
air, Ayliffe, Babb & Collins (1974) found that nasal carriers can disperse and 
that cultures of contact plates of their hair correlated better with dispersal 
than finger or face samples. Interestingly, they also showed in a small series 
that air counts were greater around subjects with nasal carriage alone than 
around those who were both nasal and perineal carriers. Any association of 
dispersal and nasal carriage has important implications for the management 
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of staff and patients who are nasal carriers of methicillin-resistant S. aureus 
during an outbreak. The patients with the heaviest load of S. aureus in their 
anterior nares are most likely to disperse.^^'^^^''^^ 
2.14.4 CONTRIBUTION OF NASAL CARRIAGE TO INFECTION 
AND EPIDEMIC SPREAD 
The contribution of patient's nasal S. aureus to auto-infection of surgical 
wounds has been known for many years. Table 2.13 summarizes several 
studies and shows that the incidence of surgical wound sepsis in nasal 
carriers ranged from 5.6 to 16.5% and that between 47 and 89% of these 
wounds were infected with phage types that were indistinguishable from 
those in the patient's nose. In contrast, post-operative infection rate for non-
carriers was only 1.1 to 6.7%. There are recent anecdotal accounts to 
suggest that wound infection with methicillin-resistant strains is preceded by 
nasal acquisition.^^^-^^ '^^ ^^ 
Table 2.14 Prevalence of S. aureus on Skin** 
Site Percentage of subjects carrving S. aureus 
Normal Cozema Psoriasis 
59 37 
63 16 
48 26 
52 16 
41 21 
63 16 
28 8 
Overall it seems unlikely that methicillin-resistant staphylococci are less 
virulent than sensitive strains and a surprisingly small inoculum of S. aureus 
will cause wound infection. Foster & Hurt (1960) showed that when only 15 
cocci from a culture of sensitive S. aureus were inoculated on to the slightly 
damaged forearm skin of healthy volunteers, 6.1 x 10^ cfu were recoverable 
after 24 h and there was an associated erythema and seropurulent 
Nose 
Cheek 
Forehead 
Umbilicus 
Groin 
Forearm 
Axilla 
34 
7 
5 
3 
3 
2 
1 
i n i 
exudates. These findings suggest that airborne transmission of methicillin-
resistant S. aureus may readily result in wound infection, especially in 
surgical and burns units.^° 
In summary, the earlier literature has predicted, often quantitatively, the 
significance of carriage during single-strain outbreaks. Nasal carriage 
presents a risk of autoinfection of surgical wounds and may be associated 
with significant dispersal, while nasal carriage among staff provides a source 
of organisms for nasal acquisition by hitherto non-colonized patients. There 
is evidence in literature that only single wards will decrease acquisition of 
hospital staphylococci by new patients. There seems little reason while 
methicillin - resistant strains should differ and recent experience of 
outbreaks with multiply resistant S. aureus is in line with results of these 
earlier studies on more sensitive strains.^^ '^^ ^^ 
2.14.5 ERADICATION OF CARRIAGE 
Eradication of methicillin - resistant S. aureus have encouraged efforts to 
find an effective means of eliminating the carrier state. In a survey from the 
United States (Bryan et ai, 1980) 71% of hospitals sampled personnel 
during staphylococcal outrbreaks and in two-thirds of this topical treatment 
was used in an attempt to eliminate carriage. Permanent eradication is 
difficult and in the many studies S. aureus recolonized at an uspecified time 
after treatment in 63 to 100% of subjects. Systemic or local antibiotic 
therapy, even with vancomycin, or with creams containing chlorhexihidine 
plus various antibiotics can reduce nasal carriage only temporarily.^^° A 
novel agent, mupirocin (formely 'pseudomonic acid') shows great potential 
for the elimination of staphylococcal carriage. It has no potential as a 
systemic antibiotic as it is broken down to inactive compounds when 
administered intravenously. It is highly active against S. aureus, including 
methicillin - resistant strains, MICs of 0.015-0.06 mg/l and MBCs of around 
16 mg/l.*'' Using 2% mupirocin formulated in white soft paraffin containing 
anhydrous lanolin it was demonstrated in a controlled trial that all 32 healthy 
nasal carriers yielded negative cultures within two days of the start of 
treatment, and all subjects remained culture negative for at least two weeks 
after a 5-day course.*"* Even 22 weeks after the end of the treatment only 
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50% of those sampled has resumed carriage, and phage typing indicated 
that in two-thirds of the subjects the anterior nares become re-colinized with 
a strain that was distinguishable from their pre-treatment isolate, that is, they 
recolonized rather than relapsed and so the use of this agent, in conjunction 
with single rooms or an isolation ward, may well contribute of the control of 
outbreaks caused by methicillin-resistant strains and avoid the necessity of 
using valuable systemic agents to treat the carrier state.^ '^^ ®° 
2.15 BIOCHEMICAL BASIS OF ANTIBIOTIC RESISTANCE IN 
STAPHYLOCOCCI 
It was initially assumed that resistance arose because of a change in the 
nature of a single gene. While this is certainly true of some bacteria, for 
example antibiotics change in the gene for folate synthesis confers 
sulphonamide resistance; it is not the sole reason. More commonly, resistant 
organisms have an additional gene (or genes) the product (s) of which 
confer resistance. For example, staphylococci resistant to penicillin have a 
gene specifically responsible for the synthesis of penicillinase, an enzyme 
absent from sensitive cells.^°° Similarly Escherichia coli carrying R factor 
produces an intracellular enzyme that inactivates chloramphenicol by 
transferring the acetyl group to chloramphenicol from acetyl CoA.^'^ Bacteria 
may already possess these additional genes, but in other cases they may be 
acquired by mutations or transmission from othpr bacteria. The transmission 
of resistance is largely due to the acquisition of plasmids and/or 
transposons. Although transfer of resistance in the laboratory has been 
shown to occur via transformation, transduction, and conjugation, only 
conjugative transfer appear to be significant in vivo}^^'^^^ The biochemical 
machinery conferring bacterial resistance to drugs of major importance in 
medicine is quite complex but provides a rational approach to the 
development of effective agents useful in treating resistant infections. 
Understandably, therefore, there is a considerable interest in the origins of 
the genes that encode drug-inactivating enzymes, drug efflux pumps and 
enzymes, that depress drug sensitivity by the covalent modification of drug 
targets.^^^ Antibiotic producing bacteria, such as streptomycetes, for 
example, protect themselves against the toxic effects of their own antibiotics, 
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with enzymes that specifically inactive compounds such as aminoglycosides, 
chloramphenicol and p-lactams. In addition, many streptomycetes express p-
lactamases even though they do not produce p-lactamases, presumably as 
a protective measure against p-lactams synthesized by other organisms in 
the micro-environment. Pumped efflux of tetracycline and the enzymic 
modification of ribosomal RNA associated with resistance to erythromycin 
have both been identified in streptomycetes. A comparison of nucleic acid 
and protein sequence data supports the possibility that the genes for 
aminoglycoside-inactivating enzymes found in aminoglycoside resistant 
clinical isolates may have originated from streptomycetes. In general, 
however, evidence for a stereptomycete origin of drug resistance genes in 
pathogenic bacteria is limited.^ '^^ ^®''^ '*'^ ^^ Among the mechanisms identified 
(Table 2.9), enzymatic inactivation of antibiotics is one of the most common 
biochemical processes that endangers resistance to a wide variety of 
antibiotic structural types in bacteria.^ ®® Determinants for the enzymic 
inactivation of antibiotics in clinical isolates have arisen in most cases only 
by the inheritance of exogenous functions (genes). Once established in 
pathogen, genes encoding enzymes that catalyze covalent modifications of 
therapeutic agents can undergo mutations that remodel the active site of the 
anzyme, changing the spectrum of antibiotic substrates that may be 
modified. In his 1992 review, Neu showed the "phylogeny" of development of 
p-lactam antibiotics in response to the evolution of bacterial resistance to this 
class of antibiotics. Of the several known mechanisms of resistance to the p-
lactam antibiotics (Table 2.9) the most elusive moving target is hydrolytic 
inactivation by p-lactamases. A single base change in the gene for a p-
lactamase can change the substrate specificity of the enzyme that resulted 
in the development of extended - spectrum p-lactamases.^^'* 
Staphylococci have an ability of developing resistance quickly and 
successfully to antibiotics. The acquired defence systems by staphylococci 
may have originated from antibiotic-producing organisms, where they may 
have been developed and then passed on to the other genera. The various 
biochemical mechanisms of antibiotic resistance for staphylococci are 
outlined in Table 2.15 
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2.15.1 RESISTANCE TO fi-LACTAM ANTIBIOTICS 
Three different mechanisms of resistance to p-lactam antibiotics have been 
identified for staphylococci: the inactivation of penicillin (and cephalosporin) 
by penicillinase (p-lactamase) mediated hydrolysis of the p-lactam ring of 
antibiotic; and intrinsic resistance resulting from a reduction in the affinity or 
the amount of the PBPs; and tolerance due to an excess of autolysin 
inhibitor 149,293 Most penicllin - resistant staphylococcal strains produce p-
lactamase. p-lactamase genes (bla) are most often found on class II 
plasmids that are distributed among many staphylococcal species.^^'^^''^'^^'' 
The products of three chromosomal genes, blal, blaR1, and blaR2, control 
the expression of the structural gene for p-lactamase, blap.^^'*^^ 
RC-N^J. ^S 
COOH 
/J Lactamase 
OK j ^COOH 
N — N r 
RC-
H H H 
Cephalosporin 
Penicillin 
Figure 2.7 Interaction of Cephalosporins and Penicillins with p-
lactamases. In Cephalosporins, opening of the p-lactam ring and expulsion 
of R^  is followed by general disintegration of the molecule, in penicillins, 
opening of the p-lactam ring occurs. 
Unlike Gram-negative bacteria, where p-lactamase is excreted in the 
periplasm, the beta-lactamase in Gram-positive bacteria including 
staphylococci is excreted into the environment. The number of beta-
lactamases has steadily risen since the introduction of penicillin. Beta-
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lactamases have been classified according to their functional aspects.^^° 
This system is based on hydrolysis rates for a number substrates and the 
level of inhibition by clavulanic acid, but simple point mutations may alter the 
classification. They have also been classified according to the nucleotide 
sequences that encode p-lactamases. Classes, A, B and D have serine at 
their active site, whereas class B has a zinc atom at the active site. Class A 
enzymes are encoded mostly on plasmids whereas class C enzymes are 
generally chromosomally encoded. Beta-lactmases range between 30 and 
40 KDa in size. The p-lactamases of Staphylococcus aureus is an inducible 
enzyme. Enzyme production is very slow in the absence of penicillin or 
cephalosporin. The addition of minute quantities of antibiotic (as little as 
0.0024 fig ml'^ of medium) increase enzyme production enormously and the 
p-lactamase may account for more than 3% of the total protein synthesized 
by the bacterium.^ '^^ '^^ ^°'^ ^2'^ ^^ Resistance to methicillin and other p-
lactamase resistant penicillins was first observed in S. aureus soon after the 
introduction of methicillin into clinical use in Britain.^^^ An aietered PBP is 
involved in methicillin resistance in staphylococci. This PBP2a (PBP-2') is 
encoded by the mecA gene. mecA is encoded by a chromosomal insert 
called the mec determinant which probably originated outside staphylococci, 
perhaps via fusion between a p-lactamase gene and a PBP gene. The mec 
determinant is not readily self-transmissible but has spread within S. aureus 
and several coagulase-negative species, indicating that some horizontal 
transfer is possible.^ '^^ '^^ 3 '^^ ^ '^^ ^^ 
2.15.2 RESISTANCE TO MACROUDES, UNCOSAMIDES AND 
STREPTOGRAMINS 
Erythromycin-resistant staphylococci often have cross-resistance of 
macrolids (roxithromycin, oleandomycin, spiramycin, clarithromycin, 
azithromycin), and not necessarily to all iincosamides (linccmycin, 
clindamycin) and streptogramin type antibiotics (designated MLS-resistant). 
2.15.2.1 Target Modification 
Modification of ribosomal target confers cross-resistance and remains the 
most frequent mechanisms of resistance to MLS antibiotics, although 
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enzymatic modification of the antibiotics and active efflux appears to be 
increasingly prevalent.^^^ 
The different types of MLS antibiotics bind to the 50s ribosomal subunit at 
overlaping binding sites, and binding interferes with transpeptidation and 
translocation reactions needed for peptide chain elongation. These sites are 
protected by the N ,^ N^ - dimethylation of an adenine - 2058 residue at the 
peptidyl transferase centre of 23S rRNA a reaction performed by an rRNA 
methylase.'*^^ Three distinct rRNA methylase genes have been detected in 
staphylococci: ermA,^^^ ermB^^° and ermC}^^ Even though of the erm gene 
classes can be distinguished by hybridization, the amino acid sequences of 
the encoded methylases are highly conserved, w/hich suggests that they 
evolved from a common encestor, possibly originating in the antibiotic 
producing organisms.^^ '^*^^ The chromosomal ermA gene is common among 
methicillin - resistant {mecA) strains of S. aureus and S. epidermis, but it is 
relatively uncommon in mecA' strains and usually accounts for only 6-11% of 
those resistant to MLS antibiotics."^'' ermB is usually not found in 
staphylococcal species indigenous to primates; hov\/ever, it appears to be 
relatively common in MLS - resistant strains of S. intermedius from dogs, in 
which expression can be either inducible or constitutive, and MLS-resistant 
strains of S. tiyicus and S. xylosus from pigs, in which expression in 
constitutive.^^^'^^^ The ermC gene is most often located on class I plasmids 
of the pSN2 and pE194 families.^^ '^^ ^^ These plasmids are present in very 
high frequencies (85-98% of strains) in most staphylococcal populations 
following treatment of the host with tylosin, erythromycin or 
clindamycin.'*° '^'* '^* Expression of MLS resistance can be constitutive or 
inducible. The character of resistance is not related to the class of erm 
determinant but, rather, depends on the sequence of the regulatory region, 
upstream from the structural gene for the methylase. Regulation by these 
regions occurs by a translational attenuation mechanism in which mRNA 
secondary structure influences the level of translation. In laboratory mutants 
and clinical isolates, single nuecleotide changes, deletion or duplications in 
the regulatory region convert indicibly resistant strains to constitutively 
resistant ones that are cross-resistant to MLS antibiotics.^^^ In staphylococci. 
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when expression is constitutive, tlie strains are resistant to all MLS 
antibiotics. Streptogramin A-type antibiotics escape resistance, and synergy 
with streptogramin B-type antibiotics is retained. When expression is 
inducible, the strains are resistant to 14- and 15-membered macrolides only. 
The 16-membered macroiids, the commercially available lincosamydes and 
streptogramins remain active. This dissociated resistance is due to 
differences in the inducing abilities of MLS antibiotics, only 14- and 15-
membered macrolides are effective inducers of methylase synthesis in 
staphylococci. 
2.15.2.2 Antibiotic Inactivation 
Unlike target modification, which causes resistance to structurally distinct 
antibiotics, enzymatic inactivation confers resistance only to structurally 
related drugs.^^^ Enzymes (Ere A and Ere B) that hydrolyze the lactone ring 
of the macrocyclic nucleus and phosphotransferases [type I (mphA) and type 
II] that inactive macrolides by introducing a phosphate on the 2' hydroxyl 
group of the amino sugar have been reported in members of the family 
Enterobacteriaceae and S. aureus. The gene linA mediates resistance to 
lincosamides. The product of linA has been partially purified and 
demonstrated to act as a lincosamide 0-nucleotidyl transferase. Lactonases 
that are capable of cleaving the macrocyclic lactone ring structure of type B 
streptogramins have been identified in staphylococci {vgb gene). Two 
staphylococcal - related determinants vat and vatB, encoding an 
acetyltransferase that inactivates type A streptogramins, have been 
characterized. The vat and vgb genes are adjacent to each other on plasmid 
plP630. This vat-vgb region is flanked by inverted copies of insertion 
sequence IS257, suggesting a role for this element in dissemination of these 
determinants.^^"' ^^ ^ 
2.15.2.3 Active Efflux 
The presence of multicomponent macrolide efflux pump in staphylococci 
{msrA, msrB) has been documented, msr genes confer resistance only to 14 
and 15 membered ring macrolides. The presence of a plasmid-mediated 
gene, vga, encoding for a putative ATP-binding protein, has been associated 
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with an active efflux of streptogramin A group compounds. This gene has 
been chiefly found in coagulase - negative staphylococci.^^''' ^ ^' ^^^' ^^^' 
2.15.3 RESISTANCE TO FLUOROQUINOLONES 
Fluoroquinolone antibiotics exert their antibacterial effects by inhibition of 
certain bacterial topoisomerase enzymes, namely DNA gyrase (bacterial 
topoisomerase II) and topoisomerase IV. DNA gyrase is the only enzyme 
that can effect supercoiling of DNA.^°^ Inhibition of this activity by 
fluroquinolones is associated with rapid killing of the bacterial cell.^^^ 
Topoisomerese IV is predominantly responsible for separation of daughter 
DNA strands during cell division. Three mechanisms for fluoroquinolone 
resistance have been postulated for staphylococci. One mechanism found in 
S. aureus and S. epidermids involves mutations in the chromosomal gene 
gyrA, encoding the DNA gyrase subunit A, so that its function is no longer 
inhibited by the antibiotic.''^ '^^ ^®''*^ '^'*'*° A second mechanism found in S. 
aureus, S. epedermids and S. haemolyticus involves mutations in the 
chromosomal gene norA (or its regulatory region) that encodes a membrane 
efflux protein for hydrophilic fluoroquinolones and other unrelated 
antibiotics.^^^ The NorA protein has a hydropathic amino acid profile 
consistent with a location in the cytoplasmic membrane and it exhibits a low 
level of fluoroquinolone efflux, with a preference for hydrophilic 
fluoroquinolones. NorA - mediated fluoroquinolone resistance is due to over 
expression of the wild-type gene norA}^^-^^^-^^^ A third mechanism found in 
S. aureus involves mutations in the chromosomal gene grIA that encodes the 
A subunit of DNA topoisomerase IV. Clinical isolates of S. aureus that have 
mutations in both gyrA and grIA genes generally exhibit higher levels of 
ciprofloxacin resistance (MIC 16 - 128 ngml'^), These data support the 
finding that in S. aureus, grIA mutations precede gyrA mutations in 
developing resistance to ciprofloxacin. The S. saprophyticus and S. sciuri 
species groups inhibit an intermediate susceptibility (MIC 1 - 4 ^g/ml) to 
fluoroquinolones and this property may be related to their intrinsic resistance 
(MIC 1 6 - 6 4 |ig/ml) and nalidixic acid resistance (MIC 64-1024 |ig/ml), 
presumably due to modifications of the gyrB gene and/or its 
regulation.2^"^^'^°^ 
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2.15.4 RESISTANCE TO TETRACYCLINES 
Tetracyclines probably penetrate bacterial cells by passive diffusion 
Tetracycline act by reducing the affinity of the A and P sites of the 30s 
ribosomal subunit for aminoacyl - transfer RNA, resulting in the inhibition of 
protein synthesis.^^ Tetracycline resistance is widespread among 
Staphylococcal species. There are 2 mechanisms of tetracycline resistance 
recoginized in staphylococci. The most common one involves an energy-
dependent pumping (efflux) of tetracycline and doxycycline from the cell, so 
that levels of these antibiotics are reduced below that required to inhibit the 
ribosome. The efflux protein is most often encoded by the inducible gene 
tetk which is located on class I plasmids of the pT181 family.^ '*® The gram-
positive tetK and tetL genes encoding tetracycline - efflux proteins are 
regulated by mRNA attenuation like gram-positive erm genes encoding 
rRNA methylase and cat genes encoding chloramphenicol acetyltransferase. 
Tetracycline specific exporters pump their substrate into the periplasm and 
not across the outer membrane, as found for the multidrug efflux pumps. The 
second mechanism, one that is controlled by the gene tetM, involves 
ribosome protection such that protein synthesis is unaffected by the 
presence of tetracycline, or minocycline. However, todate the biochemical 
basis of tetracycline resistance mediated by TetM protein remains unclear. 
One possibility is that TetM stabilizes the ribosome-transfer RNA interaction 
in the presence of tetracycline. ^^ '^ ® 
2.15.5 RESISTANCE TO AMINOGLYCOSIDES 
Aminoglycosides bind to the ribosomes and thus interfere, with protein 
synthesis. There are 3 mechanisms responsible for aminoglycoside 
resistance in staphylococci. One mechanism involves changes in ribosomal 
proteins as a consequence of certain mutations in their structural genes, 
such that ribosomes can no longer bind streptomycin. A second mechanism 
involves the energization and permeability of the cell membrane. Some 
energy-deficient, small -colony mutants of S. aureus have been shown to be 
resistant to aminoglycosides due to a diminished uptake of the antibiotics, 
presumably as a consequence of cell membrane impermeability. The third 
and most common mechanism of resistance involves modification of 
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aminoglycosides by aminoglycoside-modifying enzymes so that the 
antibiotics are inactive to bind to ribosomes. Genes encoding these enzymes 
are either piasmid or transposon mediated. Evidence suggests that the 
enzymes have arisen from both antibiotic-producing organisms and by 
mutation of resident host genes. The modifying enzymes are present in the 
cytoplasm In quantities sufficient only to inactivate drug that enters during 
the slow uptake phase. Therefore resistant cells are characterized by growth 
in media containing unmodified antibiotic. There are classes of 
aminoglycoside - modifying enzymes: acetyltransferases (AACs); adenyl-
transferases/nucleotidyl-transferases (ANTs); and phospho-transferases 
(APHs). The AACs acetylate amino groups whereas ANTs and APHs 
adenylate and phosphorylate hydroxyl groups, respectively.^^'* 
Aminoglcoside resistance in staphylococci is well documented. The 
resistance of staphylococci to kanamycin has been to be caused by a 
kanamycin - neomycin phosphotransferase. Upto six genes have been 
identified.^'*°'^^^ Often more then one resistance gene is present. One of the 
most remarkable aminoglycoside enzymes is the bifunctional AAC (6') APH 
(2") enzyme, which is found on Jn4001 of S. aureus and in Enterococcus 
faecalis isolates. Nucleotide sequencing data suggest that the enzyme arose 
through the fusion of two genes, each encoding one of the partners. The 
epidemiology of Tn4G01 is well studied and Illustrates that substitutions, 
insertions and deletions play an important role in the adaptation of these 
elements to new hosts.^°^ Hybridization studies in Australia showed that 
Tn4001 could be present on the bacterial chromosome as well as on a 
number of structurally related plasmids,^°^ and this was linked to the rapid 
spread of gentamicin and tobramycin-resistant S. aureus in Australia. The 
same was also observed in North America but with shorter inverted repeats 
and insertion sequences flanking the resistance gene.^ ^ '^^ ^® 
2.15.6 RESISTANCE TO TRIMETHOPRIM AND SULPHONAMIDES 
Trimethoprim and sulfonamides are synthetic agents that effect the 
biosynthesis of tetrahydrofolic acid, an essential derivative used in amino 
acid and nucleotide synthesis Trimethoprim resistance is either mediated by 
alterations in the expression of the intrinsic chromosomal dfr gene (e.g. dfrB 
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of S. aureus or dfrC of S. epidermids), possibly resulting in over production 
of the native dihydrofolate reductase (DHFR) or a reduced affinity of the 
native DHFR for trimethoprim, or by the acquisition of a second 
chromosomal or plasmid dfr gene (e.g. dfrA in S. aureus, S. epidermidis and 
S. hominis) that encodes a trimethoprim - resistant DHFR capable of 
rescuing the reduction step leading to Tetrahydrofolate in the presence of 
trimethoprim. The differences in resistance level of staphylococci correlate 
with differences in transcription caused by deletions adjacent to a copy of 
IS257 in Tn4003,^^'' which effects the promoter used by dfrA.^^^ The S. 
epidermids trimethoprim-sensitive chromosomal DHFR gene dfrC, differs 
from dfrA by only four base pairs, strongly suggesting that dfrA originated 
from the S. epidermids chromosomal gene.^^'' Site directed mutagenesis of 
dfrA and kinetic analysis of the purified DHFRs indicate that a* single 
alteration (Phe-98 to Tyr) is responsible for the trimethoprism resistance of 
the type SI DHFR.^^° 
Chromosomally encoded salfonamide resistance has been described and 
resistance seems to be due to increased production of Periplasm-amino-
benzoic acid. Furthermore alterations of dihydropteroate synthase (DHPS) 
could lead to low affinity for sulfonamides. Acquired sulfonamide resistance 
can result from the acquisition of plasmids that encode drug-resistant DHPs. 
2.15.7 RESISTANCE TO CHLORAMPHENICOL 
Chloramphenicol contains a nitrobenzene ring and is a derivative of 
dichloroacetic acid. Chloramphenicol inhibits protein synthesis by binding to 
the 508 subunit of 70S ribosome at a site that prevents the attachment of 
aminoacyle transfer RNA (tRNA) to its binding site. Without this attachment, 
peptide bond formation cannot occur. Chlorampheincol attaches to the 
ribosome in proximity to the targets for erythromycin and clindamycin. The 
most common mechanism of resistance to chloramphenicol is the enzymatic 
inactivation of the compound. In resistant strains, chloramphenicol is 
acetylated by a cytoplasmic enzyme chloramphenicol acetyltransferase 
(CAT). CAT acetylates chloramphenicol at the C3-hydroxyl. Acetylated form 
of chloramphenicol cannot bind to the ribosome. Subsequent isomerization 
of the C3 - acetylated molecule results in the formation of substrate for a 
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second acetylation, resulting in 1,3-diacetyl-chloramphenicol. The ability of 
different CAT enzynnes to catalyze this second acetylation varies, as do the 
conditions under which it occurs. In any case, the second acetylation is 
unlikely to be of substantial clinical significance, because the pnmaiy 
acetylation inactivates the molecule. There are at least a dozen different 
CAT enzymes. These enzymes may be plasmid encoded or chromosomally 
encoded.^^^'*^^ Nucleotide sequence data suggest some conservation of 
CAT, but their spectra of activity are essentially the same. An interesting 
feature of type I CAT (encoded by transposon Tn9) is its ability to bind (but 
not inactivate) fusidic acid, resulting in resistance to this unrelated antibiotic 
in addition to resistance to chloramphenicol. Nucleotide sequences, have 
defined seven distinct classes of cat genes.®^ Unlike gram-negative bacteria 
expression of cat genes in Staphylococcus aureus is typically inducible, and 
expression appears to be regulated by translational attenuation in a similar 
manner to the erm genes conferring resistance to macrolides. The cat gene 
is preceded by a nine amino acid leader peptide, and the leader mRNA can 
form a stable stem-loop structure, which masks the ribosome binding site of 
the cat gene. Chloramphenicol appears to cause the ribosome to stall on the 
leader sequence, opening the stem-loop structure, thereby exposing the cat 
ribosome-binding site, allowing caf expression. ''^ ^ 
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Figure 2.8 Modification of Cliloramphenicol by Acetyltransferase 
2.15.8 RESISTANCE TO GLYCOPEPTIDES 
The glycopeptide antibiotics vancomycin and teicoplanin inhibit cell wall 
synthesis in Gram-positive bacteria by interacting with the terminal D-alanyl-
D-alanine (D-Ala-D-Ala) group of the pentapeptide side chains of 
peptidoglycan precursors. This interaction prevents the transglycosylation 
and transpeptidation reactions required for polymerization of peptidoglycan. 
Since this mode of action is different from that of p-lactams, glycopeptides 
are being used to treat severe infections caused by methicillin and other p-
lactam-resistant staphylococci.^^^ Although resistant to glycopeptides in 
enterococci is mediated through van genes but, resistant to glycopeptides in 
staphylococci is phenotypically diverse. The van genes have been 
introduced into a laboratory strain of S. aureus and were fully functional. ^^ ^ 
Thus, the possibility that methicillin-resistant staphylococci will acquire 
resistance to vancomycin is very real.®^ Teicoplanin-resistant derivatives of 
teicoplanin-susceptible S. aureus strains have also been obtained in vitro ^^® 
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Studies of glycopeptide resistance in staphylococci have provided evidence 
that resistance may be related to alteration in the bacterial cell wall. 
Glycopeptide-resistant organisms have thicker, more irregular cell walls than 
glycopeptide-susceptible organisms. Although there is speculation about the 
role of PBPs that may compete with vancomycin for binding to cellular 
targets and changes in cell wall turnover (enhanced production of cell wall 
precursors), the exact mechanism for the heterogeneously reduced 
vancomycin susceptibility remains unclear. 
2.15.9 RESISTANCE TO OTHER ANTIBIOTICS 
Rifampin is a very potent bactericidal anti-staphylococcal agent with MICs of 
0.05 ng/ml or less. It blocks protein synthesis by inhibiting RNA polymerase. 
High-level reisitance occurs if rifampin is used alone due to point mutations 
in the rpoB gene encoding B-subunit of the RNA polymerase, making the 
drug ineffective as monotherapy for clinical infections. 
Mupirocin is pseudomonic acid, a natural product of Pseudomonas 
fluorescens. Mupirocin inhibits and kills staphylococci by inhibiting isoleucyl-
tRNA synthetase. Mupirocin contains an epoxide side chain structurally 
similar to isoleucine and competes with this amino acid for the binding site 
on isoleucyl-tRNA synthetase. As a result of this, no isoleucine is 
incorporated into the nascent peptide chain and protein synthesis is aborted. 
Resistance to mupirocin has been described in staphylococci. Low level 
resistance (MIC < 100 j^g/ml) may be mediated by altered access to binding 
sites on isoleucyl-tRNA synthetase. This results due to point mutations in the 
gene of the target enzyme. High level resistance (MIC>1000 ng/ml), is due 
to the presence of a modified isoleucyl-tRNA synthetase gene, which has 
been located on a conjugative plasmid encoding gentamicin resistance, that 
renders mupirocin ineffective. Analysis of this gene product suggests it was 
acquired from another organisms. ^ •"'•^ ^^  
Fusidic acid a protein synthesis inhibitor interferes with ribosome-associated 
elongation factor G, the 505 ribosome translocation protein. The 
chromosomal mutation {fusA) loweres the affinity of the G factor for the 
antibiotic in S. aureus. A plasmid-borne determinant (fasB) also encodes for 
decreased permeability.^^ 
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CHAPTER-3 
MATERIALS AND METHODS 
In order to carry out the proposed research work "Biochemical Studies on 
Antibiotic Resistance among Staphylococci from Eyes and Other Clinical 
Sources in Health and Disease", the organisms were isolated, characterized 
and identified by various biochemical tests, and subsequent experiments 
were performed by standard methods and protocols described in this 
chapter. 
3.1 MATERIALS USED 
The various materials including antibiotics and chemicals used while 
performing different experiments in the present study were shown in Table 
3.1 and Table 3.2. 
Table 3.1 List of Antimicrobial Agents with their Disk Contents 
Purchased from Hi-IVIedia Laboratories, Pvt. Ltd. Mumbai, India 
Antimicrobial Agent 
Amikacin 
Ampicillin 
Cefazolin 
Cephalexin 
Cephotaxime 
Chloramphenicol 
Ciprofloxacin 
Clindamycin 
Co-trimoxazole 
(trimethoprim/ 
Sulphamethoxazole 
Fusidic acid 
SYMBOL 
Ak 
A • 
Cz 
Cp 
Ce 
C 
Cf 
Cd 
Co 
Fc 
Disk Content ^  
30 ng 
10 ^g 
30 ^g 
30 i^g 
30 i^g 
30 ^g 
s^g 
2^g 
1.25/23.75 yig 
10 ^g 
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Gentamicin 
Imipenem 
Methicillin 
Novobiocin 
Penicillin G 
Rifampin 
Roxithromycin 
Tetracyclin 
Vancomycin 
G 
1 
M 
Nv 
P 
R 
Ro 
T 
V 
10 ^g 
10 ^g 
5|^g 
30 ^g 
10 units 
5^9 
30 i^g 
30 ng 
30 i^g 
^In accordance to Performance Standards for Antimicrobial Disk 
Susceptibility Tests, NCCLS. 
Table 3.2 Chemicals/Materials Used in Experimental Work 
Chemicals /Materials 
Acetone 
Acridine orange 
Acriflavine 
Acrylamide 
Agar agar 
Agarose 
Amikacin sulphate 
Ammonium chloride 
Ammonium oxalate 
Ammonium persulphate 
Amoxycillin 
Ampicillin 
Bacitracin 
Source 
SRL, India 
Hi-Media, India 
Hi-Media, India 
Hi-Media, India 
Hi-Media, India 
Hi-Media, India 
Hi-Media, India 
SRL, India 
SRL, India 
Hi-Media, India 
Hi-Media, India 
Hi-Media, India 
Hi-Media, India 
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Barium chloride 
Benzyl penicillin 
Bis-acrylamide 
Bromocresol purple 
Bromophenol blue 
CaCl2 
Cefazolin 
Cephalexin 
Cephotaxime 
Chloramphenicol 
Chloroform 
Ciprofloxacin 
Coomassie brilliant blue R-250 
Cotton swab 
Crystal violet 
DNA 
DNase test agar 
EDTA 
Erythromycin 
Ethanol 
Ethedium bromide 
Glacial acetic acid 
Glycerol 
Hydrochloric acid 
Hydrogen peroxide 
Iodine crystals 
Hi-Media, India 
Hi-Media, India 
Hi-Media, India 
Hi-Media, India 
Hi-Media, India 
SRL, India 
Hi-Media, India 
Hi-Media, India 
Hi-Media, India 
Ranbaxy, India 
SRL, India 
Hi-Media, India 
Hi-Media, India 
Hi-Media, India 
Hi-Media, India 
Hi-Media, India 
Hi-Media, India 
SRL, India 
Hi-Media, India 
E. Merck, India 
Sigma, USA 
E. Merck, India 
SRL, India 
SRL, India 
SRL, India 
Hi-Media, India 
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Isoamyl alcohol 
KCI 
KOH 
Luria-BertanI broth 
Lysostaphin 
Lysozyme 
Mannitol salt agar 
2-mercaptoethanol 
Methicillin 
MgCl2 
MnC(2 
MOPS 
Mueller-Hinton agar 
Mueller-Hinton broth 
Na2HP04 
NaH2P04.H20 
NaOH 
Novobiocin 
Nutrient agar 
Nutrient broth 
Oxacillin salt agar 
Oxacilline 
Phenol 
Phenol red 
Phenolphthalein phosphate agar 
Potassium iodide 
SRL, India 
SRL, India 
Hi-Media, India 
Hi-Media, India 
Sigma, USA 
Sigma, USA 
Hi-Media, India 
Sigma, USA 
Ranbaxy, India 
SRL, India 
SRL, India 
Sigma, USA 
Hi-Media, India 
Hi-Media, India 
Hi-Media, India 
Hi-Media, India 
SRL, India 
Hi-Media, India 
Hi-Media, India 
Hi-Media, India 
Hi-Media, India 
Ranbaxy, India 
SRL, India 
Hi-Media, India 
Hi-Media, India 
Hi-Media, India 
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RNase 
RbCl2 
Rifampin 
Safranine 
SDS 
Sodium acetate 
Sodium bicarbonate 
Sodium cliloride 
TEMED 
Tris-HCI 
Vancomycin hydrochloride 
Xylene cyanol 
Promega, USA 
Sigma, USA 
Hi-Media, India 
Sigma, USA 
Hi-Media, India 
SRL, India 
Hi-Media, India 
Hi-Media, India 
Hi-Media, India 
E. Merck, India 
Hi-Media, India 
Bio-Rad, USA 
3.2 SOURCE OF ORGANISMS 
All the bacterial strains of Staphylococci used in this study were isolated 
from: 
1. Eye (n=120) and nose (n=50) of the patients having various ocular 
infections/diseases, who attended the out patient department (OPD) 
or were admitted in the wards, and normal eyes (n=50) of the hospital 
workers of the Institute of Ophthalmology, J.N. Medical College, 
Aligarh Muslim University, Aligarh India. 
2. Nose (n=50) of the patients having wound infections (n=56) and nose 
(n=50) of the hospital workers attending the patients having wound 
infections in an Orthopaedic Surgical Ward of J.N. Medical College, 
A.M.U., Aligarh. 
3. Different clinical sources (n=399) of patients having various 
infections/diseases, who attended the out patient department (OPD) 
or were admitted in the wards and nose (n=75) of hospital workers of 
S.K. Institute of Medical Sciences Kashmir. 
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The details of isolated staphylococcal strains have been depicted in Table 3.3. 
Table 3.3 Distribution of Staphylococcal Isolates (n=850) from Eyes and 
Other Clinical Sources in Health and Disease 
Clinical Source 
n=850(100%) 
Conjunctiva 
n=76 (8.9) 
Corneal scrapings 
n=29 (3.4) 
Vitreous humour 
n=15(1.8) 
Pus^ 
n=151 (17.8) 
Urine 
n=153(18.0) 
Blood 
n=70 (8.2) 
Cerebrospinal fluid 
n=14(1.6) 
Semen 
n=18(2.1) 
Catheter tip 
n=18(2.1) 
Other" 
n=31 (3.6) 
Nasal swabs'^  
n=225 (26.5) 
Ocular swabs'* 
n=50 (5.9) 
No. of 
Staphylococcal 
Isolates 
n=850 (100%) 
76 (8.9) 
29 (3.4) 
15(1.8) 
151 (17.8) 
153(18.0) 
70 (8.2) 
14(1.6) 
18(2.1) 
18(2.1) 
31 (3.6) 
225 (26.5) 
50 (5.9) 
No. of 
Staphylococcus 
aureus Isolates 
n=513(60.3%) 
21 (4.1) 
6(1.2) 
3 (0.6) 
115(22.4) 
76 (14.8) 
58(11.3) 
4 (0.8) 
18(3.5) 
16(3.1) 
21 (4.1) 
175(34.1) 
-
No. of Coagulase-
negative 
Staphylococcal 
Isolates 
n=337 (39.7%) 
55(16.3) 
23 (6.8) 
12 (3.6) 
36(10.7) 
77 (22.8) 
12(3.6) 
10(3.0) 
-
2 (0.6) 
10(3.0) 
50 (14.8) 
50 (14.8) 
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'strains isolated from wound exudate, ulcer, abscess etc. 
''Sputum or tracheal aspirate, ear fluid, drained fluid, tissue sample, vaginal 
swabs etc. 
*^Strains isolated from nose of patients having wound infections and hospital 
workers attending wound infections n=(50+50), nose of hospital workers 
(n=75) and nose of patients having eye infections (n=50) respectively in 
Orthopaedic Surgical Ward of J.N. Medical College, A.M.U. Aligarh; S.K. 
Institute of Medical Sciences Kashmir, and Microbiology Section, Institute of 
Ophthalmology, A.M.U., Aligarh. 
''strains isolated from normal eyes of hospital workers of Institute of 
Ophthalmology, A.M.U., Aligarh. 
3.3. PROCEDURE FOR OBTAINING CULTURES 
The cultures were obtained with moist cotton swabs or sterile loops under 
aseptic conditions as described by Fedukowiez and Stenson in 1983. All the 
glassware were thoroughly washed with tap water followed by distilled water 
and were sterilized in the hot air oven at 170+10 °C for at least one hour. 
The cotton swabs were sterilized by autoclaving at a temperature of 121°C 
and 151 b/i^  pressure for 15-20 minutes. 
3.3.1 CORNEAL CULTURES 
The conjunctival cultures are inadequate in case of corneal ulcer; therefore, 
direct sampling from the corneal ulcer bed is necessary both for smears and 
cultures. Topical anaesthesia, xylocaine (4%) was used before taking 
culture, depending upon the response of patients. The exudates and 
necrotic material were removed from the ulcer crater with a moist swab/loop, 
which was then cultured. Causative organism are often best recovered 
underneath this debris, therefore, additional specimens were obtained with a 
sterile swab or loop by taking care to avoid excess pressure especially with 
deep ulcers or severe thinning. 
3.3.2 NASAL CULTURES 
A single sterile cotton swab moistened in nutrient broth was swirled in the 
anterior portion of each naris of five clockwise and five counter clockwise 
rotations.^^°'^ ^ '^^ °^ The swab was immediately reintroduced into the culture 
tube, transported to lab and inoculated on blood agar plates. The plates 
were incubated at 37 °C for 48 h. S. aureus isolates were selected by 
1 -> n 
mannitol salt agar and identified by catalase and coagulase testing of 
colonies with typical morphology. 
3.3.3 CULTURES FROM OTHER CLINICAL SOURCES 
The isolation of staphylococci from various clinical specimens was 
performed as per routine operations in the concerned clinical laboratories. 
However, some recommended procedures for collecting and processing 
specimens as described in the American Society for Microbiology's Manual 
of Clinical Microbiology, were followed. '^'•^ '^^ ^^ The cultures from clinical 
specimens were taken with the help of cotton swabs or inoculation loops and 
streaked on blood agar and loops and nutrient agar plates. The plates were 
incubated at 37 °C for 48 hour and then stored at room temperature for 4 
days to enhance pigment production and colony morphology. 
3.4 PREPARATIONS AND COMPOSITION OF MEDIA 
There is a wide variety of media available for the growth of microorganisms 
in the laboratory. Most of these are available from the commercial sources 
with all the components premixed and requiring only addition of water and 
sterilization for use. When it is desirable to grow bacteria on a solid medium, 
a solidifying agent such as agar (polysaccharide derived from a marine alga) 
is added to the medium. 
All the media used in the study were either prepared in the laboratory or 
supplied by Messers Hi-Media Pvt. Ltd. Mumbai. 
3.4.1 NUTRIENT BROTH (CoWee and Marr, 1989) 
Nutrient broth was used for growing the bacterial strains prior to testing their 
antibiotic sensitivity and minimum inhibitory concentrations (MIC's) of some 
antibacterial agents. 
Composition: (Ingredients/litre) 
Peptone 5 g, Sodium chloride 5 g, 
Beef extract 1.5 g, Yeast extract 1.5 g 
pH 7.4+0.2 
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Dissolved the ingredients in water, heated to obtain a homogenous solution 
and poured this solution into clean test tubes (3 ml into each tube) stopper 
with cotton plugs. The tubes were autoclaved for 15-20 minutes. 
3.4.2 NUTRIENT AGAR (Finegold and Martin, 1982) 
It is the simple or basal medium commonly used in microbiological 
laboratories, whenever, needed. It contains all basic nutritional requirements, 
sources of energy, carbon, nitrogen and mineral salts. 
Composition: (Ingredients per litre) 
Peptone 5 g, Sodium chloride 5 g, Beef extract 1.5 g, 
Yeast extract 1.5 g. Agar 15 g, pH (approx.) 7.4+0.2 
Dissolved the ingredients in distilled water in a conical flask, plugged firmly 
with cotton, wrapped in almunium foil. Autoclaved it at 121 °C for 15 minutes 
and poured into sterile petriplates under aseptic conditions. Allowed to cool 
to form a homogenous layer about 4 mm in thickness. A few plates from 
each batch were incubated overnight at 37 °C to check their sterility. 
3.4.3 BLOOD AGAR 
Blood agar in addition to being an enriched medium is an indicator medium 
showing the hemolytic properties of bacteria. 
Composition: 
Nutrient agar 100 ml 
Sheep a blood 5-10 ml 
The method of preparation of this medium was essentially the same as that 
for nutrients agar. The sterile citrated sheep's blood (5-10%) was added to 
autoclaved nutrient agar from a screw capped bottle after the mixture had 
cooled down to about 50°C+20°C in a water bath and was poured aseptically 
into sterile petriplates. 
3.4.4 MANNITOL SALT AGAR (Cappuccino and Sherman, 1983)^^ 
It is both a selective and an indicator medium. Most strains of S. aureus 
ferment mannitol. 
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Composition: (Indgredients per litre) 
Beef extract 1 g, Proteose peptone 10 g, 
Sodium Chloride 75 g, D-Mannitol 10 g, Phenol Red 0.025, Agar 15 g, 
pH 7.4+0.2 
Dissolved the ingredients in distilled water and adjusted the pH by adding 
diluted acid or base and autoclaved. 
3.4.5 PHENOLPHTHALEIN PHOSPHATE AGAR 
(Barber and Kuper, 1951)^" 
This indicator medium assists the identification of S. aureus in mixed 
cultures. 
Composition: (Ingredients/litre) 
Nutrient agar 980 ml, 
Sodium phenolphthalein diphosphate (0.6% soln.) 20 ml, pH 7.4 
Dissolved sodium phenolphthalein diphosphate in water to 0.6% 
concentration, filtered and at once added 20 ml of this solution to melted 
nutrient agar just before pouring into sterile petriplates. 
3.4.6 DNA AGAR 
It used for identifying S. aureus strains. 
Composition: (Ingredient/litre) 
Tryptose 20 g, DNA 2 g, Sodium chloride 5 g. 
Agar powder 12 g, pH 7.3 
Dissolved the ingredients in distilled water and autoclaved for 15-20 minutes. 
3.4.7 MUELLER-HINTON AGAR 
Of the many media available, the NCCLS^ '^''^ '* '^^ '*^ considers Mueller Hinton 
agar to be the best for routine susceptibility testing of non-fastidious bacteria 
for the following reasons; 
• It shows acceptable batch-to-batch reproducibility for susceptibility 
testing. 
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• It is low in sulfonamide, trimethoprim, and tetracycline inhibitors. 
• It gives satisfactory growth of most non-fastidious pathogens. 
Composition: (per litre) 
Casen acid hydrolysate 17.5 g, 
Beef heart infusion 2.0 g 
Starch, soluble 1.5 g 
Agar 17.0 g 
Final pH (at 25 °C) 7.3+0.2 
Preparation of Mueller-Hinton Agar: 
Mueller-Hinton agar preparation includes the following steps: 
(1) Mueller-Hinton agar should be prepared from a commercially 
available dehydrated base according to the manufacture's 
instructions. 
(2) Immediately after autoclaving, allow it to cool in a 45 to 50°C water 
bath. 
(3) Pour the freshly prepared and cooled medium into glass or plastic, 
flat-bottomed petridishes on a level, horizontal surface to give a 
uniform depth of approximately 4 mm. This corresponds to 60 to 70 
ml of medium for plates with diameters of 150 mm and 25 to 30 ml for 
plates with a diameter of 100 mm. 
(4) The agar medium should be allowed to cool to room temperature and, 
unless the plate is used the same day, stored in a nefTigeic(tor(2to8°C). 
(5) Plates should be used within seven days after preparation unless 
adequate precautions, such as wrapping in plastic bags, have been 
taken to minimize drying of the agar and unless they have been 
shown to perform correctly with the quality control organisms. 
(6) A representative sample of each batch of plates should be examined 
for sterility by incubating at 30 to 35 °C for 24 hours or longer. 
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(7) The pH of each batch of Mueller-Hinton agar should be checked when 
the medium is prepared. The agar medium should have a pH between 
7.2 and 7.4 at room temperature after gelling. 
(8) If, just before use, excess surface moisture is present, the plates 
should be placed in an incubator (35 °C) or a laminar flow hood at 
room temperature with lids ajar until excess surface moisture is lost by 
evaporation (usually 10 to 30 minutes). The surface should be moist, 
but no droplets of moisture should be apparent on the surface of the 
medium or on the petridish covers when the plates are inoculated. 
3.4.8 OXACILLIN SALT AGAR 
The oxacillin salt-agar was used for the detection of MRSA. Oxacillin salt-
agar was prepared by taking Muellar Hinton agar and was supplemented 
with NaCI (4% w/v; 0.68 mol/L) and 6 mg oxacillin/L. 
3.5 IDENTIFICATION AND CHARACTERIZATION OF 
BACTERIAL ISOLATES 
After incubating the culture plates for 18-24 hours at 37 °C, the isolated 
colonies were obtained, which were later picked up aseptically preserved on 
nutrient agar slants at 4 °C. Each of the isolate was marked with a prefix -JS 
(e.g., JS-1, JS-2, JS-3—etc) and subculture on fresh nutrient agar slants, 
time to time. 
All the isolated bacteria were further studied for their morphological, cultural 
and biochemical characteristics as per recommendations of Buchanan and 
Gibbons (1974) and Finegold and Martin (1982) "'^ •"^  
3.5.1 CULTURAL CHARACTERS 
The cultural characters included the appearance of colonies to naked eye, 
their size, outline, elevation, translucency, color, pigmentation and hemolytic 
characters. 
3.5.2 MORPHOLOGY AND STAINING (Mucker's modification) 
Gram's staining was employed to determine whether a particular organism 
was Gram-positive or Gram-negative and its size, shape, arrangement of 
cells and grouping. 14,82 
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A. Staining Reagents 
1. (a) Stock crystal violet solution: 
Crystal violet (85% dye) - 20 g 
Ethanol(95%)-100ml 
(b) Stock oxalate solution: 
Ammonium oxalate - 1 g 
Distilled water-100 ml 
Working solution: 
Diluted the stock crystal violet solution 1:10 with distilled water and mixed it 
with 4 volumes of stock oxalate solution and stored in a glass stoppered 
bottle. 
2. Gram's Iodine solution: 
Iodine crystals - 1 g 
Potassium iodine - 2 g 
Dissolved these two in 5 ml of distilled water. Then following solutions were 
added. 
Distilled water - 240 ml 
Sodium bicarbonate solution (5% aqueous) - 60 ml 
The contents were mixed well and stored in amber glass bottles. 
3. Decolourizer: 
Ethanol (95%) - 200 ml 
Acetone - 200 ml 
Mixed, and stored in glass stoppered bottles. 
4. Counter stain: 
Stock Safranine-D - 2.5 g 
Ethanol (95%)-100 ml 
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Working Solution: 
Diluted the stock safranine solution to 1:5 or 1:10 with distilled water and 
stored in glass stoppered bottle. 
B. Staining Method (Finegold and Martin, 1982) 
(a) A thin film of the material to be examined was prepared on a glass 
slide, dried and heat fixed. 
(b) Flooded the slide with crystal violet stain and allowed to remain for 10 
seconds. 
(c) Poured off the stain by washing the slide with iodine solution. 
(d) Rinsed off this mordant after 10 seconds with running water. 
(e) The slide was then decolourized with alcohol - acetone solution for 
about 10-20 seconds. 
(f) The slide was then counterstained with safranine for 10 seconds and 
washed off with water. 
(g) Blotted the slide between clean sheets or filter paper and examined 
microscopically, under oil immersion. 
3.5.3 BIOCHEMICAL REACTIONS 
The biochemical reactions were studied as described eisewhere.^ ^^-^^ '^^ ^^ 
3.5.3.1 Mannltol Fermentation Test 
Mannitol fermentative capability of the test strains of staphylococci was 
examined according to method described by Cappuccino and Sherman 
(1983).^^ 
Principle: 
The mannitol salt agar containing high salt concentration (7.5% NaCI) is 
inhibitory to the growth of most bacteria other than Staphylococcus species 
and also performs a differential function as it contains carbohydrate 
mannitol, which some staphylococci are capable of fermenting. The phenol 
red pH indicator is used for detecting acid produced by mannitol 
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fermentating staphylococci. The Staphylococcus aureus exhibit a yellow 
zone surrounding their growth. 
Method: 
Spreaded the inoculunn under test thinly over the mannitol salt agar plate 
and incubated for 18-24 hours at 37 °C. Strains of Staphylococcus aureus 
fermented mannitol and exhibited yellow zones surrounding their growth in 
contrary to Staphylococcus epidermidis that do not ferment mannitol and 
hence did not produce change in colouration. 
3.5.3.2 Catalase Test (Cappuccino and Sherman, 1983)®^ 
During aerobic respiration, microorganisms produce H2O2 and in some 
cases extremely toxic superoxides. Accumulation of these substances will 
result in the death of organisms unless they are enzymatically degraded. 
These substances are produced when aerobes, facultative anaerobes and 
microaerophiles use the aerobic respiratory pathways in which oxygen is the 
final electron acceptor during degradation of carbohydrates for energy 
production. The organisms capable of producing catalase or peroxidase 
rapidly degrade hydrogen peroxide as follows: 
Catalase 
2H2O2 ^ 2H2O+O2 
Peroxidase Free oxygen 
Method: 
Transferred a small portion of overnight grown culture under study with the 
help of a clean glass rod into a tube containing 30% of (v/v) hydrogen 
peroxide and watched for the evolution of bubbles of free O2, indicative of 
catalase activity. 
3.5.3.3 Coagulase Test 
The enzyme coagulase is produced by strains of Staphylococcus aureus, 
which coagulates human and rabbit plasma by converting the fibrinogen into 
fibrin. Coagulase plays an important role in the pathogenesis of 
staphylococcal infections. This test was performed for differentiating 
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coagulase positive from coagulase negative strains, as the demonstration of 
coagulase production is the best single test to identity pathogenic 
Staphylococcus species.^^^ 
(a) Tube Test (Gillespie, 1943)^^^ 
Citrated human or rabbit plasma 
Saline (0.85% NaCI) 
Soluble or free coagulase can be demonstrated by adding a drop of young 
staphylococcal broth culture (overnight) into a tube containing 0.5 ml citrated 
human or rabbit plasma diluted 1 in 10 with isotonic (0.85% NaCI) saline. It 
turns the citrated plasma into a firm gel. 
Method: 
(1) Took 0.5 ml of the diluted plasma in each of the three test tubes and 
inoculated 0.1 ml of 18-24 h. broth culture (strain under test) into the 
plasma of one tube. 
(2) A control test was setup with known coagulase positive culture in the 
second tube, whereas, the third tube was left unseeded as negative 
control to confirm that it did not coagulate spontaneously. 
(3) AH the three tubes were incubated at 37 °C, and examined for 
coagulation at 1, 3 and 6 h and again if still negative after standing 
overnight at room temperature. Examination at each of the 
prescribed times was necessary as the coagulum may liquefy after it 
has been formed. Test was read positive in which plasma had been 
converted into a stiff gel and read the test negative in which plasma 
remained wholly liquid or free flowing. 
(b) Slide Test (Williams and Harper, 1946)^^^ 
Method: 
(1) Placed a drop of saline (0.85% NaCI) solution on a clean microscopic 
slide and with minimum of spreading, emulsified the material obtained 
from one or two colonies of culture under test in it. 
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(2) Dipped the tip of inoculating wire into the undiluted plasma warmed to 
room temperature and added its traces to the bacterial suspension on 
slide. Flamed the inoculating wire and repeated the procedure for the 
control bacterial suspension. 
(3) Coagulase was demonstrated when clumping of staphylococci 
occurred within 20 seconds of adding a trace of undiluted plasma to a 
saline suspension of organism on glass slide after verifying that there 
is no spontaneous agglutination. 
3.5.2.4 Phosphatase Plate Test (Barber and Kuper, 1951)^° 
This test assists the identification of Staph, aureus in mixed cultures. All 
coagulase-positive S. aureus strains produce phosphatase and their 
colonies liberate phenolphthalein. 
Method: 
Inoculum under test was spreaded thinly over the phenolphthalein 
phosphate agar plate and incubated for 18-24 h at 37 °C. After incubation, 
placed 0.1 ml of ammonia solution (SG 0.88) in the lid of plate and placed 
the dish with culture over the ammonia for a minute or so. Colonies of S. 
aureus strains became bright pink due to liberation of phenolphthalein. 
3.5.3.5 Deoxyribonuclease Plate Test (Collee and Marr, 1989p^ 
The following method is modified from Jeffries (1961). This test determines 
the ability of coagulase +ve strains of Staph, aureus to produce nuclease 
that hydrolyses DNA. 
Method: 
Inoculated material from the test culture by spotting it onto a small area in 
the middle of one of the marked sections of the DNA-agar plate. Similarly 
spot inoculated other cultures to be tested on the other sections, including 
DNase positive control strain. Incubated the plate aerobically for 16-24 h at 
37 °C. After incubation, flooded the plate with 1 mol/litre (3.6%) hydrochloric 
acid to precipitate unhydrolysed DNA and let the plate to stand for a few 
minutes until a white cloudiness was seen in the agar. Examined the plates 
under strong indirect light against a dark background. Those spot cultures 
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were read as DNase positive which were surrounded by a clear unclouded 
zones (3mm from the edge of colony) comparable with those around control 
culture and cultures with markedly smaller zones and cloudiness, were read 
as DNase negative strains. 
3.5.3.6 Heamolysin production 
The culture under test was inoculated on blood agar plates with the help of 
sterile inoculating loop and incubated for 18-24 h at 37 °C. Heamolysin 
producing organisms lysed red blood cells and thereby, exhibited clear 
zones around their colonies. 
3.5.3.7 Novobiocin Sensitivity 
The resistance to novobiocin distinguishes S. saprophyticus from other 
clinically important Staphylococcus species. In routine identification of 
staphylococci from urine, it is generally sufficient to test by including a 5|ig 
novobiocin disc in the disc diffusion test for antibiotic sensitivities. S. 
epidermidis shows a large zone of inhibition of growth, e.g. over 15 mm in 
diameter around 7 mm disc, while S. saprophyticus shows a much smaller 
zone or grows right up to the disc. 
3.5.3.8 |3-lactamase test 
P-lactamases are the main cause of bacterial resistance to penicillins and 
cephalosporins, p-lactamase detection was carried out by two simple 
tests^ '^^ '^*'^ ^^ described as: 
3.5.3.8.1 lodometric Test 
Hydrolysis of penicillin yields penicilloic acid, which reduces iodine, 
decolorizing the starch-iodine complex. This reaction can be exploited to 
detect p-lactamase activity in tubes or on paper strips. 
(A)^ Tube method: Benzylpenicillin, 6mg/ml in 0.1 M phosphate buffer pH 
6.0, is distributed in 0.1 ml quantities in tubes or a microtitre tray. Bacterial 
growth from agar is suspended in these solutions until they are heavily 
turbid. The suspensions are held at room temperature for 30-60 min then 20 
fil volumes of 1% (w/v) soluble starch in distilled water are added, followed 
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by 20 |xl of 2% (w/v) iodine in 53% (w/v) in aqueous potassium iodide, p-
lactamase activity is demonstrated by decolourization of the iodine within 5 
min. Positive and negative controls are vital as extraneous protein reduces 
iodine and heavily inoculated tests may give false-positive results. 
v^B) Paper strip method: To prepare iodometric paper strips, 0.2 g of 
soluble starch is added to 100 ml of distilled water and dissolved by boiling. 
After cooling 1 g of benzylpenicillin is added. Filter papers (1x5 cm, 
Whatman No, 3) are soaked in this solution, and then air-dried for 2 h. The 
strips, which are stable for 1 year at - 20 °C, are moistened with 2% (w/v) 
iodine in 53% aqueous potassium iodide before use. They are then smeared 
with colonies from an overnight culture plate. Decolorization within 5 min 
indicates p-lactamase activity. Positive and negative controls are mandatory. 
3.5.3.8.2^cidometric Test 
Hydrolysis of the p-lactamase ring generated a carboxyl group, acidifying 
unbuffered systems. The resulting acidity can be tested in tubes or on filter 
papers. 
(A) ~ Tube method: For the tube method, 2 ml of 0.5% (w/v) aqueous 
phenol red solution is diluted with 16.6 ml distilled water and 1.2 g of benzyl-
penicillin is added. The pH is adjusted to 8.5 vyith 1M NaOH. The resulting 
solution, which should be violet in colour, can be stored at 20 °C. Before use, 
100 )il portions are distributed into tubes or microtitre wells and inoculated 
with bacteria from culture plates to produce dense suspensions. A yellow 
colour within 5 min indicates p-lactamase activity. Positive and negative 
controls must be run in parallel. 
(B)^ Paper Strip Method: For the acidometric paper method, filter paper 
(Whatman No.1) is cut into 5x1 cm strips and soaked in a freshly prepared 
solution containing 125 g/l benzylpenicillin, 0.1% (w/v) bromocresol purple 
and 1.25 mM NaOH. The strips are dried and can be stored at 4 °C for 6 
months with a silica gel desiccant. Before use the strips must be moistened 
with non-acidic distilled water. Bacteria from agar cultures are smeared on 
the strip and development of a yellow colour within 5 min indicates p-
lactmase activity. Controls must be run in parallel. 
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3.5.3.9 Chloramphenicol acetyl tansferase Test 
The most common mechanism of resistance to chloramphenicol is the 
enzymatic inactivation of the compound. In resistant strains the cytoplamic 
enzyme, chloramphenicol acetyltransferase (CAT) acetylates 
chloramphenicol at the C3-hydroxyl, leading its inability to bind to the 
ribosome. CAT was detected by a rapid method called modified Slack's 
method.'*^^'''^^''"''*^'' A plate of Mueller-Hinton agar was flooded with a barely 
turbid broth culture (McFarland Opacity of 0.5) of chloramphenicol 
susceptible E. coli ATCC 25922. The plate was dried to remove the surface 
fluid and discs of Whatmann no.1 filter paper 8.5 mm were placed on the 
inoculated plate. With the help of an inoculating wire loop, growth was 
scraped from the surface of the S. aureus culture to be tested. This heavy 
inoculum of the organism was applied evenly over the surface of the 8.5 mm 
filter paper (6 mm size) discs wetted with chloramphenicol, were carefully 
placed centrally on the larger Whatmann filter disc, which has been 
inoculated with the test organism. CAT produced by test strain diffuses 
through the larger outer disc and inactivates the chloramphenicol and hence 
E. CO//growth is not inhibited. 
If chloramphenicol has diffused into the external medium in the active form it 
inhibits E. coli, thereby producing a zone of inhibition of E. coli and this is 
associated with the production CAT. Results are interpreted within 4 h and 
zone of inhibition less than 18 mm signifies CAT positive strain and a zone of 
inhibition more than 18 mm is interpreted as CAT negative. 
3.6 ANTIBIOTIC SUSCEPTIBILITY TESTING 
A variety of laboratory methods can be used to measure the in vitro 
susceptibility of bacteria to antimicrobial agents. However the method 
employed in the present study is the standardized method recommended by 
the NCCLS Subcommittee on Antimicrobial Susceptibility Testing '^*'''^ ''^ '^ ''^  
which is based on the method originally described by Bauer et al.'*^ This is 
the most thoroughly described disk method for which interpretive standards 
have been developed and supported by laboratory and clinical data. 
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3.6.1 PROCEDURE FOR PERFORMING THE DISK DIFFUSION TEST 
3.6.1.1 Storage of Antimicrobial Disks 
Cartridges containing commercially prepared paper disks specifically for 
susceptibility testing are generally packaged to ensure appropriate 
anhydrous conditions. Disks were stored as follows: 
• Refrigerated the containers at 8 °C or below or froze at -14 °C or 
below, in a non-frost free freezer until needed. 
• The unopened disk containers, were removed from the refrigerator or 
freezer 1 to 2 hours before use to equilibrate these to room 
temperature. 
• Once a cartridge of disks has been removed from its sealed package, 
it was placed in tightly sealed, desiccated box. 
3.6.1.2 Turbidity Standard for Inoculum Preparation 
To standardize the inoculum density for a susceptibility test, a BaS04 tubidity 
standard, equivalent to a 0.5 McFarland standard was used. BaS04 0.5 
McFarland standard was prepared as follows: 
(1) A 0.5 ml aliquot of 0.048 mol/L BaCl2 (1.175% w/v BaCl2.2H20) was 
added to 99.5 ml of 0.18 mol/l H2SO4 (1% v/v) with constant stirring. 
(2) The correct density of the 0.5 McFarland standard was verified by 
determination of absorbance at 625 nm with a 1cm path length and 
was found to be 0.08 to 0.10. 
(3) The turbidity suspension was transferred in 4 to 6 ml aliquots into 
screw-cap tubes of the same size or those used in growing or diluting 
the bacterial inoculum. 
(4) The tubes were tightly sealed and stored in the dark at room 
temperature. 
(5) The turbidity standard was vigorously agitated on a mechanical vertex 
mixer before each use and inspected for a uniformly turbid 
appearance. 
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3.6.1.3 Inoculum Preparation 
(A)^ Growth Method: The growth method was performed as follows: 
(1) A least three to five well-isolated colonies of same morphological 
types were selected from an agar plate culture. The top of each 
colony was touched with a loop and the growth was transferred into a 
tube containing 5 ml of a suitable medium such as tryptic soy broth. 
(2) The broth culture was incubated at 35 °C until it achieved or exceeded 
the turbidity of the 0.5 McFarland standard (usually 2 to 6 hours). This 
results in a suspension containing approximately 1 to 2x10° CFU/ml. 
(3) The turbidity of the actively growing broth culture was adjusted with 
sterile saline or broth to obtain turbidity optically comparable to that of 
the 0.5 McFarland standard. This results in a suspension containing 
approximately 1.5^10° CFU/ml. 
(B) -^  Direct Colony Suspension Method: As a convenient alternative 
method, the inoculum was prepared by making a direct broth or saline 
suspension of isolated colonies selected from a 16 to 24 hour agar plate, 
such as blood agar or nutrient agar and adjusted to match the 0.5 McFarland 
turbidity standard. 
3.6 .1 .^ Inoculation of Test Plates 
(1) Optimally, within 15 minutes after adjusting the turbidity of the 
inoculum suspension, a sterile cotton swab was dipped into the 
adjusted suspension. The swab was rotated several times and 
pressed firmly on the inside wall of the tube above the fluid level to 
remove excess inoculum from the swab. 
(2) The dried surface of a Mueller-Hinton agar plate was inoculated by 
streaking the sv/ab over the entire sterile agar surface. This procedure 
was repeated by streaking two more times, rotating the plate 
approximately 60° each time to ensure an even distribution of 
inoculum. As a final step the rim of the jar was swabbed. 
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(3) The lid was kept ajar for 3 to 5 minutes to allow for any excess 
surface moisture to be absorbed before applying the drug-
impregnated disks. 
3.6.1.1^ Application of Disks to Inoculated Agar Plates 
(1) As soon as possible and not more than 15 minutes after the 
inoculation of plates, the antibiotic disks were applied so that diffusion 
and growth could proceed simultaneously. The disks were applied 
with the help of forceps. To ensure complete contact of the disk with 
the agar surface, the disks were pressed down with slight pressure. 
(2) Nine disks were applied on each agar plate arranged at least 15 mm 
from the edge of the plate and apart from each other by a distance of 
15 to 20 mm. 
(3) The plates were inverted and placed in an incubator set to 35 °C 
within 15 minutes after the disks were applied. The incubation period 
was maintained for 18 to 24 hours. 
3.6.1.6 Reading Plates and Interpreting Results 
(1) After 18 to 24 hours of incubation, each plate was examined. The 
zones of inhibition were uniformly circular due to a confluent lawn of 
growth. The diameters of the zones of complete inhibition were 
measured, including the diameter of the disk. The zones were 
measured to the nearest whole millimeter, using a ruler, which was 
held on the back of the inverted petriplate. The petriplates were held a 
few inches above a black, nonreflecting background and illuminated 
with reflecting light. 
(2) Discrete colonies growing within a clear zone of inhibition were 
subcultured, re-identified, and retested. 
(3) The sizes of the zones of inhibition were interpreted by referring to 
standard tables in NCCLS documents '^*'*'^ '*^ '^ '*® and the staphylococci 
were reported as either susceptible, intermediate or resistant to the 
agents that have been tested. 
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3.6.1.7 Detection of Methicillin-resistant Staphylococci (IVIRS) 
For best recognition of MRS strains, the following points were considered. 
• Besides, methicillin disks the l^g oxacillin disks were tested for 
methicillin/oxacillin resistance. 
• The inoculun was prepared using the direct colony suspension 
method rather than the inoculum growth method. 
• Tests to detect MRS were incubated for a full 24 hours (rather than 16 
to 18hours)at<35°C. 
3.6.1.8 Control Strains 
To control the precision and accuracy of the disk test procedures the control 
strains Staphylococcus aureus ATCC 25923 and Staphylococcus 
epidermidis ATCC 12228 were obtained from Hi-Media Pvt. Ltd. Mumbai, 
India. Working control cultures were stored on tryptic soy agar at 4 to 8 °C 
and subcultured weekly. For prolonged storage these stock cultures were 
maintained at -20 °C in tryptic soy broth with 15% glycerol. The quality 
control strains were tested by the standard disk diffusion test procedures 
using the same antimicrobial agents that were used to test clinical isolates of 
staphylococci. 
3 . 7 ' DETERMINATION OF MINIMUM INHIBITORY 
CONCENTRATIONS (MIC) 
Minimum inhibitory concentrations (MICs) are defined as the lowest 
concentration of an anti-microbial that will inhibit the visible growth of a 
microorganism after overnight incubation and minimum bactericidal 
concentrations (MBCs) as the lowest concentration of anti-microbial that will 
prevent the grov/th of an organism after subculture on to antibiotic free 
media. MICs are used by diagnostic laboratories mainly to confirm 
resistance, but most often as research tool to determine the In vitro activity of 
new antimicrobials, and data from such studies have been used to determine 
MIC break points. MBC determinations are taken less frequently and their 
major use has been reserved for isolates from the blood of patients with 
endocarditis. 
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The range of antibiotic concentrations used for determining MICs is 
universally accepted to be in serial twofold dilutions indexed to the base 1 
(e.g., 1,2,4,8,16 mg/ml, etc). Other dilution schemes have also been used, 
including use of as few as two widely separated or "breakpoint" 
concentrations between the usual values (e.g., 4, 6, 8, 12, 16 mg/ml). The 
method described below was used in the present study to check the in vitro 
activity of few antimicrobials against methicillin-resistant Stapfiylococcus 
aureus isolates.^^ 
3.7.1. PREPARATION OF ANTIBIOTIC STOCK SOLUTIONS 
The selected antibiotics were purchased from Ranbaxy Laboratories Ltd. 
Secunderbad, and Hi-Media Laboratories Pvt. Ltd., Mumbai. Inorganic Lab, 
Department of Chemistry A.M.U. Aligarh supplied few newly synthesized 
antimicrobial agents, the activity of these agents was assayed against MRSA 
isolates. The powders were stored as recommended by the manufacturer or 
at < -20 °C in a desiccator, when the desiccator was removed from the 
refrigerator or freezer, it was allowed to come to room temperature before 
being opened to avoid condensation of water. Stock solutions were prepared 
at 20 times the highest MIC range, by weighing the desired amount of 
powder on an analytical balance. The antimicrobial agent was dissolved in 
water, buffer or specific solvent, as indicated (Table 3.4). Either of the 
following formulae was used to determine the amount of powder or diluent 
needed for a standard solution; 
Weiaht (mg)- ^^^""^^ (^^) ^ Concentration {jug I ml) 
Assay Ptency {/ug I mg) 
or 
Volume (ml)= ^^'g^^ ("'g) ^ "^^^^y Potency (//g / mg) 
Concentration {/ugl ml) 
or 
. , , , ,, Weight of powder {mg)x Activity {%) ,^„ 
Volume (ml)= —-—-^-^ ^-^ =^ -^ -^^ xlOO 
Desired Concentration {/ug I ml) 
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Example: to prepare a stock solution containing 1,280 fig/ml of antimicrobial 
agent with antimicrobial powder that has a potency of 750 f^g/mg, 182.6 mg 
of antimicrobial powder should be dissolved in 107.0 ml of diluent, provided 
that the actual weight of powder is 182.6 mg: 
Volume (ml) = 182.6 mgx750 |ig/mg 
(Actual wieght) (Potency) 
= 107.0w/ 
\2%0mg/ml 
(Desired concentration) 
Small volumes of the sterile stock solutions were dispensed into sterile 
polypropylene vials carefully sealed, and stored at - 70 °C but never at a 
temperature warmer than - 20 °C. Vials were thawed as needed and used 
the same day. 
Table 3.4 Solvents and Diluents for Preparation of Stock Solutions of 
Antimicrobial Agents that Require Solvents Other Than Water''^  
Antimicrobial agent Solvent Diluents 
Amoxicillin, clavulanic 
acid, sulbactam, and 
ticarcillin 
Ampicillin 
Azithromycin 
Aztreonam 
Phosphate buffer, 
pH 6.0, 0.1 mol/liter 
Phosphate buffer, 
pH 8.0, 0.1 mol/liter 
95% ethanol 
Saturated solution of 
sodium bicarbonate 
Phosphate buffer, 
pH 6.0, 0.1 mol/liter 
Phosphate buffer, 
pH 6.0, 0.1 mol/liter 
Broth media 
Water 
Cefepime 
Cefotetan 
Cefpodoxime 
Ceftazidime 
Cephalothin 
Phosphate buffer. 
pH 6.0, 0,1 mol/liter 
Dimethylsulfoxide 
0.10% aqueous sodium 
bicarbonate 
Sodium carbonate 
Phosphatebuffer, 
pH6.0, 0.1 mol/liter 
Phosphate buffer. 
pH 6.0, 0.1 mol/liter 
Water 
Water 
Water 
Water 
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Chloramphenicol and 
Erythromycin 
Cinoxacin and nalidixic 
acid 
Enoxacin, norfloxacin 
and ofloxacin 
Imipenem 
Moxalactam 
(diammonium salt) 
Nitrofurantoin 
Rifampin 
Sulfonamides 
TrimethoDrim 
95% ethanol 
0.5 volume water, then 
NaOH, 0.1 mol/liter, drop 
wise to dissolve 
0.5 volume water, then 
NaOH, 0.1 mol/liter, drop 
wise to dissolve 
Phosphate buffer, 
pH 7.2, 0.01 mol/liter 
0.04N (0.04 mol/liter HCI 
(let sit for 1.5 to 2h) 
Phosphate buffer, 
pH 8.0, 0.1 mol/liter 
Methanol 
0.5 volume of hot water 
and minimal amount of 
NaOH, 2.5 mol/liter, to 
dissolve 
0.05N (0.05 mol/liter) 
lactic or hydrochloric 
acid, 10% of final volume 
Water 
Water 
Water 
Phosphate buffer, 
pH 7.2, 0.01 mol/liter 
Phosphate buffer, 
pH 6.0, 0.1 mol/liter 
Phosphate buffer, 
pH 6.0, 0.1 mol/liter 
Phosphate buffer, 
pH 8.0, 0.1 mol/liter 
Water 
Water (may require 
heat) 
3.7.2 PREPARATION OF TEST DILUTIONS 
Test dilutions were generally prepared from the antibiotic stock solutions as 
a series of doubling dilutions (Table 3.5). For the sake of standardization and 
comparison of results the antimicrobial was diluted in order to provide 
doubling dilutions above and below a baseline concentration of 1 ^g/ml, i.e., 
0.007, 0.01, 0.03, 0.06, 0.12, 0.25, 0.5, 1, 2, 4, 8, 16, 32, 64, 128; etc. 
3.7.3 INOCULUM PREPARATION FOR DILUTION TESTS 
A standardized inoculum for the agar dilution and broth dilution methods was 
prepared by either growing microorganisms to the turbidity of the 0.5 
McFarland standard or suspending colonies directly to achieve the same 
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density. Cultures adjusted to the 0.5 McFarland standard contain 
approximately 1 to 2x10® CFU/ml with most species, and the final inoculum 
required is 10'* CFU per spot of 5 to 8 mm in diameter which was obtained 
by diluting 0.5 McFarland suspension to 1:10 in sterile broth or saline so as 
to get a concentration of 10'' CFU/ml, and subsequently inoculated 1 to 2 |il 
of the diluted suspension on the agar surface. In case of broth dilution 
method (macrodilution and microdilution) the adjusted inoculun suspension 
was diluted so that, after inoculation, each tube or well contained 
approximately 5x10^ CFU/ml. This was achieved by preparing antibiotic 
ranges one step higher than the final dilution range required, i.e. if a final 
dilution range of 0.5, 1, 2, 4 and 16 iig/ml is required then a range of 1,2,4, 
and 16 and 32 mg/ml was prepared to compensate for the addition of an 
equal volume of inoculum. 
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Table 3.5 Scheme for Preparing Dilutions of Antimicrobial Agents to be 
used in Agar Dilution Susceptibility Tests^^ 
Antimicrobial solution 
Step 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
( i^g/mL) 
5120 
5120 
5120 
1280 
1280 
1280 
160 
160 
160 
20 
20 
20 
2.5 
Source 
Stock 
Step 1 
Stepi 
Steps 
Steps 
Steps 
Step 6 
Step 6 
Step 6 
Step 9 
Step 9 
Step 9 
Step 12 
Volume 
(ml) 
Distilled 
water 
(ml) 
1 
S 
1 
3 
7 
1 
3 
7 
1 
3 
7 
' 
Intermediate 
concentration 
5120 
2560 
1280 
640 
320 
160 
80 
40 
20 
10 
5 
2.5 
1.25 
Final 
concentration 
at 1:10 dilution 
In agar or 
broth (^ ig/ml)^  
512 
256 
128 
64 
32 
16 
8 
4 
2 
1 
0.5 
.25 
0.125 
^The final concentration is based on the addition of 2 ml of antibiotic solution 
plus water to 18 ml of melted agar or on the addition of 0.5 ml of antibiotic 
solution plus water to 4.5 ml of Muller-Hinton broth. 
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3.7.4 AGAR DILUTION PROCEDURE 
The agar dilution metlioci for determining antimicrobial susceptibility is a well-
established technique. The antimicrobial agent is incorporated into the agar 
medium with each plate containing a different concentration of the agent. 
The inocula can be applied rapidly and simultaneously to the agar surfaces 
using an inoculum-replicating apparatus. Most replicators currently available 
transfer 32 to 36 inocula to each plate. 
Dilutions prepared as indicated in Table 3.5 were incorporated in melted 
agar allowed to cool to 45 °C to 50 °C. The antibiotic was added to this agar 
in a ratio of 1/10, i.e., 2 ml of antibiotic solution plus 18 ml of melted agar 
when using 9 cm round petri plates. The plates were then set on a horizontal 
flat surface and allowed to harden undisturbed for at least 10 minutes. 
Before usage the plates were dried for 10 minutes in an incubator. Two 
control plates, prepared under the same conditions but without the 
antibiotics, were prepared and included in every MIC determination. 
3.7.4.1 Inoculating Agar Dilution Plates 
(1) The tubes containing the adjusted and diluted bacterial suspensions 
(10''CFU/ml) were arranged in order in a rack. 
(2) The agar plates were marked for orientation of the inoculum spots. 
(3) A 1- to 2-^1 aliquot of each inoculum was applied to the agar surface 
with standardized loops or pipettes. 
(4) A growth control plate (no antimicrobial agent) was inoculated first 
and then, starting with the lowest concentration, the plates containing 
the different antimicrobial concentrations were inoculated. A second 
growth control plate was inoculated last to ensure that there was no 
contamination or significant antimicrobial carry over during the 
inoculation. 
(5) A sample of each inoculum was streaked on a suitable agar plate and 
incubated overnight to detect cultures and to provide freshly isolated 
colonies in case retesting proved necessary. 
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3.7.4.2 Incubating Agar Dilution Plates 
The inoculated plates were allowed to stand at room temperature until the 
moisture in the inoculum spots was absorbed into the agar, i.e., until the 
spots were dry, but not more than 30 minutes. The plates were inverted and 
incubated at <35 °C for 16 to 24 hours. 
3.7.4.3 Determining Agar Dilution End Points 
(1) The plates were placed on a dark, non-reflecting surface to determine 
the end points. The MIC was recorded as the lowest concentration of 
antimicrobial agent that completely inhibited growth, disregarding a 
single colony or a faint haze caused by the inoculum. 
(2) If two or more colonies persisted in concentrations of the agent 
beyond an obvious end point, or if there was no growth at lower 
concentrations but growth at higher concentrations, the culture purity 
was checked and test repeated. 
3.7.5 MACRODILUTION PROCEDURE 
(1) Sterile 13-'< 100-mm test tubes were used to conduct the test. 
(2) A control tube containing broth without antimicrobial agent was used 
for each test. 
(3) The tubes were closed with cotton plugs. 
(4) The final twofold dilutions of antibiotic were prepared volumetrically in 
the broth by taking 1 ml of diluted antibiotic solution (Table 3.5) and 1 
ml of adjusted inoculum. The adjusted inoculum was prepared by 
diluting the 0.5 McFarland Suspension (1xlo^ CFU/ml) to 1:10 to 
yield 10^ CFU/ml, and adjusted to 10^ CFU/ml by mixing 100 ml of 
diluted suspension and 900 ml of Mueller-Hinton broth. Within 15 
minutes after the incolum has been standardized as described above, 
1 ml of the adjusted inoculum was added to each tube already 
containing 1 ml of antimicrobial agent in the dilution series (and a 
positive control tube containing only broth), and each tube was mixed. 
This resulted in a 1:2 dilution of each antimicrobial concentration and 
a 1:2 dilution of the inoculum (5x10^ CFU/ml). 
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(5) The inoculated macrodilution tubes were incubated at <35 °C for 16 to 
24 hours in an ambient air incubator. 
(6) The MIC was determined as the lowest concentration of antimicrobial 
agent that completely inhibited growth of the organism in the tube 
detected by the unaided eyes. The amount of growth in the tubes 
containing the antibiotic was compared with the amount of growth-
control tubes (no antibiotic) used in each set of tests while 
determining the growth end points. 
3.7^6 MICRODILUTION PROCEDURE 
This method is called "microdilution", because it involves the use of 
small volumes of broth dispensed in sterile, plastic microdilution trays that 
have round or conical bottom wells. Each well should contain 0.1 ml of broth. 
(1) A growth control well (without antibiotic) and a negative (uninoculated) 
well were used for each test. 
(2) The final two-fold dilutions of antibiotics were prepared by taking 50 |j,l 
of diluted antibiotic solution (Table 3.5) and 50|il of adjusted inoculum. 
The adjusted inoculum was prepared by diluting the 0.5 McFarland 
Suspension (1x10° CFU/ml) to 1:10 to yield 10^ CFU/ml, and adjusted 
to 10^CFU/ml by mixing 5|il of diluted suspension and 45 yii of 
Mueller-Hinton broth. Within 15 minutes after the inoculum has been 
standardized as described above, 50 ^1 of adjusted inoculum was 
added to each well already containing 50 \i\ of antimicrobial agent in 
the dilution series (and a positive control well containing only broth). 
This resulted in a 1:2 dilution of each antimicrobial concentration and 
a 1:2 dilution of the inoculum (5x10^ CFU/ml). 
(3) To prevent drying, each tray was sealed in a plastic bag, with plastic 
tape, or with a tight-fitting plastic cover before it was incubated. 
(4) The inoculated microdilution trays were incubated at 35 °C for 16 to 
24 hours in an ambient air incubator. 
(5) The MIC was determined as the lowest concentration of antimicrobial 
agent that completely inhibited growth of the organism in the 
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microdilution wells containing antibiotic as compared to the amount of 
growth in the growth-control wells (no antibiotic) detected by the 
unaided eyes. 
3.7^ DETECTION OF METHICILLIN/OXACILLIN RESISTANT 
STAPHYLOCOCCI 
Historically resistance to the antistaphylococcal p-lactamase-stable 
penicillins has been referred to as "methicillin resistance", thus the acronyms 
"MRSA" (for methicillin - resistant S. aureus) or "MRS" (for methicillin -
resistant staphylococci), are still commonly used even though methicillin is 
no longer the agent of choice for testing or treatment. For detection of MRS, 
following precautions were taken: 
(1) Oxacillin being the preferred agent to test, for methicillin/oxacillin 
resistance, was used in addition to methicillin to detect the resistance. 
(2) NaCI (2% w/v; 0.34 mol/l) was added to the medium for both broth 
and agar dilution for testing of the penicillinase stable penicillins. 
(3) The inoculum was prepared using the direct method of colony 
suspension rather than the inoculum growth method. 
(4) Tests to detect MRS were incubated for a full 24 hours (rather than 
16 to 20 hours) at a 33 °C to 35 °C (never exceeded 35 °C). 
(5) If the MIC test result was in doubt with a possible methicillin-resistant 
Staphylococcus aureus, additional confirmatory test was performed 
such as the oxacillin-salt agar-screening test as described below. 
3.7.7.1 Oxacillin Screening Plates 
The oxacillin salt-agar screening-plate procedure was used in addition to the 
dilution methods for the detection of MRSA. The test was performed by 
inoculating an S. aureus isolate onto Mueller-Hinton agar that was 
supplemented with NaCI (4% w/v; 0.68 mol/l) and that contained, 6 |ag 
oxaciilin/ml. The agar was either inoculated as a spot or streak using a 
cotton swab that was dipped into a direct colony suspension equivalent to a 
0.5 McFarland standard. The plate was incubated no higher than 35 °C for 
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24 hours and examined carefully with transmitted light for evidence of small 
colonies (>1 colony) or a light film of growth, indicated oxacillin resistance.^ '*® 
3.7.8 DETERMINATION OF REDUCED SUSCEPTIBILITY TO 
VANCOMYCIN 
The occurrence of strains of S. aureus and coagulase-negative 
staphylococci with decreased susceptibility to vancomycin (MICs 4 to 8 
fag/ml) was reported from different parts of the world.^ °^ '^ ® '^'*^ ° The exact 
mechanism of resistance that results in these elevated MICs is unknown 
although it likely involves alterations in the cell wall and hyper expression of 
penicillin binding proteins (PBPs). To date, all these S. aureus strains appear 
to have developed from MRSA. 
In order to recognize strains with vancomycin .MICs of 4 to 8 ^ig/ml, MIC 
testing was performed or the vancomycin agar screen test was used to 
detect these isolates, incubated the plates for a negative quality control 
strain, such as S. aureus ATCC 29213, was used to ensure specificity. 
3.8 PROTOCOL FOR ISOLATION OF PLASMIDS 
The protocol employed for isolation of plasmids from staphylococci is a 
modified form of Birnboin and Takahashi methods. '^*'^ °°''*^° This protocol 
separates plasmid from chromosomal DNA by taking advantage of the fact 
that most plasmids exist in supercoiled state and hence are more resistant to 
denaturation in alkaline solution than is chromosomal DNA. Exposure of 
these DNA preparations to alkaline solutions denatures the chromosomal 
and nicked plasmid DNA, and this denatured DNA segregates with the cell 
wall pellet following neutralization. Supercoiled plasmid remains in solution 
and can be precipitated with salt and alcohol. The buffers used in this 
protocol were as follows: 
Buffer A (pH 8.0) (1 OX): 
4000 mol/liter Tris-acetic acid 
20 mmol Ethylenediaminetetra acetic acid (EDTA) 
Buffer B (pH 5.5): 
3 mol/liter Sodium acetate/acetic acid. 
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Buffer C (pH 8.0): 
10 mmol/liter Tris-acetic acid 
2 mmol/liter disodium EDTA 
Lysostaphin Solution (pH 6.9): 
12 units/mL Lysostaphin 
100 mmol/liter NaCI 
40 mmol/liter Tris - NaOH 
50 mmol/liter disodium EDTA 
Lysing Solution: 
4% Sodium dodecyl Sulphate (SDS) 
100 mmol/liter Tris 
0.4 N NaOH 
Lysing solution was prepared by taking 4% SDS/100 mmol/liter Tris and 
mixing it with equal volume of freshly prepared 0.4 N NaOH. 
TE Buffer (pH 8.0): 
50 mmol/liter Tris 
10 mmol/liter EDTA 
(1) Took culture as a broth culture grown overnight in 3 to 5 ml of Nutrient 
broth or Luria-Bertani (LB) at 35 °C. 
(2) Harvested cells by centrifugation at room temperature at 4000 rpm for 
5 minutes. 
(3) Resuspended cells in 200 \x\ of either Buffer A or Lysostaphin solution 
with 100 |jg/ml RNase. Transferred to 1.5-ml polypropylene eppendorf 
tube and incubated for 15 minutes at 35 °C. 
(4) Added Lysing solution (400 |al) and gently inverted 5 to 10 times. 
Allowed to stand at room temperature for 5 minutes. 
(5) Added 300 1^ of cold (4 °C) buffer B and gently inverted 10 to 20 
times. 
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(6) Maintained at 0 °C for 20 minutes, centrifuged at room temperature 
for 15 minutes, and then maintained at 0 °C for 10 minutes. 
(7) Centrifuged @ 12000 rpm for 10 minutes at 0 °C and then transferred 
the supernatant to a fresh tube. 
(8) Extracted with an equal volume of chloroform/isoamyl alcohol (24:1). 
(9) Transferred 500 [i\ of the aqueous phase to a fresh tube. Added 1 ml 
of cold 95% ethanol and mixed by inversion. Placed on ice for 30 
minutes. 
(10) Centrifuged @ 12000 rpm at 0 °C for 30 minutes. 
(11) Washed pellet v\/ith 70% ethanol. 
(12) Resuspended in 70 ^1 of TE Buffer. 
(13) Separated 10 )il on an agarose gel to determine plasmid content. 
3.8.1 AGAROSE GEL SEPARATION 
After plasmid isolation, resulting samples were separated on agarose gels 
and visualized under UV illumination after staining with ethidium 
bromide.^°°'^^^ Buffers used were as follows: 
Loading buffer: For 10 ml solution took, 
5 ml Glycerol 
0.5 ml of 1% Bromophenol blue 
0.5 ml of 1% Xylene cyanol 
4 ml water 
Running Buffer (SOX) (Tris/Acetate/EDTA(TAE)Buffer): Fori litersoiution, 
242 g/liter Tris base (2 mol/liter) 
28.55 ml Glacial acetic acid (1 mol/liter) 
37.2 g/liter EDTA (0.1 mol/liter) 
(1) Added 0.7% solid agarose to TAE buffer. 
(2) Heated the agarose/buffer mixture until dissolved. 
(3) Allowed the agarose to cool, with stirring, to 50 °C to 55 °C. 
(4) Added 30 |il of ethidium bromide (1.5mg/ml)/100ml of agarose. 
(5) Poured agarose into a gel tray with an inserted comb and allowed 
polymerization for 30 to 45 minutes. 
(6) Removed the well comb and placed the gel within an electrophoresis 
chamber. Filled both cathode and anode chambers with running 
buffer (1X) to cover the top of the gel by at least 1 mm. 
(7) Loaded the sample with Loading Buffer (mixed 5 jxl of sample with /|al 
of Loading Buffer), into the wells. 
(8) Ran the gel at a constant voltage for the desired period of time. 
(9) Visualized the gel under UV light and photographed. 
3.9 TRANSFORMATION 
Transformation involves the uptake and expression of DMA from a donor 
strain by a recipient strain and has been shown for both chromosomal and 
plasmid markers in S. aureus.^ ° '^^ ®^ The ability of a strain to be transformed 
is described as competence and depends on a number of factors, which 
have been well defined. The conditions under which transformation occurs 
are very similar to those required for the uptake of free phage DNA by 
transfections.'*^^ The competence of a strain is dependent on the presence 
of a high concentration of divalent ions. Ba^*, Mg^*, Ca^* and Rb^ "^  ions all 
enhance competence but Ca^* ions are most commonly used in labs. 
3.9.1 PREPARATION OF COMPETENT STAPHYLOCOCCAL CELLS FOR 
HEAT SHOCK TRANSFORMATION (RbCh METHOD) 
Competent E. coll cells were prepared by RbCb method, using 
transformation buffer and all the solutions and tubes were chilled on ice prior 
to use, sterilized by autoclaving wherever applicable.^"" 
Transformation buffer 1 (Tfb1): For 100 ml solution took, 
30 mM KCI (0.29 g) 
100mMRbCl2(1.2g) 
10mMCaCl2.2H2O(0.14g) 
162 
50 mM MnCb. 4H2O (0.98 g) 
Glycerol (15 ml) 
H2O (85 ml) 
Adjusted pH to 5.8 with 1-2 |xl of diluted acetic acid. Kept unexposed to air 
for more than a couple of minutes to avoid formation of reddish brown 
precipitate of MnOa. Tfbl was filter sterilized. 
Transformation buffer 2 (Tfb2): 
10 mM MOPS (0.21 g) 
75mMCaCl2.H20(1.1 g) 
10mMRbCl2(0.12g) 
Glycerol (15 ml) 
H2O (85 ml) 
Adjusted pH to 6.5 with IM KOH and filter sterilized. 
(1) Inoculated an LB plate (no antibiotic) with DH5 cells from frozen 
stock. 
(2) Incubated overnight at 37 °C. 
(3) Picked a large, well-isolated colony and inoculated 80 ml of pre-
warmed LB containing 20 mM MgCb (added 1.6 mi of 1 M Mg CI2). 
Grown at 37 °C until ODeoo reached 0.55-0.6. 
(4) Harvested the cells in SS 34 tubes at 4000 rpm at 4 °C for 15 
minutes. Discarded the supernatant. 
(5) Resuspended cells in (2/5)**^  original volume (32 ml) Tfbl. Kept on ice 
for 5 minutes and spun down the cells as in step 4. Discarded the 
supernatant. 
(6) Now suspended cells in 1/25"" original volume (3.2 ml) Tfb2. Kept the 
cell suspension on ice for 15 minutes and eliquoted desired volumes 
(50 |il) in eppendorf tubes and stored frozen in -70 °C freezer. 
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3.9.2 PREPARATION OF COMPETENT STAPHYLOCOCCAL 
CELLS USING CALCIUM CHLORIDE 
The following protocol is derived from Reference 389 
Transformation buffer (pH 8.0): 
50 mmol/liter CaCb 
10mmol/literTris-HCI 
(1) Inoculated 1 ml of LB broth with an isolated colony from an 
appropriate staphylococci sensitive strain. 
(2) Inoculated 100 ml of LB broth with 1 ml of overnight culture. 
(3) Incubated for 2 to 3 hours at 37 °C with shaking. 
(4) Placed the culture on ice for 5 to 10 minutes. 
(5) Pelleted the culture at 7000 rpm for 5 minutes at 4 °C. 
(6) Gently resuspended cells in 20 ml of sterile, ice-cold transformation 
buffer. Placed on ice for 20 minutes. 
(7) Centrifuged for 5 minutes at 7000 rpm. 
(8) Carefully resuspended the pellet in 2 ml of ice-cold transformation 
buffer. 
(9) Allowed the cells to remain on ice for 1 to 2 hours. Stored at 4 "C for 
12 to 24 hours. 
(10) For long term storage, cells were immediately separated into 200 1^ 
aliquots in 1.5 ml polypropylene tubes, snap frozen in dry ice/alcohol 
and stored at -70 °C. They were thawed on ice prior to use. 
3.9.3 PROTOCOL FOR TRANSFORMATION 
(1) Took the competent cells from -70 °C freezer. 
(2) Thawed the eliquote on ice and added 50 ng of DNA (i.e. 2-10 i^ l of 
plasmid) 
(3) Kept the mixture on ice for 30 minutes. 
(4) For heat shock kept the mixture in 42 °C water bath for 45 seconds. 
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(5) Again kept it on ice for 5 nninutes. 
(6) Added 500 ^1 of autoclaved LB broth in inoculation hood. 
(7) Incubated @ 37 °C for 1 hour. 
(8) Plated 100-200 ^1 of broth with the help of spreader. For each 
transformation inoculated two agar plates one with marker antibiotic 
and one without antibiotic. 
(9) lncubatedtheplates@37°Cfor 12 hours. 
(10) Transformants were grown in 3 ml of broth and examined for the 
presence of plasmids. 
3.10 PLASMID CURING PROTOCOL 
The spontaneous loss of a particular trait or phenotypic characteristic in a 
strain may be the first indication that the character is plasmid determination, 
though such loss does not necessarily mean that the genes responsible are 
plasmid borne. Chromosomal mutations in other bacterial species occur at 
frequencies, which might be mistaken for plasmid loss. However, point 
mutations are often reversible whereas loss of an entire plasmid is 
irreversible. There are various agents that have been found to eliminate 
resistance determinants from bacteria; these include acridine orange, 
acriflavin, ethidium bromide, refampicin, sodium dodecylsulphate, 
novobiocin, guanidine hydrochloride etc.^^^ In the present study the protocol 
for plasmid curing was followed from Reference 149. 
(1) Inoculated a single colony of staphylococcal strain having known 
resistance markers in 2 ml of Mueller-Hinton broth. 
(2) Added 0.1 ml of the overnight culture to Mueller-Hinton broth 
containing a range of doubling concentrations from 128 to 0.25 mg/ml 
of ethidium bromide. 
(3) After 18 to 24 hours of incubation, cultures, which contained a 
concentration of agent sub-inhibitory to cell growth, were plated on 
Mueller-Hinton agar plates. 
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(4) After 16 to 18 hours of incubation, colonies were tested on antibiotic 
plates to detect antibiotic segregants. 
(5) Rate of cure was the number of antibiotic sensitive colonies per 
number of colonies screened expressed as percentage. 
3.11 CONJUGATION 
A number of reports have shown that antibiotic resistance can be transferred 
from one strain to another through conjugation. As staphylococci are often 
found in close proximity to one another under natural conditions, this form of 
transfer may have contributed to the spread of antibiotic resistance in vivo. 
Mating experiments are designed to detect DNA transfer events that require 
cell-to-cell contact. Most frequently, we detect the transfer of plasmids. 
Mating experiments can also detect the transfer of specific segments of 
chromosomal DNA, via either transformation process, mobilization of the 
chromosome by plasmids, or processes yet to be defined. Mating 
experiments performed on DNase-containing media (to exclude 
transformation) or in experiments designed to allow the passage of 
bacteriophage (to exclude transduction) are required to be certain of the 
mechanism of transfer. In present study following mating experiments were 
employed to detect the transfer of antibiotic resistance markers.^^^ 
3.11.1 BROTH MATINGS (Mixed Culture Method) 
(1) Inoculated 5 ml of Luria-Bertani (LB) (Gram negative) or brain -heart 
infusion (BHI) (Gram - Positive) broth with a single colony from a 
recipient culture. Inoculated 5 ml of broth with a single colony of donor 
culture and incubated both overnight at 37 °C. 
(2) Set up three flasks with 4.5 ml of broth. Into one (mating flask), 
inoculated 50 ml of the donor overnight culture and 500 | i ! of the 
recipient overnight culture. Into the second (recipient control flask), 
inoculated 500 \i\ of the recipient overnight culture. Into the third, 
inoculated 50 /al of the donor overnight culture. 
(3) Incubated at 37 °C either 4 hours or overnight, without shaking. 
166 
(4) Inoculated selective agar plates with 100 nl from the mating mixture 
and control flasks. 
(5) Serial dilutions were performed on the mating mixtures to determine 
the number of donor and recipient CFU. 
(6) Transfer frequency was expressed as transconjugants per recipient 
CFU. 
3.11.2 FILTER MATINGS 
(1) Set up overnight cultures as described in broth matings. 
(2) Placed three sterile nitrocellulose disks on a non-selective agar plate. 
(3) Inoculated tubes with mating mixtures as described in broth matings. 
(4) Placed 100 ^1 of each mixture into a sterile 1.5 \i\, polypropylene tube, 
mixed, transferred 100 |xl to a sterile nitrocellulose filter, and allowed 
the filter to dry at room temperature. 
(5) Placed plates in an incubator overnight at 37 °C. 
(6) Picked up filters with sterile forceps and placed into test tubes with 1 
to 2 ml of sterile 0.9% saline Vortex-mixed vigorously. 
(7) Inoculated 100-^1 aliquots from each tube onto selective agar plates. 
(8) Inoculated plates selective for donor and recipient CFU determination. 
(9) Calculated the frequency of transfer as the number of transconjugants 
per recipient cell. 
3.12 PFGE PROTOCOL FOR FINGERPRINTING OF MRSA 
PFGE typing of clinical and carrier MRSA strains isolated during our study 
was performed as described previously.^'^'*'*^° 
3.12.1 PRECAUTIONS 
Gloves and safety spectacles should be worn throughout the procedure. 
Ethidium bromide is teratogenic and should not be handled if pregnant. 
Unless an enclosed gel documentation system is used, UV protective visors 
should be worn when visualizing and photographing gels. 
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3.12.2 METHOD OF DNA PREPARATION 
Genomic DNA was extracted from logarithmic-phase MRSA cultures grown 
in nutrient broth. Bacterial suspension equivalent to a McFarland standard 3 
(approx. 9x10^ cells/ml) of 0.5 ml was prepared with normal saline and 
mixed with an equal volume of 2% low melting point (LMP) agarose and 
allowed to solidify in plug moulds. Then the bacteria were lysed by 
incubation of the agarose plugs at 37 °C for 12 h in 1ml of lysostaphin 
solution (Sec. 3.8) and 1ml of lysing solution (Section 3.8). The agarose 
plugs were then washed three times with 10 ml of Tris EDTA (TE) buffer 
(Sec. 3.8) for 30 min at room temperature and transferred to a tube 
containing TE buffer placed in a refrigerator at 4 °C until use. 
DNA from the S. aureus strain NCTC 8325 used as molecular size marker 
was also prepared following the same protocol. 
3.12.3 DIGESTION (MRSA strains and NCTC 8325) 
For restriction endonuclease digestion, approximately 1 to 1.5 mm of a plug 
was cut and incubated with 250 |j,l of restriction buffer containing 20U of 
Sma-I (Bangalore Genei Pvt. Ltd. India) at 25 °C for4 h. 
3.12.3 PFGE 
After DNA digestion, the agarose plugs were incubated with 1 ml of TE 
buffer at 37 °C for 1 h. The plugs were then inserted into 1% agorose gel in 
0.5X TBE buffer, and restriction fragments were separated using a contour-
clamped homogeneous electric field system (CHEF-DRII; Bio-Rad, 
Laboratories). Electrophoresis was performed using the following conditions: 
Block 1: initial switch time - 5 sec; final switch time -15 sec; run time - 10 h; 
volatage - 200V or 6 V/cm. Block 2: initial switch time - 15 sec, final switch 
time - 60 sec. run time -13 h, voltage - 20V or 6 V/cm. 
3.12.4 STAINING, VISUALIZING AND PHOTOGRAPHING GEL, AND 
STORING IMAGE 
> Stain gel for 30-45 min in ethidium bromide (1 |jg/ml). 
> View under UV transillumination and photograph using gel 
documentation system. 
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Important: Zoom to maximum to include the whole width (20 cm) of the gel 
and save the image as tagged image file format (TIFF) file for analysis with 
BioNumerics version 2.5 software (Applied Maths, Kortrijk, Belgium). Using 
the BioRad camera gel documentation system this correspond to a file size 
of 768 X 574 pixels. This allows a resolution of tracks = 500 pixels or 100 dpi. 
3.13 POLYACRYLAMIDE GEL ELECTROPHORESIS 
In order to study the whole-cell protein banding patterns of MRSA isolates, 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)^°° 
was carried out with 12% acrylamide - 0.15% bisacrylamide in the running 
gel (13 X 18 cm). The stacking gel was composed of 5% acrylamide-0.07% 
bisacrylamide, 0.15 M Tris hydrochloride (pH 8.8), 0.1% SDS, 0.05% 
TEMED, and 0.1% ammonium persulfate. 
Bacterial suspensions of 5 |il equivalent to a McFarland 0.5 standard were 
added to 45 |il sample loading buffer containing 0.05M Tris hydrochloride 
(pH 6.8), 1.6% SDS, 0.04% bromophenol blue, and 27% glycerol and were 
boiled for 30 min. 
Samples were loaded to the gel lanes and run through the stacking gel at 75 
mV and then electrophoresed through the running gel at 120 mV for 45 to 60 
min past the time that the leading edge had passed the bottom of the 
running gel. The gels were stained with Coomassie brilliant blue and 
destained overnight with methanol-acetic acid-water (30:5:65), and 
photographed using Bio-Rad gel documentation system. 
3.14 STATISTICAL ANALYSIS 
Statistical analysis was done with the help of Windows based Graphical 
Software SPSS-11. Comparison between two groups of data was performed 
using Student's t test. Comparison of percentages between groups was 
made with the Chi-square Test using Asymptotic Exact Test mode. 
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CHAPTER-4 
RESULTS 
4.1 BIOCHEMICAL CHARACTERISTICS 
Of the 850 clinical isolates of Staphylococci, 513 were identified as S. 
aureus, 312 as S. epidermidis and 25 as other coagulase-negative 
Staphylococci (other CNS) on the basis of standard biochemical tests (Table 
4.1). Pigmentation in different shades of cream-yellow, yellow, yellow-orange 
was observed in 484 stains (56.9%) on nutrient agar after the 48 h 
incubation while as 366 (43.1%) showed no pigmentation (Chi-square, 0.0; 
degree of freedom, 5, asymptotic significance, 1.0). Although all clinical 
isolated studied grew on mannitol salt agar but only 480 (56.5%) isolates 
showed heamolysis on 5% sheep blood agar plates after 18-24 h incubation 
at 35-37 °C. Of the 513 clinical isolates of S. aureus, all were positive for 
staphylocoagulase, mannitol fermentation and DNase but only 499 (58.7%) 
showed the presence of clumping factor (slide coagulase test). Out of 850 
only 22 strains (2.6%) were negative for alkaline phosphatase and 25 were 
positive for novobiocin resistance. So 25 strains were classified as other 
CNS. As for as the p-lactamase test is concerned, 762 (89.6%) strains were 
positive and 88 (10.4%) were negative for this enzyme in the present study 
(Chi-square, 0.0; degree of freedom, 5, asymptotic significance, 1.0). 80% 
(40/50) isolates from normal eyes were p-latamase +ve as compared to 
83.3% (100/220) of clinical strains isolated from diseased eyes. Nose of 
hospital workers contributed 88.8% (111/125) of staphylococci positive to p-
lacatamase as compared to 90% (90/100) isolated from nose of patients. In 
case of other clinical sources of patients like pus, urine, blood, CSF, semen 
etc. the staphylococcal isolates positive to p-lactamase were shown to be 
92.5% (421/455). 
4.2 AGE AND GENDER DISTRIBUTION 
Of the 750 subjects studied the male: female ratio was 52.5:47.5, of whom 
175 were normal hospital workers (Table 4.2). The age range was 5 to 75 
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years. Of these 12 cases of mastatitis belonged exclusively to females and 
18 cases of prostatitis to men. Of patients having wound infections (n=122), 
the highest prevalence of staphylococci (27%; 33/122) was found in the age 
group of 45-64 years and so was the case with patients having urinary tract 
infections (32.6%; 29/89). (Chi-square, 3.286; degree of freedom, 10; 
asymptotic significance, 0.794) In this study staphylococcal conjunctivitis 
was found equally prominent in the age group of 5-14 (23.1%; 12/52) and 
45-64 (23.1%; 12/52) years. Of the 175 normal hospital workers, the highest 
number of carrier staphylococci (48%; 84/175) was isolated from the 
subjects having age between 25 and 44 years while as the age group 5-14 
years contributed none. (Chi-square, 3.143; degree of freedom, 9.0; 
asymptotic significance, 0.958). In the present study 52 subjects were 
lacking the information regarding their age and so were categorized as 
unknown age group. 
4.3 FREQUENCY OF STAPHYLOCOCCAL ISOLATES AMONG 
CLINICAL SOURCES 
Of the 850 clinical strains of staphylococci studied, 513 (60.3%) were 
Staphylococcus aureus and 337 (39.7%) coagulase-negative staphylococci 
(Table 4.3). Of these 180 (35.1%) were methicillin-resitant Staphylococcus 
aureus (MRSA) and 76 (22.5%) were methicillin-resistant coagulase-
negative staphylococci (MRCNS). The highest number of S. aureus strains 
was isolated from pus (22.7%; 115/513) followed by urine (14.8%, 76/513) 
and blood (11.3%; 58/513). Likewise, the highest number of coagulase-
negative staphylococcal isolates was found in urine (22.8%, 77/337) followed 
by conjunctivitis (16.3%; 55/337) and pus (10.7%; 36/337). Of the 225 nasal 
swabs of hospital workers and patients studied, 175 (34.1%) were S. aureus 
and 50 (14.8%) were coagulase-negative staphylococci, while as from ocular 
swabs (n=50) of hospital workers all the strains studied were coagulase-
negative staphylococci. Of the 180 MRSA strains the highest number was 
found in pus (35.5%; 64/180) followed by urine (16.1%; 29/180) and blood 
(9.4%; 17/180). (Chi-square, 3.0; degree of freedom, 8.0; asymptotic 
significance,0.934). In case of nasal swabs of hospital workers and patients 
(n=225) the frequency of MRSA isolates was 28.9% (52/180) that is 
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equivalent to MRSA carrier rate of 23.1% (52/225). Of the 76 MRCNS 
studied the highest number was obtained from urine (25.0%; 19/76) followed 
by conjunctiva (18.4%; 14/76) and nasal swabs of patients having ocular 
infections (14.5%; 11/76), while as 10.5% (8/76) of MRCNS were isolated 
from ocular swabs of hospital workers. (Chi-square, 1.5; degree of freedom, 
8.0; asymptotic significance, 0.993) 
4.4 RESISTANCE PROFILES OF STAPHYLOCOCCAL ISOLATES 
The resistance patterns of staphylococcal isolates (n=850) to 18 
antimicrobial agents were shown in Table 4.4. Vancomycin was shown to be 
the most effective drug. In case of Staphylococcus aureus (n=513), the 
highest resistance was observed to penicillin G (92.0%) followed by 
ampicillin (80.5%) and co-trimoxazole (50.0%). Though the highest 
resistance in coagulase-negative staphylococci (n=337) was shown to 
penicillin G (89.9%) but it was lesser by (2.1%) as compared to its resistance 
in Staphylococcus aureus, followed by the same pattern as to ampicillin 
(71.5%) and co-trimoxazole (40.3%). 
As far as the clinical versus carrier staphylococcal islates are concerned the 
general observation was that the resistance in carrier isolates was lesser 
than clinical strains in case of all antibiotics. In clinical (n=338) and carrier 
(n=175) isolates of S. aureus the highest resistance was found to penicillin G 
(92.6% versus 90.60%) followed by ampicillin (81.4% versus 78.8%) and co-
trimoxazole (51.8% versus 46.3%) . respectively. The least resistance 
followed to vancomycin and fusidic acid was shown to chloramphenicol 
(4.7% versus 3.4%), tetracycline (12.7% versus 7.1%) and amikacin (13.9% 
versus 10.3%) respectively in clinical and carrier isolates of S. aureus. 
Almost similar trend was observed in clinical (n=237) and carrier (n=100) 
isolates of coagulae-negative staphylococci, with the exception that in carrier 
isolates zero resistance to amikacin was seen. 
4.5 RESISTANCE PATTERNS OF METHICILLIN-RESITANT 
AND METHICILIN-SENSITIVE STAPHYLOCOCCAL ISOLATES 
The comparative resistance patterns of methicillin-resistant and methicillin-
sensitive staphylococcal isolates were shown in Table 4.5. The susceptibility 
of 180 MRSA and 76 MRCNS strains to 17 antimicrobial agents showed that 
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vancomycin was the most effective drug. Resistance to penicillin and 
cephalexin in case of MRSA, penicillin, cephelexin, ampicillin, cefazolin in 
case of MRCNS was shown to be 100%. Although methicillin resistant-
staphylococci are clinically thought to be resistant to all p-lactams and 
cephalosporins but these in vitro studies showed that 1.1%, 5.6% and 3.9% 
MRSA strains showed susceptibilities to ampicillin, cefazolin, cephotaxime 
and imipenem respectively. No MRCNS strain showed susceptibility to any 
of the p-tactam or cephalosporin antibiotics assayed except imipenem. 
There was no appreciable difference of resistance to amikacin (36.1% 
versus 35.5%) and gentamicin (84.4% versus 85.5) between MRSA and 
MRCNS isolates respectively. But chloramphenicol and clindamycin 
resistance varied by 6% and 11.3% in isolated strains of MRSA and MRCNS 
respectively. 
In case of 333 MSSA and 261 MSCNS isolates, vancomycin, methicillin and 
amikacin were shown to be most effective drugs as compared to penicillin G, 
ampicillin and co-trimoxazole, which showed least effectiveness. There was 
a significant decrease in resistance frequency against 17 antimicrobials in 
case of methicillin sensitive staphylococcal isolates. The appreciable 
difference of resistance to ampicillin (70.6% versus 63.2%); cephotaxime 
(10.2% versus 3.8); ciprofloxacin (8.1% versus 15.7%); and roxithromycin 
(6.0% versus 0.4%), was obsepyed respectively among MRSA and MRCNS 
strains in the present study. 
In addition the comparative resistance patterns of carrier staphylococcal 
isolates from eyes and nose of patients and hospital workers, depicted in 
Table 4.6, revealed that the resistance shown to chloramphenicol, (15.6%, 
nasal MRSA versus ocular MRSE; 5%, nasal MRSE versus ocular MRSE; 
1.6%, nasal MSSA versus ocular MSSE; 0.2%, nasal MSSE versus ocular 
MSSE); ciprofloxacin (11.3%, nasal MRSA versus ocular MRSE; 10% nasal 
MRSE versus ocular MRSE; 12.7%, nasal MSSE versus ocular MSSE; 3.2% 
nasal MSSE versus ocular MSSE); and gentamicin (4.8%, nasal MRSA 
versus ocular MRSE; 27.5%, nasal MRSE versus ocular MRSE; 3.8%, nasal 
MSSE versus ocular MSSE; 0.6% nasal MSSE versus ocular MSSE); was 
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higher in case of both methicillin-resistant and methicillin-sensitive ocular 
isolates as compared to nasal isolates. 
4.6 COMPARATIVE RESISTANCE PATTERNS OF METHICILLIN-RESISTANT 
AND METHICILLIN-SENSITIVE STAPHYLOCOCCAL CLINICAL AND CARRIER 
ISOLATES 
All the 18 antimicrobials assayed against both clinical and carrier MRSA and 
MSSA isolated depicted that clinical isolates were showing a bit higher 
frequency of resistance than carrier isolates with few exceptions. As shown 
in Table 4.7 and Fig 4.7, the resistance to amikacin, with respect to clinical 
and carrier MRSA was 36.7% versus 34.6%; cefazolin (93.0% versus 
48.11%); chloramphenicol (11.7% versus 9.6%); and tetracycline (30.5% 
versus 28.8%), respectively. However, in case of resistance to ampicillin 
(98.4% versus 100.0%); co-trimoxazole (96.9% versus 100.0%); and 
gentamicin (85.2% versus 82.7%), the values were fractionally less with 
respect to clinical and carrier MRSA isolates, respectively. In case of 
MRCNS clinical and carrier isolates the resistance to A, Cz, Cp, Ce, I and P 
was almost having the same frequency, while resistance frequency to other 
antibiotics was outweighed by clinical MRCNS to carrier MRNS, with few 
exceptions, respectively. The same trend was observed when clinical and 
carrier MSSA and MSCNS were observed for their frequency of resistance to 
antibiotics assayed. 
4.7 COMPARATIVE MULTI-DRUG RESISTANCE PATTERNS OF METHICILLIN-
RESISTANT AND METHICILLIN-SENSITIVE STAPHYLOCCAL CLINICAL AND 
CARRIER ISOLATES 
Resistance to 4 antibiotics or more, was observed in both S. aureus and 
Coagulase-negative staphylococci (Table 4.8, Fig 4.9). In case of MRSA 
isolates, no strain showed resistance to 5 or less than 5 antibiotics, while as 
all MRCNS strains showed resistance to 8 or more than 8 antibiotics (Table 
4.8, Fig 4.9). As for as the clinical and carrier MRSA are concerned, in the 
present study, both types of strains showed resistance to 6 or more than 6 
antibiotics assayed (Table 4.9, Fig 4.10). In case of clinical and carrier 
MSSA isolates, no strain showed resistance to more than 7 antibiotics. 
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Almost same trend of multidrug resistance patterns was observed in case of 
clinical and carrier, MRCNS and MSCNS isolates from eye and other clinical 
sources in health and diseases (Table 4.9, Fig 4.11). 
4.8 ANTIBIOTIC RESISTANCE PROFILES OF MRSA ISOLATES IN AN 
ORTHOPEDIC SURGICAL WARD 
In this study, 61 isolates turned to be MRSA, were isolated in an 
Orthopaedic Surgical Ward from wound infections (n=56); their nose (n=50); 
and nose of hospital workers attending wound infections (n=50) according to 
the method described in Section 3.3 of Chapter 3. As depicted in Table 4.10, 
only 3 MRSA isolates (JMR-8, 31, 56) showed resistance to minimum of 6 
antibiotics; and one strain showed resistance to maximum of 16 antibotics 
(JMR-41), and two strains showed resistance to maximum of 17 antibiotcs 
(JMR-28, 60) assayed in the present study. Antibiotic resistance patterns, 3, 
24, and 36 were the most common profiles found by 4 strain each in this 
study. Some strains from Table 4.10 were selected for studying antibiotic 
resistance transfer mechanisms. 
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Table 4.10 Antibiotic Resistance Profiles of 61 Strains of 
MRSA Isolated in an Orthopaedic Surgical Ward 
Pattern 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
15. 
16. 
17. 
18. 
19. 
20. 
21. 
22. 
23. 
24. 
25. 
26. 
27. 
28. 
29 
30 
31. 
32. 
33. 
34. 
35. 
36. 
37. 
38. 
39. 
40. 
41. 
42. 
Antibiotic Resistance Profiles of IVIRSA 
A,Cz,Ce,Cp,Co,G.I,M,P,R,Ro,T 
Ak,A,Cz,Ce,Cp,Cf,Cd,Co,G,l,M,P,Ro 
Ak,A,Cz,Ce,Cp,Co,G,l,M,P,Ro 
A,Cz,Ce,Cp,Cd,Co,G,l,M,P,T 
A,Cz,Ce,Cp,Cd,Co,G,M,P 
A,Cz,Ce,Cp,Cf,Cd,Co,G,M,P,R,Ro 
A,Cz,Ce,Cp,Cf,Co,M,P,R,Ro 
Ce,Cd,Co,M,P,R 
A,Cz,Ce,Cp,C,Cd.Co,M,P.R 
Ak, A, Cz,Ce,Cp,Cf,Co,G,M,P,R,Ro,T 
Ak,A,Cz,Ce,Cp,Cd,Co,G,M.P,R,Ro 
Ak,A,Cz,Ce,Cf,Cd,Co,G,l.M,P.R,Ro 
A.Cz,Ce,Cp,Cd,Co,G,M,P,R 
A,Cz,Ce,Cp,Co,M,P,R 
A,Cz,Ce,Cp,Cf,Co,G,M,P,R 
A,Cz.Ce,Cp,Cf,Co,G,M,P 
Ak,A,Cz,Ce,Cp,Cd,Co,G,M,P,R 
A,Cz,Ce,Cp,Co,G,M,P,R 
Ak,A,Cz,Ce,Cp,Co,G,M,P,Ro 
AkACz,Ce,Cp,Cd,Co,G,l,M,P,R,Ro 
A,Ce,Cp,C,Co,G,M,P,T 
Ak,A,Cz,Cp.Co,G,l,M,P,Ro,T 
A,Cz,Ce,Cp,Co,G,M,P,Ro 
Ak,A,Cz,Ce,Cp,Cf,Cd,Co,G,M,P,Ro,T 
Ak,A,Cz,Ce,Cp,C,Cf,Co,Fc,G,l,M,R,Ro,T 
A,Cz,Ce,Cp,Co,G,iV1,P,Ro,T 
A,Cz,Ce,Cp,Co,G,M,P,Ro,T 
Ak,A,Cz,Ce,Cp,C,Cf,Cd,Co,Fc,G,l,M,P,R,Ro,T 
A,Cz,Ce,Cp,C,Cd,Co,G,M,P,R,Ro,T 
A,Cz,Ce,Cp,Co,G,l,M,P,R,Ro 
Ce,Cp,Cd,Co,M,P 
A,Cz,Ce,Cp,Cf,Co,G,M.P,R,Ro,T 
A,C2,Ce,Cp,C,Cf,Cd,G,Co,l,M,P,Ro,T 
A,Cz,Ce,Cp,C,Co,G,M,P,Ro,T 
Ak,A,Cz,Ce,Cp,C,Co,G,M,F.R,Ro 
Cz,Ce,Cp,Cd,Co,M,P 
A,Cz,Ce.Cp,Cf,Co,M,P,R 
A,Cz,Ce,Cp,C,Cf,Cd,Co,Fc,G,l,M.P,R,Ro,T 
AkACz,Cp,l,M,P,Ro 
A,Cz,Ce,Cp,Cd,Co,G,M,P,R,Ro 
A,Cz,Ce,Cp,Cf,Co,G,M,P,Ro 
A,Cz,Ce,Cp,Co,G,M,P,Ro 
No. of 
resistance 
Markers 
12 
13 
11 
11 
9 
12 
10 
6 
10 
13 
12 
13 
10 
8 
10 
9 
11 
9 
10 
13 
9 
11 
9 
13 
15 
10 
10 
17 
13 
11 
6 
12 
14 
11 
12 
7 
9 
16 
8 
11 
10 
9 
Strains 
JMR-1 
JMR-2 
JMR-,3,55,33,59 
JMR-4 
JMR-5 
JMR-,6,38,51 
JMR-7 
JMR-8 
JMR-9 
JMR-10 
JMR-,11,53 
JMR-12 
JMR-13 
JMR-14 
JMR-,15,58 
JMR-16 
JMR-17 
JMR-18 
JMR-,19,61 
JMR-20 
JMR-21 
JMR-22 
JMR-23 
JMR-,24,46,48.39 
JMR-25 
JMR-,26,52 
JMR-27 
JMR-,28,60 
JMR-29 
JMR-30 
JMR-,31,56 
JMR-32 
JMR-34 
JMR-35 
JMR-,36,49 
JMR-37,45,50,54 
JMR-40 
JMR-41 
JMR-42 
JMR-43 
JMR-44 
JMr-,47,57 
186 
200 n 
Clinical diagnosis 
Figure 4.1 Distribution of Staphylococcal Isolates Among 
Infected/Colonized Subjects According to Clinical Diagnosis 
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Figure 4.2 Distribution of Staphylococcal Isolates Among 
the Clinical Sources 
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Figure 4.3 Comparative Resistance Profiles of 
Staphylococcus aureus and Coagulase-negative 
Staphylococcal Isolates from Eyes and Other 
Clinical Sources in Health and Disease 
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Figure 4.4 Comparative Resistance Patterns of Methicillin-
resistant Staphylococcus aureus (MRSA) and Methicillin-
sensitive Staphylococcus aureus (MSSA) 
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Figure 4.5 Comparative Resistance Patterns of 
Methicillin - resistant and Methicillin - sensitive 
Coagulase - negative Staphycoccal Isolates from 
Eyes and Other Clinical Sources in Health and 
Disease 
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Figure 4.6 Comparative Resistance Patterns of Methicillin-
resistant Staphylococcus aureus and Methicilline -
resistance Coagulase - negative Staphylococcal Isolates 
from Eyes and Other Clinical Sources in Health and 
Disease 
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Figure 4.7 Comparative Resistance Patterns of Methicillin-resistant 
and Methicillin-sensitive Stapylococcus aureus Clinical and Carrier 
Isolates 
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Figure 4.8 Comparative Resistance Patterns of Methicillin-
resistant and Methicillin-sensitive Coagulase-negative 
Staphylococcal Clinical and Carrier Isolates 
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Figure 4.9 Occurence of Multidrug Resistance in Staphylococcal 
Isolates (n=850) from Eyes and Other Clinical Sources in Health 
and Oesease 
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Figure 4.10 Occurance of Multidrug Resistance in 
Methicillin-resistant and Methicilli-sensitive 
Staphylococcus aureus Clinical and Carrier Isolates 
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Figure 4.11 Occurrence of Multidrug Resistance in 
Methicillin- resistant and Metliicillin-sensitive Coagulase-
negative Stapliylococcal Clinical and Carrier Isolates 
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4.9 SDS-PAGE WHOLE-CELL PROTEIN PROFILES OF MRSA STRAINS 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
was carried out with 12% acrylamide - 0.15% bisacrylamide in the running 
gel (13 by 18 cm) (Bangalore Genei Pvt. Ltd. India). The staking gel was 
composed of 5% acrylamide - 0.07% bisacrylamide. Electrophoresis was 
carried out according to the method described in Materials and Methods 
(Section 3.13). In Fig 4.12 lanes 1 and 20 were loaded with protein markers. 
Whole cell protein samples of MSSA strains were loaded in lanes 2-10, while 
as MRSA whole cell protein samples were loaded in lanes 11-19. Here the 
aim of experiment was to see the difference of protein banding patterns 
between MRSA and MSSA, but as evident from the figure through visual 
analysis there was not found any difference, however there may be 
difference in the level of expression of some proteins as is seen in few lanes 
like 15 and 16 but it seems to be non-significant. In Fig 4.13 the similar 
protein banding patterns of 42 MRSA strains representing 42 antibiograms of 
61 MRSA isolates collected from wound infections of patients (n=56); their 
nose (n=50); and nose of hospital workers (n=50) in an Orthopedic Surgical 
Ward, were shown. Here all the strains showed the same patterns as that of 
control MRSA (ATCC .43300). Similarity of whole cell protein banding 
patterns indicated that the method is not applicable for typing MRSA strains. 
4.10 PFGE PROFILES OF MRSA 
Chromosomal DMA from MRSA isolates was prepared in agarose blocks 
and was cleaved with Sma\ by method of Bannerman et al.^ "* The samples 
were run according to the protocol described in Materials and Methods 
(Section 3.12). These 61 MRSA strains were collected from wound infections 
(n=56); their nose (n=50); and nose of hospital workers attending wound 
infections (n=50) in an Orthopedic Surgical Ward. As shown in figure 4.14, 
the 14 common methicillin - resistant S. aureus (MRSA) patterns were 
identified among 61 stains of MRSA isolated in the Orthopedic Surgical 
Ward. The patterns were designated by the letters A to N based on 
difference in banding patterns. The banding type A was shown by highest 
number of MRSA strains (n=7), while as type I was shown by only one 
19:, 
MRSA isolate (Table 4.10b). These results Indicated that typing can be 
performed effectively through molecular techniques such as PFGE patterns 
but not through antibiograms as 61 strains showed 42 antibiograms which 
were narrowed down to only 14 types by PFGE. Moreover, it is evident that 
the MRSA strains which display a common antibiogram can not necessarily 
show the same PFGE pattern, for example, JMR-3, 55, 33, 59 showed 
antibiogram 3 (Table 4.10) but JMR-33 showed PFGE pattern L and JMR-59 
showed PFGE pattern H although both JMR-3 and JMR-55 showed the 
same PFGE pattern A. 
Table 4.10b PFGE Patterns of 61 MRSA Isolates 
Banding Pattern 
A 
B 
C 
D 
E 
F 
G 
H 
1 
J 
K 
L 
M 
N 
Strains 
JMR-1,2, 3, 4, 6, 38, 55 
JMR-5, 14, 18 
JMR-9, 13, 19,26,52 
JMR- 16, 25, 29 
JMR- 24, 46, 48, 39 
JMR-31, 56 
JMR-37, 50, 54, 15,58 
JMR-21.40, 42, 44, 59, 61 
JMR-8 
JMR-17, 20, 23, 27, 30, 32, 
JMR-11, 12,28.41.53 60, 
JMR- 22, 33, 34, 35, 36 
JMR-43. 45, 51 
JMR-7, 10,47,49,57 
Number of Isolates 
7 
3 
5 
3 
4 
2 
5 
6 
1 
6 
6 
5 
3 
5 
The epidemiology of carrier MRSA is evidenced in Fig 4.15 where molecular 
typing by PFGE of Smal-digested DNA from MRSA strains isolated from 
eight patients having post operative wound infections admitted in Orthopedic 
Surgical Ward, was performed. The staphylococcal strains were isolated 
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from pus, skin and nose of the patients as described in section 3.3 of 
Chapter 3. Here again the samples were run according to the protocol 
described in Materials and Methods. The banding patterns were interpreted 
visually according to the following guidelines: 1) Isolates with banding 
patterns appearing identical in sizes and number of bands were considered 
to represent the same type. This type was designated with one English 
capital letter, for example, type A. 2) Isolates with banding patterns that 
differed from the main pattern by up to three bands were considered to 
represent subtypes within the same main type and were designated with 
different number (A1, A2, A3, etc). 3) Isolates with banding patterns that 
differed from the main pattern by four or more bands were considered to be 
of a different type and designated with other English capital letters (types B, 
C, D, etc.).^ '*''*^° PFGE patterns are indistinguishable between MRSA from 
the nasal cavity (A1, A1), and pus (A1, A1) but the pattern is different for 
MRSA from the skin (B, E) nearby wounds for cases 1 and 8, respectively. 
PFGE patterns are indistinguishable between MRSA from the nasal cavity 
(C1) and Pus (C1) and closely related to that of MRSA from the skin (C2) for 
case 2 (Fig. 4.15). PFGE patterns are indistinguishable between MRSA from 
the skin (C4) and pus (C4) but closely related to that of MRSA from the nasal 
cavity (C2) for case 7. The patterns of MRSA isolates from the pus, skin and 
nasal cavity are indistinguishable for cases 3 (A2, A2, A2), 4 (C3, C3, C3), 5 
(C3, C3, C3) and 6 (D, D, D). These results indicated that self-infection 
through colonization needs to be taken into consideration and the 
appropriate measures should be followed to minimize the role of carrier 
isolates in post operative infections. Furthermore the bacteria that normally 
colonize the human body (the resident microflora) could act as reservoirs for 
resistance genes, which could then be transferred to pathogens during their 
temporary colonization of the same site, and need to be focused while 
treating infections. 
4.11 PLASMID-DETERMINED RESISTANCE TRANSFER 
In order to study the transfer of resistance genes between different species 
of bacteria, transformation of plasmid DNA from Staphylococcus aureus 
(JMR-10) (A*^ . G^, Ak'^ ) (Table 4.10) to Escherichia coli (DH5a) (A^, G^, Ak^) 
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was performed according to the protocol described in Materials and Methods 
(Section 3.9). Plasmid DNA was isolated from JMR-10 strain and 
transformed to DH5a. Transformation was tested by antibiotic sensitivity 
tests as described elsewhere.^"'' The E. coli (DH5a), which was earlier 
sensitive to Ampicillin (A), Gentamicin (G) and Amikacin (Ak) now acquired 
resistance to these three antibiotics after transformation of plasmid pJMR-10 
into it. Again plasmid was isolated from transformed E. coli (DH5a) and the 
isolated plasmid preparation from S. aureus (JMR-10) and transformed E. 
coli (DH5a) were loaded in 0.7% agarose gel. Horizontal electrophoresis 
was performed in TAE buffer (pH 8.2) for 6 h (Fig 4.16) as described in 
Materials and Methods (Section 3.8.1). From the Fig. 4.16 it is clear that the 
4.3 kb plasmid from S. aureus (Lane A) was transformed to E. coli (Lane C). 
Minimum inhibitory concentrations of A, G, Ak on S. aureus strain JMR-10 
and E. co//transformant were determined as described in Chapter 3 (Section 
3.7). The results indicated (Table 4.11) that the MIC for Ak was higher In E. 
coli than S. aureus and may be due to the fact that Ak resistance gene was 
very efficiently expressed in E. coli. 
For resistance transfer to be studied through cell - to - cell contacts 
between clinical and carrier S. aureus strains, plasmid preparations were 
electrophoresed in 0.7% agarose In TAE buffer (pH 8.2), for 6 h as described 
in chapter 3 (Section 3.8.1). The conjugation was performed through mixed 
culture tests as described In Broth Matings In Materials and Methods 
(Section 3.11.1). In our study Filter Matings experiments did not yield 
significant transconjugants and that is why we focused on Broth Matings 
only. Here S. aureus strains were isolated from a patient having post 
operative ocular infection admitted in the Post Operative Ward of Institute of 
Ophthalmology. JN-49 strain (A^, P'^ , Cf*^ , E^, G^, T^) was isolated from the 
nose of the same patient having post operative ocular infection and JS-105 
(T^, E^, G^, A^, P ,^ Cf^) was isolated from ocular swab. Plasmids were 
electrophoresed (Fig. 4.18) after Isolation from JN-49 (Lane A), JS-105 
(Lane B), and transconjugant JNS-1 (Lane E). Here transconjugants were 
screened as (A^, T'^). The transconjugant JNS-1 was subjected to curing 
treatment with ethedium bromide as described in Chapter 3 (Section 3.). 
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Three types of cured transconjugents were obtained. As shown in fig 4.18 
cured transconjugant JNS-IA (Lane C), having 38 Kb plasmid showed 
resistance pattern as G'^, E'^ , Cf^, T^, A^, P .^ Similimarly cured 
transconjugant JNS-IB (Lane D), having no plasmid depicted resistance 
profile as E'^ . Cf^, T^, G^, A^, P .^ Likewise, cured transconjugant JNS-IC 
(Lane F), having 4.4 Kb plasmid, displayed resistance pattern as T^, Cf^, E'^, 
G^, A^, P .^ The conjugation experiments clearly showed that resistant 
markers G and T got transferred from clinical S. aureus (JS-105) to carrier S. 
aureus (JN-49). Moreover the ciprofloxacin (Cf) and erythromycin (E) 
resistance seemed to be chromosomal mediated as evidenced in Lane D. 
In order to study the transfer of resistance traits from S. epidermidis to S. 
aureus, conjugational experiment was performed through Broth Matings as 
described in Materials and Methods (Section 3.). The plasmids were isolated 
as described in chapter 3 from S. epidermidis (JS-15) S. aureus (JS-79) 
(heamolytic) and transconjugant S. aureus (IS-79T). S. aureus (JS-79) was 
isolated from normal eye of a hospital worker and S. epidermidis (JS-15) 
was isolated from ocular swab from a patient having eye infection, in the 
Institute of Ophthalmology. Transconjugants were selected first on mannitol 
salt agar and letter on blood agar mixed with 64 |ig/ml gentamicin. The 
transconjugant heamolytic colonies grew on gentamicin containing blood 
agar plates. As shown in the figure 4.19, S. aureus (JS-79), having no 
plasmid (Lane A), was sensitive to gentamicin, tetracycline and erythromycin 
(G^, T^, E^), while as S. epidermidis (JS-15), having 38 kb, 4.4 kb, and 2.5 
kb plasmids (Lane B) showed resistance pattern as G'^, T*^, E'^  as per 
NCCLS recommendations.^'' There was a two-fold Increase in the MIC of 
transconjugant S. aureus (JS-769T) to Gentamicin, while its MIC level 
reduced to half against chloramphenicol and lowered by 16-folds against 
penicillin as compared to the donor S. epidermidis (Table 4.12). After curing 
experiments with ethedium bromide, the three types of cured 
transconjugants (Lanes D, E, and F in Fig 4.19) showed that the 38 kb, 4.4 
kb and 2.5 kb plasmids carry resistance traits against gentamicin, 
tetracycline and erythromycin respectively. 
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Effect of calcium chloride and temperature on the conjugation transfer 
frequency was performed according to the protocol described in Materials 
and Methods. Transfer frequency was expressed as the number of 
transconjugants per recipient cell. Transfer of resistance was studied 
between donor S. epidermidis (JS-15) (G'^, E*^ , T'^) and recipient S. aureus 
(JS-79) (G^, E^,T^) with respect to resistance markers G, E and T. At 37 °C 
transfer frequency was found to be higher with respect to G than E and T 
(Table 4.13). Furthermore, the effect of calcium chloride and 30 °C 
temperature was found to be having no significant effect on conjugation 
frequency, while at 22 °C, the temperature found in the human nose and eye 
environment, was observed to be having a profound effect on conjugation 
frequency. With respect to all the three resistance markers here studied, it 
was found that the transfer frequency dropped by more the 10,000 times. 
The results seemed to be supporting the clinical significance of lower 
temperature prevailing in the nose and eye, the two sites most exposed to 
the external environment. 
4.12 STAPHYLOCOCCAL p-LACTAMASE ASSAY 
In our study, 762 out of 850 staphylococcal strains turned to be p-
Lactamase- positive by iodometric tests as described in Chapter 3 (Section 
3.5.3.8.1). In order to see the effect of p-Lactamase on the activity of various 
penicillins and caphalosporins, a methicillin-resistant S. aureus strain (JMR-
60) was selected for isolation of p-Lactamase. MRSA (JMR-60) was having 
the highest number of resistance markers (Table 4.10). Two liters of nutrient 
broth was inoculated with 200 ml of an 18 to 24 h old culture containing 
7.5x10^ cells per ml. After 3 to 4 h of incubation with shaking at 37 °C, the 
cells were harvested by contrifugation at 10,000 rpm for 10 min in a Sorvall 
RC 2B centrifuge at 4 °C. The cell pellet was suspended in approximately 20 
ml of 0.05 M phosphate buffer, pH 7.0, recentrifuged, and resuspended in 
the same volume of fresh buffer. Cells were disrupted by sonication at 4 °C 
and the material was again centrifuged at 10,000 rpm for 30 min. The 
supernatant was collected and tested for p-Lactamase activity using 
appropriate antibiotics.^^ '^^  The assays were performed 
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spectrophotometrically by measuring the change in absorbance at the 
appropriate wavelength for each substrate by using Hitachi 228 
Sectrophotimeter with a heated attachment at 30 °C. Hydrolysis assays were 
carried out in 0.5 ml of 10 mM phosphate buffer, pH 7.4, at 30 °C. Antibiotic 
powders with known potencies were kindly provided by Hi-Media, India. The 
wavelengths were 235 nm for penicillin G (P), ampicillin (A), and amoxycillin 
(Ax), 263 nm for methicillin (M), Oxacillin (Ox) and cloxacillin (Ox), 254 nm 
for caphalexin and cefazolin, 257 nm for cefotaxime and 274 nm for 
caphalosporin C as described elsewhere.^ '^'^ '^^ ^°'^ '* '^^ ^ '^^ °^ All hydrolysis 
assays were performed three times. Value of 100 was taken arbitrarily as the 
rate of hydrolysis of pencillin G by p-Lactamase (Table 4.14). Similarly the 
concentration of p-Lactamase in the supernatant (Crude lysate) was 
arbitrarily taken as 100 (Figure 4.20). Likewise, the concentration of 100 mg 
of an antibiotic solution was arbitrarily taken as 100. Upon hydrolysis the 
unhydrolysed antibiotic was coverted to % residual concentration and plotted 
against % of stock enzyme solution. The results indicated that methicillin is 
the most stable penicillin and cephotaxime is the most stable cephalosporine 
to staphylococcal p-Lactamase. 
4.13 ACTIVITY OF A SYNTHETIC COMPOUND AGAINST MRS A 
The emergence of MRSA and now VRSA has intensified the search for 
alternative therapies for the treatment of infections caused by these 
organisms. Keeping in view the above fact, activity of a new synthetic 
compound was determined against MRSA strains by broth m.acrodilution and 
microdilution testing as described in section 3.7 of Chapter 3. The proposed 
antimicrobial agent along with control was dissolved in dimethylsulfoxide 
(DMSO). First Mueller-Hinton agar plates were prepared and wells were 
bored with well borer under aseptic conditions. Plates were swabed with 
methicillin-resistant Staphylococcus aureus, JMR-60 (Table 4.10), as it 
showed resistance to maximum number of antibiotics. In plates A, B, C, and 
D, the well-1 was loaded with the parent compound 2-mercapto 
benzimidazole (MBI), which was the basic substrate for synthesis of Nickel-
ligend-MBI-complex, the proposed antimicrobial agent (Fig 4.21). Similarly 
well-2 was loaded with a ligand derived from MBI without complexing to a 
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metal; well-3 was loaded with a copper complex of MBI (Cu-MBI); and weli-4 
was loaded with the proposed antimicrobial derived from complexing MBI 
and ligand with Nickel. Like-wise, well-5 was loaded with the solvent DMSO 
as control. In plate A, the concentration of each tested agent was 10 mg/ml, 
while as in the plates, B, C, and D, the concentration of the tested agents 
was 20 mg/ml, 30 mg/ml and 40 mg/ml, respectively. From the figure-4.21 it 
is clear that the proposed antimicrobial agent, Ni-ligand-MBI complex (well-
4) is having the highest activity against MRSA as compared to the parent 
compound (well-1), ligand alone (well-2), and Cu-MBI complex (well-3). MIC 
of the proposed antimicrobial agent (Ni-Ligand-MBI-compleX) by broth micro-
and macrodilution testing was determined to be > 64 fig/ml as compared to 
MBI (MIC, 1536 ^g/ml); ligand (MIC, 1024 ^g/ml) and Cu-MBI-complex (MIC, 
512 ^ig/ml). 
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Figure 4.12 SDS-PAGE Protein Profiles of MRSA and MSSA Isolates. 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
was carried out with 12% acryamide - 0.15% bisacrylamide in the running 
gel (13 by 18cm) (Bangalore Genei Pvt. Ltd. India). The staking gel was 
composed of 5% acrylamide - 0 07% bisacrylamide Electrophoresis was 
carried out according to the method described in Materials and Methods 
(Section 3.). In Fig 4 12 lanes 1 and 20 were loaded with protein markers. 
Whole cell protein samples of MSSA strains were loaded in lanes 2-10, while 
as MRSA whole cell protein samples were loaded in lanes 11-19. 
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Figure 4.14 Pulsed-field Gel Electrophoresis (PFGE) Profiles of MRSA. 
The preparation of chromosomal DNA for pulsed-field gel electrophoresis 
was performed as described by Bannerman et al.""* DNA restriction was 
done with Sma\ according to the manufacturer's recommendation 
(Bangalore Genei Pvt. Ltd. India). Gels for PFGE were run in a CHEF-DR II 
apparatus (Bio-Rad). The 14 common methicillin-resistant S. aureus (MRSA) 
patterns were identified among 61 strains of MRSA isolated in an 
Orthopaedic Surgical Ward. These strains were collected from wound 
infections (n=56); their nose (n=50); and nose of the hospital workers 
attending wound infections (n=50). Lanes 1, 9 and 17: S. aureus 8325 
(molecular weight marker). 
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Figure 4.15 Molecular typing by PFGE of Smal-digested DNA from 
MRSA Clinical & Carrier Isolates from Eight Patients. The preparation of 
chromosomal DNA for pulsed-field gel electrophoresis was performed as 
described by Bannerman et al."^'' DNA restriction was done with Sma\ 
according to the manufacturer's recommendation (Bangalore Genei Pvt. Ltd. 
India). Gels for PFGE were run in a CHEF-DR II apparatus (Bio-Rad). PFGE 
patterns are indistinguishable between MRSA from the nasal cavity and pus 
but the pattern is different for MRSA from the skin nearby wound for cases 1 
and 8. PFGE patterns are indistinguishable between MRSA from the nasal 
cavity and pus and closely related to that of MRSA from the skin for case 2. 
PFGE patterns are indistinguishable between MRSA from the skin and pus 
but closely related to that of MRSA from the nasal cavity for case 7,The 
patterns of MRSA isolates from the nasal cavity, skin, and pus are 
indistinguishable for cases 3, 4, 5, & 6. 
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Figures 4.18 Plasmids Transferred in Conjugation Through Mixed 
Culture Test (iVICT) Experiments (Broth iVIatings). Horizontal 
electrophoresis was performed with 0.7% agarose in TAE buffer (pH 8.2), for 
6 h as described in Materials and Methods (Section 3.8.1). 
Lane A, Carrier S. aureus, JN-49 (A^.P'^.Cf^.E'^G^.T^), having 2.8 kb 
plasmid. 
Lane B, Clinical S. aureus, JS-105 {T^,E^,G^,A^,P^,Cf), having 38 kb and 
4.4 kb plasmid; 
Lane C, Cured trasnconjugant, JNS-1A (G^E*^. Cf^,T^,A^,P^), having 38 kb 
plasmid; 
Lane D, Cured trasnconjugant, JNS-1B (E^ Cf^,T^,G^,A^,P^), having no 
plasmid; 
Lane E, Transconjugant JNS-1 (T^Cf*^,E'^ ,G'^ ,A'^ ,P'^ ), having 38 kb, 4.4 kb 
and 2.8 kb plasmid; 
Lane F, Cured Transconjugant JNS-1 C (T'^,Cf^,E'^,G^,A^,P^), having 4.4 kb 
plasmid; 
Results: Tranconjugants were screened as (A'^.T'^). The conjugation 
experiment clearly shows that resistance markers G and T got transferred 
from clinical S. aureus, JS-105 to Carrier S. aureus, JN-49. Moreover, the 
Ciprofloxacin (Cf) and erythromycin (E) resistnace seem to be chromosomal 
mediated as evidenced in Lane D. 
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Figure 4.17 Plasmid Contents of Representative Clinical and Carrier 
Isolates of S. aureus. Horizontal electrophoresis was performed with 0.7% 
agarose in TAE buffer (pH 8.2), for 6 h as described in Materials and 
Methods (Section 3.8.1). 
Lanes 1, 2 & 3, Carrier S. aureus, JN-49 (A^P^.Cf^.E^.G^.T^) having 2.8 kb 
plasmid; j . 
Lanes 4, Clinical S. aureus, JS-105 (T'^,E'',G'',A^,P^,Cf^) having 38 kb and 
4.4 kb plasmid; . , 
Lane 5, Cured Transconjugant JNS-IC (T'^, Cf^, E^, G^, P^), having 4.4 kb 
plasmid 
Lane 6, Plasmid marker, S. aureus WBG 4483. 
• / • 
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Figures 4.18 Plasmids Transferred in Conjugation Through IVIixed 
Culture Test (MCT) Experiments (Broth Matings). Horizontal 
electrophoresis was performed with 0.7% agarose in TAE buffer (pH 8.2), for 
6 h as described in r\/laterials and Methods (Section 3.8.1). | 
Lane A, Carrier S. aureus, JN-49 (A'^.P'^.Cf^.E'^G^.T^), having 2.8 kb 
piasmid. 
Lane B, Clinical S. aureus, JS-105 (I'^.E'^.G'^.A^.P^.Cf^), having 38 kb and 
4.4 kb piasmid; 
Lane C, Cured trasnconjugant, JNS-1A (G^.E'^, Cf^.T^.A^.P^), having 38 kb 
piasmid; 
Lane D, Cured trasnconjugant, JNS-1B (E'^, Cf^,T^,G^,A^,P^), having no 
piasmid; 
Lane E, Transconjugant JNS-1 (T'^,Cf^,E^,G^,A^,P'^), having 38 kb, 4.4 kb 
and 2.8 kb piasmid; 
Lane F, Cured Transconjugant JNS-1C (T'^,Cf^,E'^,G^,A^,P^), having 4.4 kb 
piasmid; | 
Results: Tranconjugants were screened as (A^,T^). The conjugation 
experiment clearly shows that resistance markers G and T got transferred 
from clinical S. aureus, JS-105 to Carrier S. aureus, JN-49. Moreover, the 
Ciprofloxacin (Cf) and erythromycin (E) resistnace seem to be chromosomal 
mediated as evidenced in Lane D. 
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Table 4.12 Minimum Inhibitory Concentrations (MICs) of Antibiotics for 
Selected Staphylococcal Strains^ 
Staphylococcal 
Strains 
JS-79 (S. 
aureus) 
JS-15 
(S. epidemidis) 
JS-79T 
(transconjugant 
S. aureus) 
MIC (|ag/ml) of given antibiotic 
G 
0.5 
64 
128 
E 
<0.25 
>128 
>128 
T 
<0.25 
>128 
128 
C 
4 
8 
4 
P 
<0.25 
16 
1 
Cf 
<0.25 
>128 
>128 
^Minimum inhibitory concentrations were determined by NCCLS 
recommended protocol.^'*'' 
Table 4.13 Effect of Calcium Chloride and Lower Temperature on 
transfer Frequency between S. epidermidis Donor (JS-15) and S. 
aureus Recipient (JS-79) 
Donor 
JS-15 
Recipient 
JS-79 
Resistance 
Marker 
G 
E 
T 
Transfer Frequency^ 
No reagent 
(37 °C) 
1 35x10"^ 
5 30x10'^ 
2 70x10"' 
CaCl2 
(37 'O 
1 20x10"* 
5 30x10"' 
62x10" ' 
No 
reagent 
(30 C) 
95x10"^ 
5 30x10" ' 
1 00x10" ' 
No 
reagent 
(22 C) 
2.9x10"^° 
3.2x10"' ' 
1 44 X 10" 
11 
No reagent 
(20 'C) 
No 
Transfer 
2 1 X 10"'* 
No transfer 
^Transfer frequency was expressed as the number of transconjugants per 
recipient cell. 
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Figure 4.19 Agarose Gel Electrophoresis of Crude Plasmid DNA of 
Donor, Recipient and Transconjugant Staphylococcal Isolates. 
Horizontal electrophoresis was performed with 0.7% agarose in TAE buffer 
(pH 8.2), for 6 h as described in Materials and Methods (Section 3.8.1). 
Lane A, S. aureus recipient, JS-79, having no plasmid but heamolytic; 
Lane B, S. epidermidis, JS-15 (G'^, T'^, E^), having 38 kb, 4.4 kb, and 2.5 kb 
plasmids; 
Lane C, Transconjugant S. aureus, JS-79T (G*^ , T*^ , E'^), having 38 kb, 4.4 
kb, and 2.5 kb plasmids; 
Lane D, Cured transconjugant S. aureus, JS-79TA (G^, E'^), having 38 kb 
and 2.5 kb plasmids; I 
Lane E, Cured transconjugant S. aureus, JS-79TB (G'^), having 38 kb 
plasmid; 
Lane F, Cured transconjugant S. aureus, JS-79TC (G'^, T^) , having 38 kb 
and 4.4 kb plasmids; 
Results: In this study the clinical strain of S. epidermidis, JS-15 has been 
attributed the resistance traits to specific plasmids based on agarose gel 
electrophoresis of DNA obtained from transconjugants and selected 
transconjugants cured for various markers by ethedium bromide. The 
transconjugant S. aureus, JS-79T, which was resistant to gentamicin, 
erythromycin, and tetracycline, was used in curing experiments. 
Furthermore, the effect of calcium chloride and the temperature of 30 °C was 
found to be having no significant effect on conjugation, while the 
temperature of 22 ''C, the temperature found in the human nose and eye 
environment, was observed to be having a profound effect on conjugation 
frequency. 
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Table 4.14 Rates of Hydrolysis of Various Substrates by Purified 
Preparations of p-lactamase from Methiciliin-resistant S. aureus 
(MRSA) 
Substrate 
Penicillin G (P) 
Ampicillin (A) 
Amoxycillin (Ax) 
Methicillin (M) 
Oxacillin (Ox) 
Cloxacillin (Cx) 
Cephalexin (Cp) 
Cephazolin (Cz) 
Cephotaxime (Ce) 
Cephalosporin C (Cc) 
Rate of hydrolysis^ 
100 
90 
85 
1.5 
4.5 
3.5 
3.5 
0.5 
0.1 
5 
^Value of 100 was taken arbitrarily as the rate of hydrolysis of penicillin G by 
p-lactamase. Here the experiment was performed according to the method 
described in section 4.12. 
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Figure 4.20 Inactivation of Penicillins (Graph A) and Cephalosporins 
(Grap B) by p-lactamase. Here the experiment was performed according to 
the method described in section 4.12. The enzyme was purified from 
methicillin-resistant S. aureus. Symbols: Penicillin G (P); Ampicillin {A); 
Amoxycillin (Ax); Methicillin (M); Oxacillin (Ox); Cloxacillin (Ox); Cephalexin 
(Cp); Cephazolin (Cz); Cephotaxime (Ce); Cephalosporin C (Cc). 
Figure 4.21 Activity of a New Antimicrobial Agent against MRSA. A 
novel metal complex derived from parent compound, 2 -
mercaptobenzimidazole was synthesized in the Inorganic Chemistry Lab of 
AMU. The activity and MIC of this compound was determined in this study 
against MRSA isolates. In plate A, the concentration of each tested agent 
was 10 mg/ml, while as in the plates B, C, and D, the concentration of the 
tested agents was, 20 mg/ml, 30 mg/ml, and 40 mg/ml, respectively. 
Weil 1, Parent Compound, 2-mercaptobenzimidazole (MB!) 
Well 2, A ligand derived from (MBI) without complexing to a metal. 
Well 3, A Cu-complex of MBI 
Well 4, The new antimicrobial agent derived by complexing MBI and ligand 
with Nickel 
Well 5, DMSO solvent as control. 
MIC of the new antimicrobial agent was determined to be > 64 ng/ml as 
compared to MBI (MIC, 1536 ug/ml); ligand (MIC, 1024 ^g/ml); and Cu-
Complex (MIC, 512 ng/ml). 
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CHAPTER-5 
DISCUSSION 
In the celebrated movie Crouching Tiger, Hidden Dragon, two warriors face 
each other in a closed courtyard whose walls are lined with a fantastic anray 
of martial-arts weaponry, including iron rods, knives, spears and swords. The 
older, more experienced warrior grabs one instrument after another from the 
arsenal and battles energetically and fluidly with them. But one after another, 
the weapons prove useless, each, in turn, is broken or thrown aside, the 
shards of an era that can hold little contest against a young, tciumphant, 
upstart warrior who has learned not only the old ways but some that are 
new. 
One of the foundations of the modern medical system is being similarly 
overcome. Healthcare workers are increasingly finding that nearly every 
weapon in their arsenal of more than 150 antibiotics is becoming useless. 
Bacteria that have survived attack by antibiotics have learned from the 
enemy and have grown stronger; some that have not had skirmishes 
themselves have learned from others that nave. The result is a rising number 
of antibiotic resistant strains. Infections - including tuberculosis, meningitis 
and pneumonia - that would once have been easily treated with an antibiotic 
are no longer so readily thwarted. More and more bacterial infections are 
proving deadly. 
The presents study was undertaken with the aim of determining 
epidemiology of clinical and carrier staphylococci and biochemical studies of 
their acquisition and dissemination of resistance. The rationale of this study 
was to assess the prevalence of methicillin-resistant staphylococci from 
different clinical sites of patients, and nose of ihe hospital workers. We were 
particularly interested in analyzing the MRSA nasal colonization rate in 
patients admitted in an Orthopaedic Surgical Ward and the medical 
personnel and its relation to frequency of MRSA isolates in wound infections. 
We also observed the prevalence of MRSE in ocular infections and its 
relationship with nasal colonization of patients and ocular colonization of 
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hospital workers. The epidemiology of MRSA was analyzed by SDS - PAGE 
protein profiles and PFGE DNA finger printing patterns of the isolated 
strains. The results would be useful for medical personnel who need to 
eradicate the troublesome organisms from the hospital environment. In 
addition to the reservoir(s) searched, the susceptibility of both MRSA and 
MRSE isolates to 17 antimicrobial agents were also performed in order to 
provide update information on the use of appropriate drug(s) in the treatment 
of MRS infections and to determine the antimicrobial susceptibility pattern 
(antibiogram) of these strains to be used as a tool in further epidemiological 
study. Furthermore, the plasmid profiles of staphylococcal isolates and 
subsequent transformation and conjugation studies were performed in the 
present study. The isolation of p-lactamase enzyme and its activity against 
different classes of antibiotics was studied together with the activity of new 
antimicrobials against MRSA using standard procedures. 
Staphylococci are important causes of human infections but are also found 
as non-pathogenic microorganisms in human samples.^ ^ '^^ '* '^'^ '^^ ^ '^^ ^^ The 
spectrum of S. aureus infections includes toxic shock syndrome,^° food 
poisoning, meningitis, as well as dermatological disorders ranging from 
minor infections and eczema to blisters and scalded skin syndrome.^^^ 
Recent reports have begun to document infections caused by 
Staphylococcus epidermidis, such as bacterial endocarditis^^^ prosthetic 
heart valve endocarditis,®^ bacteraemia, surgical wound infections,^ ® 
intravascular catheters,^°^ post-operative endophthalmitis,^^^ conjunctivitis 
and keratitis.^^ '^^ ^^ Several other coagulase-negative staphylococci (CNS) 
species have been implicated at low incidence in a variety of infections. The 
CNS species Staphylococcus saprophyticus was often regarded as a more 
important opportunistic pathogen than S. epidermidis in human UTIs, 
especially in young sexually active females. It v^as considered to be the 
second most common cause of acute cystatitis or pyelonephritis in these 
patients.^""''" 
In the "present study highest prevalence of S. aureus was found in pus 
followed by urine and blood. Likewise the highest number of coagulase 
negative staphylococcal isolates was found in urine followed by conjunctiva 
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and pus. Besides, a significant number of staphylococcal isolates were 
observed from the clinical conditions like post operative infections, 
bacteraemia, pneumonia, corneal ulcer, prostatitis, septicaemia, mastatitis 
and endophthalmitis. 
Methicillin-resistant strains of staphylococci were identified immediately upon 
the introduction of methicillin into clinical practice. Methicillin-resistant S. 
aureus (MRSA) was initially identified for the first time in 1961 by 
Jevons.^ '^^ ^^ Since then strains of methicillin-resistant Staphylococcus 
aureus and methicillin-resistant coagulase-negative Staphylococci have 
spread worldwide^^ '^^ ^® and have become established inside and outside of 
the hospital environment.^^-^^^ There are reports of emergence and high 
occurrence of strains resistant to methicillin from various parts of the 
world.'*°° Recent studies have documented the increased costs associated 
with MRSA infection, as well as the importance of colonization 
pressure.^ '* '^'*^^ Already multiresistant to different classes of antibiotics, 
MRSA had been reported to acquire resistance to gentamicin and related 
aminoglycosides,'*"®''^^ therefore the treatment of infections due to these 
organisms and their eradication is very difficult. Constant monitoring of these 
strains is essential in order to control their spread in the hospital environment 
and transmission to the community. 
Of the 513 clinical strains of S. aureus, 180 (65.1% were methicillin-resistant 
S. aureus (MRSA) and out of 337 coagulase-negative staphylococcal 
isolates 76 (22.5%) were methicillin-resistant (MRCNS). Of the 180 MRSA 
strains the highest number was found in pus followed by urine and blood. Of 
the 76 MRCNS studied the highest number was obtained from urine followed 
by conjunctiva and nasal swabs of patients having ocular infections. The 
number of MRSA isolates being drastically high in wound infections, this 
might be due to the fact that orthopedic unit is a fertile environment for 
MRSA. The open wounds and the frequent dressing changes often 
necessitate a dressing team or multiple persons plus the inherent 
immunosupression of the wound patients might lead to MRSA colonization. 
The present study confirms that MRSA remains a mainly hospital-acquired 
infection, but a significant proportion may be acquired in community facilities 
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like nursing and residential homes.^^^''^^ The major reservoir of 
staphylococci in hospitals are colonized/infected in-patients and colonized 
hospital workers, with carriers at risk for developing endogenous infection or 
transmitting infection to health care workers and 
patients,2 '^''''''^ '^ '^ '^ '''^ '2^2,282,375,5oo ^f^jig transient hand carriage of the 
organism on the hands of health care workers account for the major 
mechanism for patient to patient transmission.^^^•'^ ^^ Low prevalence of 
MRSA colonization in an adult outpatient population indicated that MRSA 
carriers most likely acquired the organism through contact with healthcare 
facilities rather than in the community.^^'*'' These data show that care must 
be taken when attributing MRSA colonization to the community if detected in 
outpatients or during the first 24 to 48 hours of hospitalization. The risk to 
patients in terms of transmission of MRSA seems to be influenced strongly 
by the proportion of patients with colonization at intensive care unit 
admission and is associated with severity of illness, length of stay, and 
exposures to antibiotics and medical devices.^°°^ 
Colonization with S. aureus can occur soon after birth and at any given time, 
the nasal carriage rate in adults is estimated at between 20% and 40%.^°^ 
Healthcare workers have a higher incidence of colonization. The carrier state 
is clinically important because carriers undergoing surgery will experience 
more infections than non-carriers. Fierobe et al.^ "*^ has shown a relationship 
between MRSA postoperative intra-abdominal sepsis and nasal colonization 
of MRSA. MRSA strains are usually introduced into an institution by an 
infected or colonized patient or by a colonized healthcare worker, and 
transfer from one patient to another has led to major epidemics in tertiary 
care hospitals as well as chronic care facilities.^^^ Colonization of anterior 
nares with MRSA carries a significantly higher risk for infection than does 
colonization by sensitive strains.^^'^^ 
Intranasal 2% mupirocin applied twice daily for five days appears to be the 
most effective topical agent against MRSA "^*'^ "^ '^ ^^ and eliminates 91% of 
stable carrier states. Rohr et al., have demonstrated significantly reduced 
MRSA levels from nose, groin and axilla after the treat.ment of nasal 
mupirosin combined with octenidine dihydrochloride whole-body wash.^^'' By 
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confining the investigation to nasal carriage in healthy state, colonization at 
other body sites may have remained undetected and the 'true' prevalence in 
this study may have been underestimated. There is, however, overall 
agreement that sensitivity of nose swabs in detecting MRSA carriage is 
reasonably high (>7o%)/o8085.ioo,43o g^^ j^ ^^^ decided to confine the 
investigation to nasal specimens for reasons of accessibility, compliance and 
consistency with other investigations. The design of the study does not allow 
one to distinguish between patients who acquired MRSA during their current 
episode of hospital stay or patients already colonized on arrival to the 
hospital. Despite this, most of the carriers appeared to have acquired the 
organisms in hospital settings, as most of the isolates seem to be of the 
same types of strains as isolated from nose of the hospital workers. 
It is imperative we continue with basic infection control principles like hand 
washing and contact isolation and barrier nursing. There are conflicting 
reports regarding control of MRSA in hospital settings. Herwaldt^°^ and 
Fekety '^*^ in their papers justified aggressive measures to counteract this 
emerging health problem. Our study did not look into the cost effectiveness 
of MRSA screening, but Papia et a\}^^^ have shown that a screening 
programme for identification of MRSA colonization may be cost effective. 
The benefit of such a screening program may need to be confirmed by a 
randomized controlled trial. 
From this study we suggest that all patients having history of previous 
hospital admission and patients admitted directly from nursing homes should 
be screened for MRSA prior to any elective surgical or orthopaedic operative 
procedures. We believe that patients for routine elective procedures should 
have a negative result before undergoing the procedure. If surgery cannot 
be delayed due to medical reason then prophylaxis against MRSA should be 
given prior to the operation, though we appreciate this may not have much 
benefit in case of emergency admissions. However we would suggest that in 
patients with any of the above risk factors admitted for emergency surgery 
which may involve prosthetic implant, should be screened as well as given 
MRSA prophylaxis prior to their operations. 
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It is well documented that MRSA is likely to be multiple resistant (Figure 
4.10). Although methicillin-resistant staphylococci are clinically thought to be 
resistant to all p-lactams and cephalosporins but our in vitro studies showed 
that 1.1%, 5.6% 3.9% and 30% of MRSA strains showed susceptibilities to 
ampicillin, cefazolin, cephotaxime and imipenem, respectively. No MRCNS 
strain showed susceptibility to any of the (3-lactam or cephalosporin 
antibiotics assayed except imipenem. Methicillin resistance gene mecA is 
associated with transposons and insertion sequences, including Tn554 and 
\S431. \S431 is a common insertion sequence in staphylococcal 
chromosome and plasmids and can be associated with host of resistance 
determinants. The ability of \S431 elements through homologous 
recombination to trap and cluster resistance determinants with similar IS 
elements explain the multiple drug resistance phenotype that is 
characteristic of methicilline resistant staphylococci. ^ '^"^ ^ 
Broad-spectrum insusceptibility of all 180 MRSA and 76 MRCNS isolates to 
common antimicrobial agents were observed. Among all 17 antimicrobial 
agents used only vancomycin was shown to be consistently effective against 
all MRSA and MRCNS. We did not find any glycopeptide resistant 
S. aureus in our study, and vancomycin and teicoplanin remain the drugs of 
choice, although decreased susceptibility as well as resistance to 
vancomycin has been reported recently.° '^^ ° '^'*^°'^ '^* 
Of the 850 stephylococcal isolates, surprisingly about 90%, 80% and 50% 
strains were resistant to Pencillin G, ampicillin and co-trimoxazole, 
respectively. This might be due to the fact that at present time these agents 
are tremendously used in the treatment of general infections. On the 
contrary to the multiple resistance of MRSA, MSSA seemed to be much 
more susceptible to all tested antimicrobial agents except for pencillin, 
ampicillin and co-trimoxozable. As far as the clinical versus carrier 
staphylococcal isolates are concerned the general observation was that 
resistance in carrier isolates was lesser than clinical strains in case of all 
antibiotics tested. In the present study it is documented that resistance to 
chloramphenicol and ciprofloxacin was comparatively higher in ocular 
isolates as compared to staphylococcal strain isolated from other clinical 
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sources. This might be due to more pronounced use of these antibiotics for 
treatment of ocular infections. 
The high rates of multiple resistance is a direct consequence of hospital and 
community use of antibiotics and its concurrent selection of resistant strains. 
In India, as in many other developing countries, antibiotics are readily 
available over the counter. A person can buy the antibiotic of their choice or 
the pharmacist will prescribe one just by describing their symptoms. 
Patients, therefore, treat themselves with the wrong antibiotic or wrong 
dosage. Thus, patients may then come to the hospital already harbouring 
resistant strains. These strains may be the cause of endogenous infections 
or exogenous infections in other patients. Another important cause of 
resistance is excessive or inappropriate use of antibiotics in hospitals.^^^ The 
magnitude of the problem of multi-resistance is such that clinicians must be 
familiar with the causes of antibiotic resistance and the measures for 
preventing or minimizing the emergence of resistance. This study 
underscores the need for hospital clinicians to be aware of the common 
bacterial isolates in their unit and their usual antibiotic susceptibility. This is 
imperative in order to make rational decisions for the prudent use of 
antibiotics, particularly for empirical therapy. 
PFGE, because of its great discriminatory power and high degree of 
specimen typeability is accepted as the gold standard for the molecular 
typing of S. aureus isolates. It has successfully been used to study the 
epidemiology of S. aureus nosocomial infection and methicillin 
resistance.^ '^^ '^^ ^ '^2^°'^ ^ '^'^ ° Nevertheless, PFGE is time-consuming and labor 
intensive, in this study PFGE exhibited superiority as a technique for 
analyzing epidemiology of S. aureus. In the present study it was observed 
that the 61 strains of MRSA isolated in an Orthopaedic Surgical Ward 
displayed 42 patterns of antibiogram. These 61 MRSA strains were 
subjected to PFGE analysis whereby 14 PFGE patterns were observed. 
These results suggest that most of the MRSA appeared to have been 
acquired by patients during their current episode of hospital stay. Moreover 
similarity of PFGE patterns of MRSA isolates from pus, skin and nasal cavity 
suggest that most MRSA types isolated from pus were derived from the 
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nasal cavity but some types were derived from the nearby skin and that 
these microorganisms occasionally cause wound infections. 
The associated between the administration of antibiotics and the occurrence 
of MRSA is complex. Since the MRSA status of our sample populations on 
admission is unclear, it becomes difficult to decide if the antibiotics had (i) 
selected for resistant strains that were already colonizing on admission, or 
(ii) supported persistent colonization by excluding competing organisms or 
by enhancing the adhesion and colonizing capacity of the carriage strains, or 
(iii) increased the susceptibility of the patients to colonization with MRSA. An 
association between the use of antibiotics and MRSA has been repeatedly 
observed in different studies^ '^''^ '^^ ^^-^"'*^^ and ciprofloxacin has been 
identified as a risk factor in outbreak situations.^^^ 
MRSA acquisition depends on 2 major and independent determinants: 
colonization pressure and antimicrobial selective pressure. In case of 
colonization with distinct multiple clones of MRSA, antimicrobial pressure 
plays a major role; in the case of colonization with a single dominant clone of 
MRSA, colonization pressure plays a major role. McGown^ '^* proposed a 
biological model to explain the relationship between antimocrobial use and 
the emergence of resistance. At the level of individual patient, antimicrobial 
treatment leads to a large modification in the endogenous flora. The usual 
result is that susceptible strains are replaced by resistant ones. At the 
collective level, antimicrobial use in a hospital unit tends to maintain the 
presence of multidrug - resistant organisms in inpatients, healthcare 
workers, and the environment. In cases in which basic infection-control 
practices are inconsistently applied, these pathogens are implicated in the 
majority of infections. Antimicrobials such as p-lactams and 
fluoroquinolones, which are ineffective against MRSA and have excellent 
tissue diffusion, could promote the acquisition of MRSA by increasing the 
'receptiveness' of the patients and thereby allowing the progression towards 
colonization and infection. 
Our observations in Orthopedic Surgical Ward through antibiograms and 
PFGE patterns indicated that most MRSA infections resulted from 
colonization in hospital settings, although the role of community-MRSA has 
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not been taken into consideration. Therefore the prevention and control of 
drug-resistant infections in hospital settings requires measures to promote 
the appropriate use of antimicrobial drugs and prevent the transmission of 
infections. At present, control policies primarily consist of both infected and 
colonized (asymptomatic) patients and increased staff hygiene measures 
(principally handwashing compliance). Both of these are intended to reduce 
patient-to-patient transmission mediated by transiently colonized health 
workers. In the strongest form of isolation, patients carrying MRSA are 
placed in dedicated isolation units (lUs). If operated appropriately with 
designated staff, such units should be effective at preventing almost all 
transmission to patients elsewhere in a hospital. 
The spread of resistance to antimicrobial agents in S. aureus is largely due 
to the acquisition of plasmids and/or transposons.^^^ Although transfer of 
resistance between staphylococcal strains in the laboratory has been shown 
to occur via transformation, transduction, and conjugation,^''"•^^^ only 
conjugative transfer appears to be significant in vivo.^^^'*" In staphylococci, 
the conjugative transfer of resistant determinants is usually mediated by 
conjugative plasmids^^ '^^ ^ '^*^^ but has also been shown to occur in the 
absence of detectable conjugative plasmids.^^^ Conjugative plasmids, 
usually 35 to 50 kb,^^^ spread resistance determinants between species and 
genera.^'^^'^^^'*" Besides transferring the resistance determinants, they can 
mobilize non-conjugative plasmids, '^* '^^ ^^ recombine with nonconjugative 
plasmids to form new plasmids,''^^ or acquire and transfer resistance 
transposons.^^^ Studies with human staphylococcal strains indicate that 
Staphylococcus epidermidis is a reservoir of antibiotic resistance genes that 
can be transferred to S. aureus under in vitro and in vivo 
conditions:'''''''''''''' 
In vitro studies of drug resistance transfer between clinical and carrier 
staphylococcal strains, was done in the present study. The results indicated 
that tetracycline resistance was transferred from clinical to carrier isolates. 
This reflects that the use of antibiotics in humans to treat infections can 
promote resistance in normal flora. 
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Plasmid transfer among bacteria provides a means for dissemination of 
resistance to multiple antibiotics. Resistance to multiple antibiotics is 
frequently found with S. aureus clinical isolates and is often plasmid 
mediated.^''°'^^^ Transduction as a mechanism of gene transfer was first 
described in S. aurues in 1958 by Ritz.^^^'' In contrast to the 
Enterobacteriaceae, transduction is believed to be virtually the only means of 
transfer of genetic material between staphylococci cells. Although 
transformation in staphylococci in vitro has been described, practically all 
cultures of S. aureus contain high levels of nuclease, which can be expected 
to prevent transformation under natural conditions."^^ 
Transfer of resistance in mixed broth cultures by S. aureus has been 
described and is dependent on the presence of calcium chloride.^^^ In some 
reports, investigators have attributed the transfer in mixed-culture transfer of 
resistance as being phage-mediated conjugation. This process requires 
calcium chloride and is abolished by citrate, and transferring particles are 
often not detectable in donor culture supernatants. Lacy '^'^  proposes that the 
bacteriophage is cell bound, causing alterations in the cell surface of either 
the donor or recipient and thereby allowing plasmid transfer. However, the 
process of transfer here characterized is not dependent on the presence of 
calcium ions. 
In light of these data, we conclude that conjugation is the probable 
mechanism for transfer. Although the role of bacteriophage cannot be 
completely excluded, our experimental data are more consistent with a 
conjugal transfer process. Cell-to-cell contact was essential for transfer since 
resistance transfer could not be shown when donor and recipient cells were 
not allowed in contact with one another, analogous to transferable plasmids 
well characterized in streptococci.^^^ The transfer process also required 
viable donor cells and was energy dependent. 
In order to see the effect of lower temperature as found in the eye and nose 
environment (i.e. 22 °C) upon the conjugation process, it was observed that 
the application of lower temperature is having a profound effect upon 
conjugation transfer frequency. At a temperature of 30 °C there was a 
marginal decrease and at 22 °C there was a substantial reduction in transfer 
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frequency. But at 20 °C there was hardly any conjugation observed as 
compared to control (at 37 °C). These results indicate that the natural 
conditions prevailing in the eye and nose environment do not favour the 
resistance transfer mechanism significantly. 
The resistance often is transferable at interspecies and intergeneric 
levels.•"'^ ••'^ •^^ '^ •^^ ^^ •^ ^^ •''^ ^ The transfer of plasmids from S. aureus to E coli 
has previously been demonstrated to be possible.^^^'' However in these 
studies, the staphylococcal plasmids were modified by in vitro manipulation 
before their introduction into E.coli cells. In contrast, the transfer reported 
here was performed without any alteration of the native plasmid structure. 
Therefore, these experiments strongly support the hypothesis that genetic 
material could successfully flow from S. aureus to E. coli by transformation. 
Other Gram-negative bacteria of medical importance may also act as 
receptors for S. aureus plasmids (i.e., bacteria of the genus Klebsiella or 
Serratia). After transfer of plasmid DNA from Gram-positive to Gram-
negative bacteria, illegitimate recombination is a likely step for stabilization of 
the exogenous resistance genes. 
The MICs for A, G and Ak are shown in Table 4.11. As can be seen, the 
resistance to A and G were lower in E. coli transformants than in S. aureus. 
However, the MIC for Ak was higher in E coli. This result indicates that the 
Ak resistance gene is very efficiently expressed in E coli. 
Although the staphylococcal resistance to methicillin in atributed to the 
altered pBPs,^ '^'"^ ®'^ ^ '^'^ -^^ '^' but virtually all the penicillin resistant strains of 
staphylococci isolated from hospital infections owe their resistance to the 
production of p-lactamase.^'^^'^^ The 'efficiency of p-lactamase depends 
not only on the maximum velocity, Vmax, of hydrolysis of the substrate but 
also on the Michaelis constant, Km, of the enzyme, and Pollack^® '^' has 
suggested the term physiological efficiency' (defined as KmA/max) to 
describe the efficiency of a p-lactamase at destroying penicillin under 
physiological conditions. In the present study the substrate profile of p-
lactamase so extracted from a methicillin-resistant S. aureus against 
different penicillins and caphalosporins indicated that methicillin and 
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cephotaxime remain the most stable antibiotics to tlie staphylococcal p-
lactamase. The results indicated that methicillin resistance is independent of 
P-lactamase production in MRSA. 
The recent emergence of MRSA with decreased susceptibility to vancomycin 
has intensified the search for alternative therapies for the treatment of 
infections caused by this organism. In this study, the anti-MRSA activity of a 
synthesized compound in an Inorganic Lab of A.M.U. was determined by in 
vitro testing. The results indicated that the Nickel-metalo complex of 
2-mercaptobenzimidazole has good activity against MRSA (MIC, > 64 
|ig/ml), and demands to be analyzed for clinical applications in future. 
5.1 SUMMARY 
The emergence of multidrug-resistant bacteria is a phenomenon of concern 
to the clinician and the pharmaceutical industry, as it is the major cause of 
failure in the treatment of infectious diseases. Staphylococci have a record of 
developing resistance quickly and successfully to antibiotics. This defensive 
response is a consequence of the acquisition and transfer of antibiotic 
resistance plasmids and the possession of intrinsic resistance mechanisms. 
The acquired defense systems by staphylococci may have originated from 
antibiotic-producing organisms, where they may have been developed and 
then passed on to other genera. There are reports of emergence and high 
occurrence of staphylococcus strains resistant to methicillin, especially 
MRSA, from various parts of the World. These organisms are mostly 
resistant to multiple antibiotics; therefore the treatment of infections due to 
these organisms and their eradication is very difficult. 
The present study was undertaken with the aim of determining epidemiology 
of clinical and carrier staphylococci and biochemical studies of their 
acquisition and dissemination of resistance. 
The prevalence of methicillin-resistant staphylococci was determined in 750 
subjects infected/colonized with staphylococci providing 850 isolates. Of 850 
strains 575 were isolated from clinical specimens, 100 from nasal cultures of 
hospitalized patients, 125 from nasal and 50 strains were isolated from 
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ocular swabs of hospital workers. It was shown that 35.1% (180/513) of 
Staphylococcus aureus and 22.5% (76/337) of coagulase-negative 
staphylococcal isolates were resistant to methicillin. Highest percentage of 
MRSA (35.5%) was found in pus specimens (n=151) while as urine samples 
(n=153) contributed 25.0% of methicillin-resistant coagulase-negative 
staphylococci. 29.7% of methicillin resistant Staphylococcus aureus isolates 
were found in nasal swabs (n=175) while as 10.0% and 16.5% of methicillin-
resistant coagulase-negative staphylococci were observed in nasal swabs 
(n=50) and ocular cultures (n=50) respectively. The results indicated that 
major reservoir of methicillin resistant staphylococci in hospitals are 
colonized/infected inpatients and colonized hospital workers, with carriers at 
risk for developing endogenous infection or transmitting infection to health 
care workers and patients. Restriction mapping and SDS-PAGE protein 
profiles of both clinical and carrier methicillin-resistant Staphylococcus 
aureus isolates confirmed the results. The multiple drug resistance of all 
MRSA (n=180) and MRCNS (n=76) isolates was detected. In case of both 
methicillin-resistant as well as methicillin-sensitive staphylococcal isolates 
zero resistance was found to vancomycin followed by fusidic acid while as 
highest resistance was found to penicillin G followed by ampicillin. 
Selective methicillin-resistant staphylococcal isolates were subjected to 
piasmid isolation and curing treatments to study their mode of resistance. 
The plasmids were transformed into antibiotic sensitive Escherichia coli 
Strain DH5-a. In one of the experiments piasmid pJMRIO from 
Staphylococcus aureus coding for ampicillin (A^), gentamicin (C )^ and 
amikacin (Ak )^ resistance was transformed into Escherichia Coli. 
Transformation efficiency was about 2 x 1 0 ^ transformants/jig of piasmid 
DNA. The minimal inhibitory concentrations (MICs) for A and G were lower in 
E. coli than in S. aureus. However, the MIC for AK was higher in E. coli 
transformants than in S. aureus. In one of conjugation studies 
transfer of erythromycin resistance was observed between clinical 
and carrier strains of Staphylococcus aureus. Furthermore enzyme 
mediated resistance particularly through p-lactamase was studied 
in selected strains. The substrate profile of p - lactamase so 
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extracted was studied against different classes of pencidins and 
cephalosporins. The results indicated that methicillin rennains the most stable 
penicillin to the staphylococcal p-lactamase. 
The anti-MRSA activities of a synthesized compound from an Inorganic Lab 
of A.M.U; was determined by in vitro testing. The results indicated that the 
Nickle-metalo, complex of 2-mercaptoben2imidazole has good activity 
against MRSA (MIC > 64 ng/ml) and demands to be analyzed for clinical 
applications in future. 
The widespread occurrence and dissemination of p-lactamase and PBP 
mediated resistance leading to multiple antibiotics ineffective, thus 
increasing the cost of health care, needs to be tackled logistically by wise 
and judicious use of existing antibiotics and by developing ideal and cost 
effective antibiotics having least chances of acquiring resistance. 
Furthermore the hospital acquired MRSA infections through colonization of 
patients and hospital workers demands appropriate and timely measure to 
counteract this health problem. 
5.2 LIMITATIONS AND FUTURE CONSIDERATIONS 
Knowledge and understanding of the growing problem of antirTiicrobial 
resistance Is a pre-requisite for a planned and coordinated scientific 
response to this challenge. The emerging threat of antimicrobial 
resistance demands sustained research that will lead to an increased 
understanding broadly of: microbial physiology, ecology, genetics, 
mechanisms of resistance, host factors, and of the impact of variable 
antimicrobial use patterns, preventive, therapeutic, and growth 
promoting agents and environmental residues on the emergence and 
spread of resistant organisms and resistance factors. In this direction 
research community needs genomics and other powerful technologies 
to identify targets in critical areas for the development of new rapid 
diagnosis methodologies, novel therapeutics and interventions to 
prevent the emergence and spread of resistant pathogens. Various 
infection control interventions have been recommended for limiting the 
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spread of MRSA in hospitals.^^ The recommendations have included 
laboratory surveillance for MRSA, implementation of a variety of barrier 
precautions, isolation procedure and cohorting, eradication of MRSA 
from colonized patients and staff, and disinfection of the inanimate 
environment of infected individuals. 
The present study though aimed at determining epidemiology of clinical and 
carrier staphylococci and biochemical studies of their acquisition and 
dissemination of resistance, has few limitations. The epidemiological study of 
MRSA infections in S.K. Institute of Medical Sciences and Institute of 
Ophthalmology although depict the clear picture of prevailing antibiotic 
resistance patterns but the source of infections would have been clear if 
molecular biological typing of both nosocomial and community acquired 
MRSA and MSSA could have been done. Studies have reportedly found little 
evidence for sustained community spread of important nosocomial MRSA 
strains, and most patients carrying MRSA in community prevalence studies 
have had recent hospital exposure.^^^ For MRSA, as with all infectious 
diseases, ultimate control depends on keeping the mean number of 
secondary cases caused by each case below one. However, when carriage 
can persist for a long time, the secondary cases by each case may be 
distributed over several hospital admissions. Even limited community 
transmission of MRSA, although difficult to detect may profoundly alter the 
dynamics. Quantifying such transmission is an important area for future 
research. 
As far as the epidemiological study of MRSA infections in Orthopedic 
Surgical Ward is concerned, the SDS-PAGE whole cell protein banding 
though help in identification of strains but its role in epidemiology is not 
clear. Although the PFGE typing is clearly showing the role of carrier-MRSA 
in nosocomial and self infections but the study would have been of 
substantial importance if the carrier state before admission to Orthopedic 
Surgical Ward would have been typed as control. 
PFGE has proven to be robust enough to type strains with great resolution, 
is highly reproducible, and is considered the 'gold standard" technique for 
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typing MRSA."''* However, PFGE is time consuming and requires both 
specialized electrophoretic equipment and software. So there is the need of 
a simple technique just like PCR based typing of MRSA that relies upon the 
length of polymorphisms of the hypervariable region of the staphylococcal 
methicillin resistance gene (mec) for strain resolution.®^ The near future will 
provide techniques for typing and for prediction of the epidemic capacity or 
pathogenecity of MRSA strains. Both structural and transcriptional 
differences in genomes can be revealed using DNA microarray assays. The 
availability of complete genome sequences of several strains will result in 
identification of new areas important for understanding the adaptive fitness 
of MRSA strains in different environments. 
The curing experiments, transfer of resistance markers through conjugation 
and transformation together with the p-lactamase assay against selected 
antibiotics reveals a missing experimental-tag, the emphasis on which we 
believe will be a safe and cost effective measure to combat antimicrobial 
resistance: the use of consumable herbs of medicinal importance. The 
extracts from these herbs can be studied as curing agents and/or the 
inhibitors of antibiotic gene transfer and resistance enzymes. The 
metabolites so identified can be used in combination with antibiotics for 
counteracting this health problem. 
The substantial decreases in frequency of conjugation at lower temperature 
particularly at 22 °C, the temperature prevailing in the anterior nares of 
human beings depicts a biological significance. Moreover, the clinical 
importance of regular nose washing as experienced by some communities 
such as Muslims, five times in a day while they offer prayers, needs to be 
analyzed based on population studies. 
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